
Title: A Phase 2, Open-label Study to Evaluate the Efficacy and Safety of Single-Agent MLN0128 and 
the Combination of MLN0128+MLN1117 Compared With Everolimus in the Treatment of Adult 
Patients With Advanced or Metastatic Clear-Cell Renal Cell Carcinoma That Has Progressed on 
Vascular Endothelial Growth Factor-Targeted Therapy
Study ID: [REMOVED]
Protocol Approve Date: 03-December-2018
Certain information  within this protocol has been  redacted (ie,  specific content is masked irreversibly from view 
with a black/blue  bar) 
to protect either personally identifiable information (PPD) or company confidential 
information (CCI)
. 
This may include, but is not limited to, redaction of the following: 
Named persons or organizations associated with the study.
Proprietary information, such as scales or coding systems, which are considered confidential  
information under prior agreements with license holder.
Other information as needed to protect confidentiality of Takeda or partners, personal  information, or 
to otherwise protect the integrity of the clinical study.
1
PROTOCOL
A Phase 2, Open -label Study to Evaluate the Efficacy and Safety of Single -Agent MLN0128 
and the Combination of MLN0128+MLN1117 Compared With Everolimus in the 
Treatment of Adult Patients With Advanced or Metastatic Clear -Cell Renal Cell Carcinoma 
That Has Progressed on Vascular Endothelial Growth Factor -Targeted Therapy
Sponsor: Millennium Pharmaceut icals, Inc, a who lly owned subsidiary o f Takeda 
Pharmaceut ical Co mpany Limit ed
40 Landsdowne Street
Cambridge, MA 02139 USA
Telephone: +1 (617) 679 -7000
Please note: Millennium Pharmaceuticals, Inc, a wholly owned subsidiary of Takeda 
Pharmaceutical Company Limited, may be referred to in this protocol as “Millennium”, “sponsor”, o r “Takeda”.
Study Number: C31005
IND Number: 126,347 EudraCT Number: 2015-002133-22
Compound: MLN0128, MLN1117
Date: 03-December -2018 Amendment Number: 10 (France)
Amendment History
Date Amendment NumberAmendment Type (for regional 
Europe purposes only) Region
22 May 2015 Initial Protocol Not applicable Global
09 February 2016 01 Nonsubstantial Global
15 September 2016 02 Nonsubstantial France
01 December 2016 03 Substantial France
17 April 2017 04 Substantial Global
17 April 2017 05 Substantial France
03 October 2017 06 Substantial Global
02 October 2017 07 Substantial France
26-October -2017 08 Substantial Hungary
03-December -2018 09 Substantial Global
03 December -2018 10 Substantial France
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
MLN0128, MLN1117
Study No. C31005 Page 2of 104
Protocol Incorporating Amendment 10 03 December 2018
1.0 ADMINISTRATIVE
1.1 Contacts
A separate contact informat ion list will be provided to each site.
Serious adverse event and pregnancy reporting information is presented in Section 11.0 , as is 
inform ation on reporting product complaints.
General advice on protocol procedures should be obtained through the monitor assigned to th e 
study  site. Inf ormation on service providers is given in Sect ion 3.1and relevant guidelines 
provi ded to the si te.
Contact Type/Role North America Europe
Serious adverse event and pregnancy reporting See Section 11.0 See Section 11.0
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
MLN0128, MLN1117
Study No. C31005 Page 3 of 104
Protocol Incorporating Amendment 10 03 December 2018
1.2 Approval 
REPRESENTATIVES OF TAKEDA This study will be conducted with the highest respect for the individual participants in accordance 
with the requirements of this clinical study protocol and also in accordance with the following:
!The ethical principles that have their origin in the Declaration of Helsinki.
!International Conference on Harmonisation E6 Good Clinical Practice: Consolidated 
Guideline.
!All applicable laws and regulations, including, without limitation, data privacy laws, clinical 
trial disclosure laws, and regulations.
SIGNATURES 
The signature of the responsible Takeda medical officer (and other signatories, as applicable) can 
be found on the signature page.
Electronic Signatures may be found on the last page of this document.
PPD
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Usedance ance 
wing:wing:
oolidatedidate
ta privacprivac
other sigther s
thihis docs do
and Subje
: For Non-Commercial Use Only an
MLN0128, MLN1117
Study No. C31005 Page 4of 104
Protocol Incorporating Amendment 10 03 December 2018
INVESTIGATOR AGREEMENT
I confirm that I have read and that I understand this protocol, the Invest igator’s Brochure, package 
inserts, and any other product informat ion provided by the sponsor. I agree to conduct this study in 
accordance with the requirements of this protocol and also to protect the rights, safet y, privacy, 
and well -being o f study subjects in accordance with the following:
The ethical principles that have their origin in the Declaration of Helsinki.
International Conference on Harmonisation, E6 Good Clinical Pract ice: Conso lidated 
Guideline.
All applicable laws and regulat ions, inc luding, wi thout limi tation, data privacy laws and 
regul ations.
Regulatory  requi rements for reporting serious adverse events defined in Sect ion11.0 of this 
protocol .
Terms outlined in the Clinical Study  Site Agreement.
Appendix B, Responsibilit ies o f the Invest igator.
I further authorize that my  personal informat ion may be processed and transferred in accordance 
with the uses contem plated in Appendix Cof this protocol .
Signature of Investi gator Date
Invest igator Name (print or ty pe)
Invest igator’s Tit le
Locati on of  Facilit y (Ci ty, State/Provence)
Locati on of  Facilit y (Country )
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
MLN0128, MLN1117
Study No. C31005 Page 5of 104
Protocol Incorporating Amendment 10 03 December 2018
1.3 Protocol Amendment 10 Summary of Changes
Rationale for Amendment 10
This document describes the changes in reference to the protocol incorporating 
Amendment No.10. The primary purpose of this amendment is to define study  closure, rem ove 
long-term follow-up, rem ove the opti on for cross -over treatment, and add the option of a 
Post-Trial Access (PT A) program. 
Minor grammat ical, editorial, formatting, and administrative changes not affect ing the conduct of 
the study  are included for clarificat ion purposes only .
For specific descript ions of text changes and where the changes are located, see Appendix L. 
Changes in Amendment 10
1.Removed l ong-term follow-up, the opti on for cross -over treatment from Arm A to Arm  B or 
Arm C, and added the opti on for p atients to transfer to a Post- Trial Access (PTA) program.
2.Study  closure was defined as when the last patient discontinues treatmen t. 
3.A new sect ion was added (10.10) detailing the PTA program.
4.Modified the exclusio n criterion rel ating to proton -pump inhibitors (PPIs). 
5.Revised the restrict ions on conco mitant use of PPIs. 
6.Physical examinat ions after Screening were changed to symptom -directed physical  
examinat ions.
7.The requi rement for a confirmatory  scan 4 weeks from the previous scan for patients with a 
complete response (CR) or partial response (PR) was removed.
8.A reco mmendat ion was added for radiographic assessment every 6 months after 12 cycles of 
treatm ent.
9.The requi rement for wei ght to be m easured at Day  15 of Cycles 1 and 2 was removed.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
MLN0128, MLN1117
Study No. C31005 Page 6of 104
Protocol Incorporating Amendment 10 03 December 2018
TABLE OF CONTENTS
1.0 ADMINISTRATIVE ....................................................................................................... 2
1.1 Contacts ..................................................................................................................... 2
1.2 Approval .................................................................................................................... 3
1.3 Protocol  Amendment 10 Summary  of Changes .......................................................... 5
2.0 STUDY SUMMARY .................................................................................................... 12
3.0 STUDY REFERENCE INFO RMATION ...................................................................... 15
3.1 Study -Related Responsibilit ies................................................................................. 15
3.2 Principal Invest igator/Coordinating Invest igator ...................................................... 15
3.3 List of Abbreviat ions............................................................................................... 16
3.4 Corporate Identificat ion........................................................................................... 18
4.0 INTRODUCTION ......................................................................................................... 19
4.1 Background ............................................................................................................. 19
4.1.1 RCC ................................................................................................................... 19
4.1.2 Study  Drugs MLN0128 and MLN1117 .............................................................. 21
4.2 Rationale for the Proposed Study ............................................................................. 23
4.2.1 Rationale for the Doses and Schedule in Arm B ................................................. 23
4.2.2 Rationale for the Doses and Schedule in Arm C ................................................. 24
4.3 Potenti al Risks and Benefits ..................................................................................... 25
5.0 STUDY OBJECTIVES .................................................................................................26
5.1 Prim ary Object ives.................................................................................................. 26
5.2 Secondary  Object ives............................................................................................... 26
5.3 Qualit y of Life Objective ......................................................................................... 26
6.0 STUDY ENDPOINTS ................................................................................................... 27
6.1 Primary Endpo int..................................................................................................... 27
6.2 Secondary  Endpo ints............................................................................................... 27
6.3 QOL Endpo ints........................................................................................................ 27
7.0 STUDY DESIGN .......................................................................................................... 28
7.1 Overview of Study  Design ....................................................................................... 28
7.2 Number of Patients .................................................................................................. 30
7.3 Durati on of  Study .................................................................................................... 30
8.0 STUDY POPULATION ................................................................................................ 31
8.1 Inclusio n Cri teria..................................................................................................... 31
8.2 Exclusion Criteria.................................................................................................... 32
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
MLN0128, MLN1117
Study No. C31005 Page 7of 104
Protocol Incorporating Amendment 10 03 December 2018
9.0 STUDY DRUG ............................................................................................................. 35
9.1 Study  Drug Administration ...................................................................................... 35
9.2 Reference/Control Therapy ...................................................................................... 36
9.3 Dose Modificat ion Guidelines .................................................................................. 36
9.3.1 Intrapatient Dose Escalation ............................................................................... 36
9.3.2 Criteria for Beginning or Delaying a Subsequent Treatment Cy cle..................... 36
9.3.3 Criteria for Dose Interruption During a Cycl e..................................................... 36
9.3.4 Criteria for Dose Reduction ................................................................................ 37
9.3.5 Criteria for Di scontinuati on of  Study  Drug ......................................................... 38
9.4 Excluded Conco mitant Medi cations and Procedures ................................................ 38
9.4.1 Excluded Conco mitant Medi cations and Procedures for Arm A ......................... 38
9.4.2 Excluded Conco mitant Medi cations and Procedures for Arms B and C .............. 39
9.4.3 Potenti al for Drug -Drug Interactions with MLN0128 and/or MLN1117 ............. 39
9.5 Permi tted Concomitant Medications and Procedures ................................................ 40
9.6 Precauti ons and Restri ctions.................................................................................... 40
9.7 Management of Clinical Events ............................................................................... 41
9.7.1 Management of Hyperglycemia ......................................................................... 42
9.7.2 Management of Hyperlipidemia ......................................................................... 43
9.7.3 Management of Oral Mucosit is.......................................................................... 44
9.7.4 Management of Rash ......................................................................................... 45
9.7.5 Management of Nausea/Vo miting...................................................................... 46
9.7.6 Management of Cardiac Abnormalit ies.............................................................. 47
9.7.7 Management of Other Nonhematologic Toxicit ies............................................. 48
9.7.8 Management of AST/ALT Elevat ions................................................................ 49
9.7.9 Management of Noninfectious Pneumo nitis....................................................... 50
9.7.10 Management of Opportunistic Infections ............................................................ 51
9.7.11 Blinding and Unblinding .................................................................................... 51
9.8 Descript ion of Invest igational Agents ...................................................................... 52
9.9 Preparati on, Reconstitution, and Dispensat ion.......................................................... 52
9.10 Packaging and Labeling ........................................................................................... 52
9.11 Storage, Handling, and Accountabilit y..................................................................... 53
9.12 Other Protocol -Specified Materials .......................................................................... 53
10.0 STUDY CONDUCT ...................................................................................................... 54
10.1 Study Personnel and Organizations .......................................................................... 54
10.2 Arrangements for Recruit ment of Patients ................................................................ 54
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
MLN0128, MLN1117
Study No. C31005 Page 8of 104
Protocol Incorporating Amendment 10 03 December 2018
10.3 Treatment Group Assignments ................................................................................. 54
10.4 Study  Procedures ..................................................................................................... 54
10.4.1 Inform ed Consent ............................................................................................... 55
10.4.2 Patient Dem ographi cs........................................................................................ 55
10.4.3 Medical History .................................................................................................55
10.4.4 Physical Examinat ion......................................................................................... 55
10.4.5 Patient Hei ght and Weight ................................................................................. 55
10.4.6 Vital Signs ......................................................................................................... 55
10.4.7 Pregnancy Test ................................................................................................... 55
10.4.8 Concomitant Medications and Procedures .......................................................... 56
10.4.9 AEs.................................................................................................................... 56
10.4.10 Enrollment .................................................................................................... 56
10.4.11 ECG .............................................................................................................. 56
10.4.12 Clinical Laboratory  Evaluat ions.................................................................... 56
10.4.13 Fasting Serum Glucose ................................................................................. 57
10.4.14 In-Hom e Daily Fast ing Glucose Monitoring .................................................. 58
10.4.15 Disease Assessment ...................................................................................... 58
10.4.16 PK Measurements ......................................................................................... 59
10.4.17 Pharmacodynamic Measurements .................................................................59
10.4.18 DNA Measurements ...................................................................................... 59
10.4.19 Banked Tum or Specimen Measurements; Tumor Biopsies ............................ 60
10.4.20 QOL and Symptom Assessments .................................................................. 60
10.5 Com pletion of Treatment ......................................................................................... 61
10.6 Com pletion of Study ................................................................................................ 61
10.7 Discontinuati on of  Treatment Wi th Study  Drug and Pati ent Repl acement ................ 61
10.8 Withdrawal o f Patients From  Study ......................................................................... 61
10.9 Study  Com pliance .................................................................................................... 62
10.10 Post-Trial Access Program ....................................................................................... 62
11.0 ADVERSE EVENTS .................................................................................................... 63
11.1 Definitions............................................................................................................... 63
11.1.1 PTE Definit ion................................................................................................... 63
11.1.2 AE Definit ion.................................................................................................... 63
11.1.3 SAE Definit ion.................................................................................................. 63
11.2 Procedures for Recording and Reporting AEs and SAEs .......................................... 64
11.3 Moni toring of AEs and Period of  Observat ion......................................................... 65
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
MLN0128, MLN1117
Study No. C31005 Page 9of 104
Protocol Incorporating Amendment 10 03 December 2018
11.4 Procedures for Reporting Drug Exposure During Pregnancy and Birth Events ......... 65
11.5 Procedures for Reporting Product Complaints .......................................................... 66
11.6 Safety Reporting to Invest igators, IRBs or IECs, and Regulatory  Authori ties........... 66
12.0 STUDY -SPECIFIC COMMITTEES ............................................................................. 67
13.0 DAT A HANDLING AND RE CORDKEEPING ............................................................ 68
13.1 eCRFs ...................................................................................................................... 68
13.2 Record Retention ..................................................................................................... 68
14.0 STATISTICAL METHODS .......................................................................................... 70
14.1 Statistical and Analyt ical Plans ................................................................................ 70
14.1.1 Analysis Sets ...................................................................................................... 70
14.1.2 Analysis of Demographics and Other Baseline Characterist ics........................... 70
14.1.3 Efficacy Analysis ............................................................................................... 70
14.1.4 PK Analysis ....................................................................................................... 71
14.1.5 Pharmacodynamic Analysis ............................................................................... 71
14.1.6 Other Analyses ................................................................................................... 71
14.1.7 Safety Analysis .................................................................................................. 71
14.2 Interim Analysis and Criteria for Early Terminat ion................................................ 72
14.3 Determinat ionof Sam ple Size .................................................................................. 72
15.0 QUALITY CONTROL AND QUALITY ASSURANCE ............................................... 74
15.1 Study -Site Moni toring Visit s................................................................................... 74
15.2 Protocol  Deviat ions.................................................................................................. 74
15.3 Qualit y Assurance Audits and Regulatory  Agency  Inspect ions................................ 74
16.0 ETHICAL ASPECTS OF T HE STUDY ........................................................................ 76
16.1 IRB and/or IEC Approval ........................................................................................ 76
16.2 Subject Informat ion, Inform ed Consent, and Subject Authorizat ion......................... 77
16.3 Subject Confidentialit y............................................................................................ 78
16.4 Publicat ion, Di sclosure, and Clinical Trial Registration Policy .................................78
16.4.1 Publicat ion and Disclosure ................................................................................. 78
16.4.2 Clinical Trial Registration .................................................................................. 79
16.4.3 Clinical Trial Result s Disclosure ........................................................................ 79
16.5 Insurance and Co mpensation for Injury .................................................................... 79
17.0 REFERENCES .............................................................................................................. 80
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
MLN0128, MLN1117
Study No. C31005 Page 10of 104
Protocol Incorporating Amendment 10 03 December 2018
LIST OF IN -TEXT TABLES
Table 4.a DLT Observed Wit h Weekly  MLN0128 in Study  MLN0128 -1004 .................... 23
Table 4.b DLT Observed Wit h MLN0128 Plus MLN1117 (3 Days Per Week) in Study  
C32001 .............................................................................................................. 24
Table 9.a Examples of a Light Meal .................................................................................. 35
Table 9.b Dose Modificat ions for Single -Agent MLN0128 ................................................ 37
Table 9.c Dose Modificat ions for MLN0128 in Co mbinat ion with MLN1117 ................... 38
Table 9.d Management of Hyperglycemia ......................................................................... 43
Table 9.e Management of Hyperlipidemia ......................................................................... 44
Table 9.f Management of Oral Mucosit is.......................................................................... 45
Table 9.g Management of Rash ......................................................................................... 46
Table 9.h Management of Nausea/Vo miting...................................................................... 47
Table 9.i Management of Left Ventricular Dysfunct ion.................................................... 48
Table 9.j Management of QTc Interval Prolongat ion......................................................... 48
Table 9.k Management of Other Nonhematologic Toxicit ies (Including Asthenia, 
Weakness, and Fat igue) ...................................................................................... 49
Table 9.l Management of AST/ALT Elevat ions................................................................ 50
Table 9.m Management of Noninfectious Pneumo nitis....................................................... 51
Table 10.a Clinical Chemistry , Hem atology, and Coagul ation Tests.................................... 57
Table 10.b Clinical Urinalysis Tests .................................................................................... 57
Table 10.c Fasting Lipid Profile .......................................................................................... 57
LIST OF IN -TEXT FIGURES
Figure 7.a Study  Design ...................................................................................................... 29
LIST OF APPENDICES
Appendix A Schedule of Events ............................................................................................. 83
Appendix BResponsibilit ies o f the Invest igator ..................................................................... 89
Appendix C Invest igator Consent to Use of Personal Informat ion.......................................... 91
Appendix D Karno fsky Performance Status ........................................................................... 92
Appendix E Methods of Contraception Considered to be Eff ective ........................................ 93
Appendix FCockcroft -Gaul t Equati on.................................................................................. 94
Appendix G New York Heart Associat ion Classificat ion of Cardi ac Disease .......................... 95
Appendix HList of Relevant Cy tochrom e P450 Inhibitors and Inducers ................................ 96
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
MLN0128, MLN1117
Study No. C31005 Page 11of 104
Protocol Incorporating Amendment 10 03 December 2018
Appendix I List of BCRP, OCT1, and OCT2 Substrates ....................................................... 97
Appendix J EORTC QLQ -C30 Version 3 ............................................................................. 98
Appendix K Funct ional Assessment of Cancer Therapy  Kidney Symptom  
Index -Disease -Related Symptoms .................................................................... 100
Append ix L Detailed Descript ion of Amendments to Text ................................................... 101
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
MLN0128, MLN1117
Study No. C31005 Page 12of 104
Protocol Incorporating Amendment 10 03 December 2018
2.0 STUDY SUMMARY
Name of Sponsor(s):
Millennium Pharmaceuticals, IncCompound:MLN0128, MLN1117
Title of Protocol: A Phase 2, Open -label Study to Evaluate 
the Efficacy and Safety of Single -Agent MLN0128 and the 
Combination of MLN0128+MLN1117 Compared With 
Everolimus in the Treatment of Adult Patients With Advanced or Metastatic Clear -Cell Renal Cell Carcinoma 
That Has Progressed on Vascular Endothelial Growth 
Factor -Targeted TherapyIND No.: 126,347 EudraCT No.:
2015-002133 -22
Study Number: C31005 Phase: 2
Study Design:
This phase 2, open -label, randomized, 3 -arm study is designed to evaluate the efficacy and safety of single -agent 
MLN0128 and the combination of MLN0128 and MLN1117 compared with single -agent everolimus in the treatment 
of patients with metastatic clear -cell renal cell carcinoma (mccRCC) that has progressed on vascular endothelial 
growth factor (VEGF) -targeted therapy. Patients who meet the eligibility criteria will be stratified according to the 
number of prior lines of therapy (1, >1 prior line) and the International Metastatic Renal Cell Carcinoma Database 
Consortium risk category (favorable, interme diate, or poor) and will be randomized at a ratio of 1:1:1 to one of 
3treatment groups:
Arm A: single -agent everolimus.
Arm B: single -agent MLN0128.
Arm C: combination of MLN0128+MLN1117.
Safety assessments (which include vital signs, hematology, serum ch emistry, and urinalysis) will be performed ever y 
2 weeks for the first two 28 -day cycles and then at the beginning of each subsequent cycle thereafter. 
Primary Objectives:
To compare the efficacy of single -agent MLN0128 versus single -agent everolimus in patients with mccRCC. 
To compare the efficacy of the combination of MLN0128+MLN1117 versus single -agent everolimus in patients 
with mccRCC. 
Secondary Objectives:
To assess the safety and tolerability of MLN0128 and MLN0128+MLN1117.
To compare the efficacy of the combination of MLN0128+MLN1117 versus single -agent MLN0128 in patients 
with mccRCC.
To evaluate the efficacy (endpoints other than progression -free survival [PFS]; ie, overall survival [OS], 
time-to-progression [TTP], objecti ve response rate [ORR], and clinical benefit rate [CBR]) among the 3 treatment 
groups.
To collect plasma concentration -time data with sparse pharmacokinetic (PK) sampling to contribute to future 
populatio n PK analy sis.
Quality of Life Objective:
To assess the health -related quality of life and symptoms as measured by the European Organization for Research 
and Treatment of Cancer Quality of Life Questionnaire -Core 30 and the Functional Assessment of Cancer 
Therapy -Kidney  Symptom Index -Disease -Related Symptom s questionnaire among the 3 treatment groups.
Subject Population: Patients aged ≥18 years with mccRCC that has progressed on VEGF -targeted therapy
Number of Subjects: Approximately 189 patients
Arm A: everolimus; n=approximately 63.Number of Sites:
Approximately 60 -70 sites in North America and 
Europe
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
MLN0128, MLN1117
Study No. C31005 Page 13of 104
Protocol Incorporating Amendment 10 03 December 2018
Arm B: MLN0128; n=app roximately 63.
Arm C: MLN0128+MLN1117; n=approximately 63.
Dose Level(s):
Arm A: everolimus, 10 mg once daily (QD; ever y day 
of a 28 -day treatment cycle).
Arm B: MLN0128, 30 mg ever y week on Days 1, 8, 15, 
and 22 of a 28 -day treatment cycle.
Arm C: MLN0128 4 mg+MLN1117 200 mg, both 
QD 3 day s per week (on Days 1 -3, 8-10, 15 -17, and 
22-24 of a 28 -day treatment cycle).Route of Administration:
MLN0128: oral.
MLN1117: oral.
Everolimus: ora l.
Duration of Treatment:
Patients will receive MLN0128, MLN0128+MLN1117, or 
everolimus until they experience disease progression or unacceptable toxicity, withdraw consent, die ,or transfer to 
the Post -Trial Access (PTA) program. The maximum 
duratio n of treatment will be 24 months. Period of Evaluation:
The study  will be closed when the last patient 
discontinues study treatment . 
Main Criteria for Inclusion:Adult patients with histologically confirmed renal cell carcinoma with a clear -cell component, measurable disease per 
RECIST version 1.1, adequate bone marrow reserve and renal and hepatic function based on minimum laboratory 
criteria, Karnofsky performanc e status of 70% or higher, and life expectancy of at least 3 months. Eligible patients 
must have received at least one prior line of VEGF -targeted therapy and must have had radiographic evidence of 
progressive disease either on or within 6 months of stoppi ng their most recent systemic therapy for advanced 
mccRCC, and may have received up to 4 total prior lines of therapy.
Main Criteria for Exclusion:
Patients who have central nervous system metastases, uncontrolled comorbidities such as pulmonary disease o r 
infection that might compromise the patient’s participation in the study, and women who are either breast-feeding or 
pregnant, will be excluded.
Main Criteria for Evaluation and Analyses:
The primary endpoint of the study is PFS. The secondary endpoints are the incidence of treatment -emergent adverse 
events, OS, TTP, ORR (complete response [CR]+partial response [PR] per RECIST version 1.1), CBR (defined as 
CR+PR+stable disease[SD]) with SD of any duration, and CBR with SD duration of at least 4 months.
Statistical Considerations:The primary endpoint of the study is PFS, defined as the time from the date of randomization to the date of first 
documentation of disease progression or death due to any cause, whichever occurs first. For a patient whose disease 
has not progressed and is last known to be alive, PFS will be censored at the last response assessment that is SD or 
better. The primary efficacy analysis will be based on the full analysis set.
The Kaplan -Meier method will be used to analyze the distribution of PFS for each treatment arm. Kaplan -Meier 
survival curves; the 25th, 50th (median), and 75th percentiles along with associated 2 -sided 95% CIs; hazard ratio 
along with associated 95% CI; and Kaplan -Meier estimates at relevant time points will be presented. The primary 
hypothesis is to be tested at the 0.15 significance level (2 -sided). The p -values from a stratified log -rank test and 
hazard ratios and will be presented for each pair -wise comparison.
Secondary efficacy endpoints include OS, ORR, TTP, CBR (CR+PR+SD of any duration), and CBR with SD duration 
of at least 4 months.
OS is defined as the time from the date of randomization to the date of death. Patients without documentation o f death 
at the time of analysis will be censored at the date last known to be alive. OS will be analyzed using similar methods as 
the primary endpoint of PFS in the full analysis set.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
MLN0128, MLN1117
Study No. C31005 Page 14of 104
Protocol Incorporating Amendment 10 03 December 2018
ORR is defined as the proportion of patients who achieve a best response of CR or PR. CBR is defined as the 
proportion of patients who achieve a best response of CR, PR, or SD. CBR will also be presented for a best response of 
CR, PR, and SD of at least 4 months. A stratified Cochran -Mantel -Haenszel test will be used to compar e ORR and 
CBR between treatment arms. The Mantel -Haenszel estimate of the odds ratio and the associated 95% CIs will be 
presented for each pair-wise comparison.
TTP is defined as the time from the date of randomization to the date of first documentation of progression. For a 
patient whose disease has not progressed, TTP will be censored at the last response assessment that is SD or better. 
TTP will be analyzed using similar methods as the primary endpoint of PFS in the full analysis set.
Sample Size Justif ication: 
Approximately 189 patients will be enrolled in the 3 treatment arms.
The primary efficacy endpoint is PFS. Assuming that the median PFS is 5 months for everolimus and that MLN0128 
(either as a single agent or in combination with MLN1117) can impr ove the median PFS to 8 months (hazard ratio of 
0.625), then a total of 95 PFS events are needed for each pair -wise comparison, and approximately 63 patients are 
required for each treatment arm. The calculations are based on a power of 80%, 2 -sided alpha o f 15%, and a dropout 
rate of 10% due to either lost to follow -up or withdrawal of consent.
The sample size for the study assumes the total accrual will be approximately 14 months, w here 10% of the patients 
are enrolled within the first 3 months and 40% are enrolled at the end of 7 months. The final analysis for the pair -wise 
comparisons of PFS between single -agent MLN0128 and everolimus and between the combination of 
MLN0128+MLN1117 and everolimus will occur approximately 9 months after the last patient is randomized.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
MLN0128, MLN1117
Study No. C31005 Page 15of 104
Protocol Incorporating Amendment 10 03 December 2018
3.0 STUDY REFERENCE INFO RMATION
3.1 Study -Related Responsibilities
The sponsor will perform all study -related activit ies wi th the except ion of those i dentified in the 
Clinical Study  Supplier List. The i dentified vendors in the template for specific study -related 
activit ies will perform these act ivities in full or in partnership wi th the sponsor.
3.2 Principal Investigator/Coordinating Investigator
Takeda will select a Signatory  Coordinat ing Investigator or Investigators from the invest igators 
who partici pate in the study . Selection cri teria for this invest igator will include significant 
knowl edge of the study  protocol , the study  medicati on, thei r expert ise in the therapeut ic area and 
the conduct of clinical research as well as study  parti cipati on. The Si gnatory  Coordi nating 
Invest igator will be required to review and sign the clinical study report and by do ing so agrees 
that it accurately describes the results of the study .
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
MLN0128, MLN1117
Study No. C31005 Page 16of 104
Protocol Incorporating Amendment 10 03 December 2018
3.3 List of Abbreviations
4E-BP1 eukary otic translation initiation factor 4E -binding pr otein 1
AE adverse event
AKT serine/threonine -specific protein kinase (also known as protein kinase B)
ALT alanine aminotransferase
ANC absolute neutrophil count
AST aspartate aminotransferase
ATP adenosine triphosphate
BCRP breast cancer resistance protein
CBR clinical benefit rate
CFR Code of Federal Regulations
CNS central nervous system
CR complete response
CRO contract research organization 
CT computed tomography
CYP cytochrome P450
DLT dose-limiting toxicity
ECG electrocardiogram
eCRF electronic case report form
EOT End-of-Treatment (visit)
FBG fasting blood glucose
FDA Food and Drug Administration
EORTC QLQ -C30 European Organization for Research and Treatment of Cancer Quality of Life 
Questionnaire -Core 30
FKSI -DRS Functional Assessment of Cancer Therapy Kidney Symptom Index -Disease -Related Symptoms
GCP Good Clinical Practice
GI gastrointestinal
HbA1c glycosylated hemoglobin, hemoglobin A1c
HDPE high-density polypropylene
HIF hypoxia -inducible factor
IB Investigator’s Brochure
ICH International Conference on Harmonisation
IEC independent ethics committee
IRB institutional review board
IV intravenous; intravenously
IXRS interactive voice and/or web response system 
mccRCC metastatic clear -cell renal cell carcinoma
MedDRA Medical Dictionary for Regulatory Activities
Millennium Millennium Pharmaceuticals, Inc and its affiliates
MLN0128 also known as TAK -228
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
MLN0128, MLN1117
Study No. C31005 Page 17of 104
Protocol Incorporating Amendment 10 03 December 2018
MLN1117 also known as TAK -117
MRI magnetic resonance imaging
MTD maximum tolerated dose
mTOR mechanistic (or mammalian) target of rapamycin
NCI CTCAE Natio nal Cancer Institute Common Terminology Criteria for Adverse Events
OCT1 organic cation transporter protein 1
OCT2 organic cation transporter protein 2
ORR objective response rate
OS overall survival
p- phosphorylated
PCP Pneumocystis carinii pneumonia
PDGF platelet -derived growth factor
PFS progression -free survival
PI3K phosphoinositide 3 -kinase
PI3Kα phosphoinositide 3 -kinase alpha subunit
PIK3CA phosphoinositide -3-kinase, catalytic alpha polypeptide
PJP Pneumocystis jiroveci pneumonia
PK pharmacokinetic(s)
PPI proton pump inhibitor 
PR partial response
PRO patient -reported outcomes
PTA Post-Trial Access
PTE pretreatment event
PTEN phosphatase and tensin homolog
QD quaque die ; each day; once daily
QD3 QW once daily  for 3 days each week
QOL quality  of life
QW every week
QTc rate-corrected QT interval (msec) 
RCC renal cell carcinoma
RECIST Response Evaluation Criteria in Solid Tumors
RP2D recommended phase 2 dose
S473 serine 473
S6K ribosomal protein S6 kinase
SAE serious adverse event
SD stable disease
SmPC Summary of Product Characteristics
SUSAR suspected unexpected serious adverse reaction
TAK -117 MLN01117
TAK -228 MLN0128
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
MLN0128, MLN1117
Study No. C31005 Page 18of 104
Protocol Incorporating Amendment 10 03 December 2018
TEAE treatment -emergent adverse event
TORC1 mammalian (or mechanistic) target of rapamycin complex 1
TORC2 mammalian (or mechanistic) target of rapamycin complex 2
TTP time-to-progression
ULN upper limit of normal (range)
US United States
USPI United States Prescribing Information
VEGF vascular endothelial growth factor 
VHL von Hippel -Lindau
WHO World Health Organization
3.4 Corporate Identification 
Millennium Millennium Pharmaceuticals, Inc, a wholly owned subsidiary of Takeda Pharmaceutical 
Company Limited
TDC Japan Takeda Development Center Japan
TDC Asia Takeda Development Center Asia, Pte Ltd
TDC Europe Takeda Development Centre Europe Ltd
TDC Americas Takeda Development Center Americas , Inc
TDC TDC Japan, TDC Asia, TDC Europe and/or TDC Americas, as applicable
Takeda Millennium Pharmaceuticals, Inc, TDC Japan, TDC Asia, TDC Europe and/or TDC Americas, as 
applicable
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
MLN0128, MLN1117
Study No. C31005 Page 19of 104
Protocol Incorporating Amendment 10 03 December 2018
4.0 INTRODUCTION
4.1 Background
Kidney cancer is the twelft h most commo n cancer world- wide, wi th an est imated 338,000 new 
cases based on 2012 global data [1].The incidence of kidney  cancer i s higher in men than in 
wom en, wi th 214,000 new cases in men and 124,000 new cases in wo men. Geographically, the 
highest incidence rates are in Northern and Eastern Europe, North America, and Australia [1,2] . 
However, the overall incidence rates have been increasing over the last 3 decades [3]. More than 
90% of kidney cancers are renal cell carcino ma (RCC), of which 80% have a clear -cell 
morphol ogy [4].
4.1.1 RCC
RCC is a highly vascularized tumor that is refractory  to chem otherapy  and can be treated with 
molecularly  targeted anti angiogenic com pounds, including ty rosine kinase inhibitors that act on 
the vascular endothelial growth factor (VEGF) rece ptor (such as sunit inib, sorafenib, axit inib, and 
pazopanib), ant i-VEGF ant ibody  (bevacizumab), and rapalogs (temsiro limus and everolimus).
Approximately 80% to 90% of clear -cell carcino mas have either biallelic mutation or inact ivation 
of the von Hi ppel-Lindau (VHL) gene, which regulates hypoxia -inducible factor (HIF) -1α and 
HIF-2α transcription factors that are invo lved in the hypoxia response [5-8] . As part of the hypoxic 
response, the HIF -1α and HIF -2α tra nscript ion factors lead to an increase in the expression o f 
angiogenic growth factors, such as VEGF, platelet -derived growth factor -β (PDGF -β), 
transforming growth factor -α, and angiopo ietin-1 [5,7,8].
Whe n oxygen is restored, the VHL protein forms a mult iprotein complex that is invo lved in the 
ubiquit ination and subsequent proteasomal degradation of the HIF transcript ion factors. When 
VHL is absent, the angiogenic growth factors are expressed const itutively in the absence of 
hypoxia.
Therapy  has focused on the growth factor (eg, VEGF, PDGF) and mechanist ic (or mamma lian) 
target of rapamycin (mTOR) signaling pathways. Ty rosine kinase inhibitors that inhibit 
angiogenic growth factor receptors, such as VEGF an d PDGF receptors, and anti -VEGF ant ibody 
(bevacizumab) are approved for first -line therapy in RCC; however, development of resistance to 
VEGF -targeted therapy  occurs almost invariably .
The mTOR Pathway as a Therapeutic Target in RCC
The m TOR pathway  is ano ther therapeutic target in RCC. The mTOR serine/threonine kinase has 
a central  role in regulating cellular growth and metabo lism in response to external environmental 
factors [9,10] . The mTOR kinase binds wit h other proteins to form 2 dist inct mult iprotein 
complexes, mTOR co mplex 1 (TORC1) and mTOR complex 2 (TORC2). The TORC1 co mplex is 
stimulated by growth factors and amino acids, and regula tes cell growth by controlling the activit y 
of the riboso mal protein S6 kinase (S6K) and eukary otic transl ation initiation factor 4E -binding 
protein 1 (4E -BP1) [11]. The TORC2 compl ex is activated by  growth factors, and prom otes cell 
survival, proliferat ion, and act in cytoskeleton organizat ion by phosphorylat ing and activat ing 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
MLN0128, MLN1117
Study No. C31005 Page 20of 104
Protocol Incorporating Amendment 10 03 December 2018
kinases, such as serine/threonine -specific protein kinase (AKT, also known as protein kinase B), 
which is a regul ator of apoptosi s [12,13] .
Two major classes of mTOR inhibitors are under development: allosteric inhibitors and adenosine 
triphosphate (ATP) -compet itive inhibitors. The first -generation, or allo steric, inhibi tors incl ude 
rapamycin and the related analogs or rapalogs temsiro limus, evero limus, and ridaforolimus. The 
rapal ogs effect ively inhibit phosphorylat ion of S6K, but only partially inhibit the phosphorylat ion 
of 4E-BP1, which regulates cap -dependent transl ation of t ranscripts for cell survival, proliferat ion, 
and angiogenesis [9,10] . Thus, rapamycin and the rapalogs are only partial inhibitors of TORC1 
[9,10] .
The ATP -competitive inhibitors (also known as mTOR kinase inhibitors or TORKinibs), such as 
MLN0128, bind to the cataly tic dom ain of mTOR. Thus, these agents inhibit both TORC1 and 
TORC2 com plexes, including the rapamycin -insensi tive or -resistant acti ons of TORC1, such as 
phosphorylat ion of 4E -BP1 [14-17] .
Resistanc e to Rapalogs
The rapalogs temsiro limus and everolimus have been approved by the United States (US) Food 
and Drug Administration (FDA) as monotherapy  for pati ents wi th advanced RCC. However, 
resistance to single -agent rapal og therapy  occurs frequent ly and may be related to either 
incomplete inhibit ion of the targeted pathway  (such as phosphorylat ion of 4E -BP1) or the loss of 
S6K-mediated feedback inhibit ion of growth -factor receptor signaling, leading to paradoxic 
hyperact ive signaling. The normal feedback loop involves activated S6K, which phosphorylates 
and inact ivates insulin -receptor substrate -1 and inhibits signaling through the phospho inosit ide 
3-kinase (PI3K) pathway [13,18] . In the presence of rapalogs, the feedback loop is abrogated, 
leading to con tinued PI3K signaling, TORC2 activation, and subsequent phosphorylat ion of AKT 
at threonine 308 and serine 473 (S473), which markedly enhances the activit y of AKT 
[9,10,13,18] . This leads to continued signaling from the receptor through the PI3K pathway, 
TORC2, and AKT, leading to cell survival and proliferat ion.
The loss o f feedback inhibit ion by rapalogs has been demo nstrated in clinical tri als. In an analysis 
of either pai red fresh tum or sam ples or skin biopsies obtained fro m 55 pati ents who received 
different doses of everolimus, either daily  or weekly  in a phase 1 tri al, everolimus inhibited 
TORC1 in a dose -and schedule -depend ent m anner, wi th near com plete i nhibit ion of S6K [19]. 
Half o f the pai red tum or sam ples had a posttreatment increase in the phosphoryl ation of AKT at 
S473 [19]. These results provide direct evidence that loss of S6K feedback and subsequent 
PI3K/TORC2 -induced activatio n of AKT occurs commo nly in patients wi th nonhematol ogic 
tumors receiving single -agent everolimus. 
The rapalog evero limus is an allosteric inhibitor of TORC1. In a phase 3 study of single -agent 
evero limus in pat ients whose VEGF- targeted therapy  had f ailed, single -agent everolimus 
prolonged m edian progressi on-free survival (PFS) by approximately 3 months co mpared w ith 
patients who received placebo and best supportive care (median PFS 4.9 months vs 1.9 months) 
[20]. The less -than-expected anticancer activit y of single -agent rapalogs may be due to inco mplete 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
MLN0128, MLN1117
Study No. C31005 Page 21of 104
Protocol Incorporating Amendment 10 03 December 2018
inhibit ion of TORC1 actions, such as 4E -BP1, or the loss o f feedback inhibit ion of the signaling 
pathway  mediated by  S6 kinase fo llowing pharm acologic inhibit ion of TORC1.
4.1.2 Study Drugs MLN0128 and MLN1117
MLN0128
MLN0128 (also known as TAK -228) is a potent and select ive catalyt ic mTOR (TORC1/2) 
inhibitor that has the potential to improve upon everolimus treatment response in metastatic 
clear-cell RCC (mccRCC) through a m ore com plete inhibit ion of TORC1 signaling (S6 and 
4E-BP1) and through inhibit ion of TORC2 substrates, such as AKT. This could lead to a more 
profound block of the angiogenic growth and survival signaling than that achieved with rapalogs.
Clinical Experience With MLN0128
Single-agent MLN0128 is in clinical development with 3 phase 1 studies in patients with advanced 
non-hematol ogic tum ors (Studi es INK128- 001, MLN0128- 1004, and C31002). In addit ion, 
MLN0128 is being investigated in combinat ion with paclitaxel, wit h or without trastuzumab, in a 
phase 1 study  in pat ients with advanced so lid tumors (INK128- 003).
Milled MLN0128 is being invest igated either as a single agent or in combinat ion with paclitaxel in 
an add itional phase 1 study in patients with advanced solid tumors (Study MLN0128- 1004) and in 
a phase 1/2 study  in pat ients with advanced estrogen receptor -posit ive, human epidermal growth 
factor receptor -2 negative breast cancer (Study  C31001).
The m ost comm ontreatm ent-emergent adverse events (TEAEs) observed wit h MLN0128 are 
consistent with the pharm acodynamic mechanism of mTOR inhibit ion that i s also seen wi th 
rapal ogs (TORC1 inhibit ion) or other dual mTORC1/2 inhibitors. The TEAEs observed across the 
MLN012 8 single -agent studi es include di arrhea, fati gue, vo miting, rash, mucosal inflammat ion, 
asthenia, dy sgeusia, thrombocy topenia, stom atitis, blood creatinine increased, hyperglycemia, 
nausea, anorexia, and decreased appetite.
MLN0128 has been shown to have a ntitumor activity against RCC in a murine xenograft model. In 
addition, preliminary clinical data from a tumor -specific expansio n cohort in Study INK128 -001 
suggests that MLN0128 has ant itumor activit y in pati ents wi th RCC.
Further details are presented in the current edit ion of the MLN0128 Investigator’s Brochure (IB).
MLN1117 in Combination With MLN0128
MLN1117 (also known as TAK -117) is a potent and highly selective small- molecule inhibitor of 
the class I PI3K alpha subunit (PI3K ) isoform. PI3K is act ivated by upstream receptor tyrosine 
kinases such as epidermal growth factor receptors, human epidermal growth factor receptor -2, 
insulin -like growth factor -1 receptor, and insulin receptors, and possibly by act ivated Ras. 
The addit ion of the PI3Kα inhibit or MLN1117 to MLN0128 should counteract the reactivat ion of 
this pathway and enhance MLN0128 activit y. This is supported by  indirect evidence fro m 
nonclinical studies wit h NVP -BEZ235, a dual PI3K/mTOR inhibitor, and rapamycin in RCC cell 
lines and murine x enograft m odels. In these invest igations, NVP -BEZ235 was associated with 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
MLN0128, MLN1117
Study No. C31005 Page 22of 104
Protocol Incorporating Amendment 10 03 December 2018
more profound reduction in tumor size and more complete inhibit ion of phosphorylat ion of 
TORC1/2 and PI3K substrates, including AKT, eukary otic translati on ini tiation factor 4E, and 
4E-BP1, than rapamycin [21]. Thus, the combinat ion of MLN0128 and milled MLN1117 has the 
potenti al to improve MLN0128 treatment response in mccRCC th rough a m ore com plete and 
prolonged inhibit ion of this signaling pathway.
Clinical Experience of MLN1117 in Combination With MLN0128
MLN1117 is in clinical development for the treatment of advanced non -hematol ogic tum ors, as a 
single agent (Study  INK1117 -001) and in co mbination (Study  C32001). These studies have been 
designed to i nvest igate the safet y, pharm acokinet ics (PK), pharmacodynamics, and preliminary 
efficacy  of MLN1117, ei ther as a single agent or in co mbination wit h MLN0128.
Potenti al overlapping toxicities associated wi th MLN0128 and MLN1117, and the ident ified and 
potenti al risks of both drugs, including data fro m nonclinical and clinical studies for each product, 
have been reviewed. More detailed information on the ident ified and potential risks of both drugs 
is included in the individual, single -agent IBs. Cl ass effects of mTOR inhibitors (for MLN0128) 
and PI3K inhibitors (for MLN1117) have also been considered. Potential overlapping toxicit ies for 
both agents include:
Derm atologic disorders (pruritus, rash).
Gastrointestinal (GI) disorders (diarrhea, mucosal inflammat ion, nausea, stomat itis, vo miting).
Generalized disorders (anorexia, asthenia, decreased appetite, fat igue).
Hem atologic disorders (lymphoid, bone marrow deplet ion).
Metabo lic di sorders (decreased blood chloride, hypercho lesterol emia, hyperglycemia).
On the basis o f current clinical experience, and the previous list of potential overlapping toxicit ies, 
hyperglycemia, diarrhea, nausea, vo miting, fat igue, and rash are the most antic ipated adverse 
events (AEs) associated with the MLN0128+MLN1117 combination regimen. These events are 
expected to be manageable.
Further details are presented in the current edit ion of the MLN0128, MLN0128+MLN1117, and 
MLN1117 IBs.
Preliminary PK of MLN012 8
The PK parameters measured for unmilled MLN0128 active pharmaceutical ingredient in the 
phase 1 clinical studies have been generally  consistent across a range of doses and mult iple 
schedules. MLN0128 has shown linear PK and fast oral absorption with firs t time o f occurrence o f 
maximum (peak) concentration occurring between 1 and 4 hours after a single dose. The mean 
half-life of MLN0128 is approximately 8 hours, and no accumulat ion has been observed in plasma 
after repeat daily  dosing.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
MLN0128, MLN1117
Study No. C31005 Page 23of 104
Protocol Incorporating Amendment 10 03 December 2018
4.2 Rationale for the P roposed Study
A TORC1/2 inhibitor would be expected to provide more complete inhibit ion of the mTOR 
pathway  than a rapalog, and the combinat ion of a PI3Kα inhibitor with a TORC1/2 inhibitor would 
be expected to provide more robust inhibit ion of the mTOR an d growth factor signaling pathways 
than eit her agent alone. This rando mized, open -label, 3-arm invest igation of MLN0128, 
MLN0128+MLN1117, and evero limus will test the hypothesis that TORC1/2 inhibit ion, either 
with or wi thout addi tional PI3Kα inhibi tion, will provide better efficacy co mpared with 
single- agent rapal og inhibit ion of TORC1 in patients with mccRCC and progressive disease after 
VEGF -targeted therapy .
4.2.1 Rationale for the Doses and Schedule in Arm B
The selected dose and schedule for Arm B of 30 mg MLN0128 every week (QW) is based on the 
findings fro m 2 studi es: Study  INK128 -001 and Study  MLN0128 -1004. 
Study  INK128 -001was the first -in-human study  of MLN0128. Study  INK128 -001 was an 
open -label study  designed to determine the maximum tolerated dose (M TD) and to ident ify 
dose-limit ing toxicit ies (DLTs) for oral administratio n of single -agent unmilled MLN0128, and to 
characterize the safet y and tol erabilit y of escalat ing doses of MLN0128 in patients with advanced 
solid tumors. In this study , 116 pati ents with advanced solid tumors received single- agent 
MLN0128 (2- 40 m g via 4 dosing schedules) in the dose escalat ion phase.
Doses of 40 mg QW, 30 mg QW, and 5 mg o nce daily (QD) were further evaluated in an addit ional 
82patients in the expansio n phase.
Improved tolerabilit y, including a reduced frequency  of TEAEs leading to dose interruptions and 
modificati ons, respectively (5 mg QD [26% and 67%] vs 30 mg QW [24% and 41%] vs 40 mg QW 
[19% and 77%] as of a data cut on 09 December 2015), and longer duration of clinical benefit 
favored 30 m g QW dosing as a recommended phase 2 dose (RP2D) and schedule for further 
development.
With the introduction of milled MLN0128, the recommended dose to be used in Arm B of this 
study  (30 mg milled MLN0128 QW) was further confir med in Study MLN0128 -1004 ( Table 4.a). 
A total o f 14 pati ents were enrolled and assigned, sequent ially, to 2 QW dosing cohorts. PK, 
safet y, and tol erability were assessed.
Table 4.a DLT Observed With Weekly MLN0128 in Study MLN0128 -1004
Dose of Milled MLN0128 Number of Evaluable Patients DLTs Observed in Cycle 1
20 mg QW 6 None
30 mg QW 6 None
As none of the patients in eit her dose cohort experienced DLT in Cycle 1, a dose of 30 mg 
MLN0128 QW was selected for further development. No clinically meaningful differences in the 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
MLN0128, MLN1117
Study No. C31005 Page 24of 104
Protocol Incorporating Amendment 10 03 December 2018
PK of MLN0128 were noted between the unmilled MLN0128 (Study  INK128 -001) and milled 
MLN0128 (Study  MLN0128 -1004) when given QW. 
4.2.2 Rationale for the Doses and Schedule in Arm C 
The dose and schedule selected for Arm C of 4 mg MLN0128 plus 200 mg of MLN1117 (both 
once daily for 3 days each week [QD 3 QW]) are based on the results of Study  C32001 conducted 
under IND 117,524. Study C32001 i s an ongoing, open -label study  designed to determine the 
MTD and DLTs for oral administration of milled MLN0128 given in combinat ion with MLN1117 
and was designed to characterize the safet y and to lerabilit y of escalat ing doses of MLN0128 
and/or MLN1117 in patients with advanced so lid tumors. The study  featured a dose -escalat ion 
phase evaluat ing 3 dosing schedules. A favorable tolerabilit y profile was observed when 
increasing doses o f MLN0128 (3 to 8 mg) were administered with a fixed dose of MLN1117 (both 
given QD 3 QW). The MTD for MLN0128 in combinat ion with MLN1117 both given QD 3 QW 
was 6 m g MLN0128+200 mg MLN1117 ( Table 4.b). 
Table 4.b DLT Observed With MLN0128 Plus MLN1117 (3 Days Per Week) in Study 
C32001
Dose of Milled 
MLN0128+MLN1117Number of Evaluable 
Patients DLTs Observed in Cycle 1
6 mg+200 mg QD 3 QW 6 1 patient experienced DLT of aspartate aminotransferase/ 
alanine aminotransferase elevation)
4 mg+200 mg QD 3 QW 8 None
While both combination dose levels were considered safe on the basis of 3+3 rules, the lower dose 
level of 4 mg+200 mg QD 3 QW was chosen as the RP2D for milled MLN0128+MLN1117 for 
further development.
The m echanist ic justification for comparing the effectiveness o f either single -agent MLN0128 or 
the combination o f MLN0128 and MLN 1117 wi th that of evero limus in pat ients with RCC is 
outlined in detail in Sect ion 7.0.
Briefly, a TORC1/2 inhibitor like MLN0128 would be expected to provi de m ore com plete 
inhibit ion of the mTOR pathway than a rapalog (eg, everolimus as an allosteric TORC1 inhibitor), 
and the combinat ion of a PI3Kα inhibitor (MLN1117) with a TORC1/2 inhibitor (MLN0128) 
woul d be expected to provide more robust/sustain ed inhibit ion of the mTOR and growth factor 
signaling pathways than eit her agent alone. This rando mized, open -label, 3 -arm invest igation of 
MLN0128, MLN0128+MLN1117, and evero limus will test the hypothesis that TORC1/2 
inhibit ion, either wi th or wi thout ad ditional PI3Kα inhibi tion, will provi de better efficacy 
compared wi th single -agent rapal og inhibit ion of TORC1 in pat ients with mccRCC and 
progressive disease after VEGF -targeted therapy .
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
MLN0128, MLN1117
Study No. C31005 Page 25of 104
Protocol Incorporating Amendment 10 03 December 2018
4.3 Potential Risks and Benefits
The m ost comm on TEAEs observed with MLN 0128 are consistent with the pharmacodynamic 
mechanism o f mTOR inhibit ion that i s also seen wit h rapalogs (TORC1 inhibit ion) or other dual 
mTORC1/2 inhibitors. The TEAEs observed across the MLN0128 single -agent studi es include 
diarrhea, fati gue, vomi ting, rash, m ucosal  inflammati on, asthenia, dy sgeusia, thrombocy topenia, 
stom atitis, blood creatinine increased, hyperglycemia, nausea, anorexia, and decreased appetite. 
Potenti al overlapping toxi cities associated wi th MLN0128 and MLN1117 and the identified and
potenti al risks of both drugs, including data fro m nonclinical and clinical studies for each product, 
have been reviewed. More detailed information on the identified and potential risks of both drugs 
is included in the individual single -agent IBs. Cl ass e ffects of mTOR inhibitors (for MLN0128) 
and PI3K inhibitors (for MLN1117) have also been considered. Potential overlapping toxicit ies for 
both agents include:
Derm atologic disorders (pruritus, rash).
GI disorders (diarrhea, mucosal inflammat ion, nausea, st omatitis, vo miting).
Generalized disorders (anorexia, asthenia, decreased appetite, fat igue).
Hem atologic disorders (lymphoid, bone marrow deplet ion).
Metabo lic disorders (decreased blood chloride, hypercho lesterol emia, hyperglycemia).
On the basis o f curr ent clinical experience and the previous list of potential overlapping toxicit ies, 
hyperglycemia, diarrhea, nausea, vo miting, fat igue, and rash are the most anticipated TEAEs 
associ ated wi th the MLN0128+MLN1117 co mbination regimen. These events are expecte d to be 
manageable.
During this study, risk mit igation strategies include, but are not limited to, strict applicat ion of the 
study  inclusio n and exclusio n criteria, frequent m onitoring of clinical and laboratory  resul ts, 
guidelines for m anagement and proph ylaxis o f potent ial toxicit ies, cri teria for dose m odificat ion, 
and regular monitoring of TEAEs and serious adverse events (SAEs) by the sponsor. The benefits o f MLN0128 and MLN0128+MLN1117 are discussed in Section 4.1.2 .
Further details are presented in the current edit ions of the MLN0128, MLN0128+MLN1117, and 
MLN1117 IBs.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
MLN0128, MLN1117
Study No. C31005 Page 26of 104
Protocol Incorporating Amendment 10 03 December 2018
5.0 STUDY OBJECTIVES
5.1 Primary Objectives
The primary  object ives of the study are:
To com pare the efficacy of single- agent MLN0128 versus single -agent everolimus in pat ients 
with mccRCC.
To com pare the efficacy of the combinat ion of MLN0128+MLN1117 versus single -agent 
evero limus in pat ients with mccRCC. 
5.2 Secondary Objectives
The secondary  objectives of the study  are:
To assess the safet y and tol erabilit y of MLN0128 and MLN0128+MLN1117.
To com pare the efficacy of the combinat ion of MLN0128+MLN1117 versus single -agent 
MLN0128 in pat ients with mccRCC . 
To evaluate the efficacy  (endpoints other than PFS; ie, overall survival [OS], 
time- to-progression [TTP], object ive response rate [ORR], and clinical benefit rate [CBR]) 
among the 3 treatment groups.
To collect plasma concentration- time data wi th sparse PK sampling to con tribute to future 
popul ation PK analysis.
5.3 Quality of Life Objective
The health -related quali ty of life (QOL) object ive is:
To assess the health -related QOL and symptoms as measured by  the European Organizat ion 
for Research and Treatment of Cancer Qualit y of Life Questionnaire -Core 30 
(EORTC -QLQ -C30) and the Funct ional Assessment of Cancer Therapy Kidney  Symptom  
Index -Disease -Related Symptoms (FKSI- DRS) questionnaire amo ng the 3 treatment groups.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
MLN0128, MLN1117
Study No. C31005 Page 27of 104
Protocol Incorporating Amendment 10 03 December 2018
6.0 STUDY ENDPOINTS
6.1 Primary Endpoint
The primar y endpo int is PFS.
6.2 Secondary Endpoints
The secondary  endpoints are:
The number and percentage of patients with TEAEs.
OS.
TTP.
ORR (defined as co mplete response [CR]+partial response [PR] per Response Evaluat ion 
Criteria in Solid Tumors [RECIST] version 1.1).
CBR (defined as CR+PR+stable disease [SD]) with SD of any duration, and CBR with SD 
durati on of  at least 4 m onths.
6.3 QOL Endpoints
The health -related QOL endpoints are:
Changes fro m Baseline in funct ional and symptom scores, and global healt h status and QOL 
score from the EORTC QLQ -C30 and symptom scales from the FKSI -DRS quest ionnaire.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
MLN0128, MLN1117
Study No. C31005 Page 28of 104
Protocol Incorporating Amendment 10 03 December 2018
7.0 STUDY DESIGN
7.1 Overview of Study Design
This is a phase 2, open -label study  of the safet y and efficacy o f MLN0128, as a single agent and in 
combinat ion with MLN1117, in adu lt patients wi th advanced or m ccRCC that has progressed on 
VEGF -targeted therapy . Eligibilit y will  be determined during the Screening period, which may 
last for up to 28 days before the Cy cle 1 Day  1 visit. Pati ents who m eet all  eligibilit y criteria and 
provide wri tten informed consent will be enro lled in this study. Approximately 189 patients who 
meet the eligibilit y criteria will bestratified according to the number of prior lines of therapy 
(1,>1prior line) and the Internat ional Metastatic Renal Cell Carcino ma Database Consortium risk 
category  (favorable, intermediate, or poor) [22], and will be rando mized at a ratio of 1:1:1 to one of 
3treatm ent arms:
Arm A: single -agent everolimus.
Arm B: single- agent MLN0128.
Arm C: combinat ion of MLN0128+MLN1117.
Patients will  receive study  drug(s) (i e, MLN0128, MLN1117, and evero limus) in 28 -day cycles. 
Patients in Arm A will receive evero limus 10 mg QD according to current prescribing informatio n 
in either the Uni ted States Prescribing Informat ion (USPI) [23] or Summary  of Product 
Characteristics (SmPC) [24] for everolimus. Patients in Arm B will receive MLN0128 30 mg 
orally  once weekly (on Days 1, 8, 15, and 22 of a 28 -day treatm ent cy cle). Pati ents in Arm C will  
receive MLN0128 4 mg and MLN1117 200 mg orally both QD 3 days per week (on Day s 1-3, 
8-10, 15 -17, and 22 -24 of a 28- day treatm ent cy cle). Pati ents will receive MLN0128, 
MLN0128+MLN1117, or everolimus unt il they experience disease progression or unacceptable 
toxicity, withdraw consent, die, or transfer to the Post -Trial Access (PTA) program. The study  
design i s displayed in Figure 7.a.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
MLN0128, MLN1117
Study No. C31005 Page 29of 104
Protocol Incorporating Amendment 10 03 December 2018
Figu re 7.a Study Design
The rati onale for the pl anned doses for Arm B and Arm C are described in Sect ion 4.2.1 . 
Radiographic tumor eval uations will be performed by  contrast -enhanced computed tomography 
(CT) scan with intravenous (IV) contrast or magnetic resonance imaging (MRI) with IV contrast, 
unless contraindicated. CT of the chest, and CT or MRI of the abdomen and pelvis, will be used to 
evaluate disease response according to RECIST version 1.1 [25]. Supplemental x -ray and/or bone 
scanning may be performed, but these methods are not suitable for lesio n measurement. 
Radiographic tumor eval uations will be performed at the time points specified in Appendix A
Schedule of Events .
Study  data w ill be reviewed after the first 30 patients in each arm have received 2 cy cles of study  
drug. If at the end of Cycle 2, 50% or more patients in a treatment arm (ie, Arm B [single agent 
MLN0128] or Arm C [MLN0128+MLN1117]) have eit her progressive disease or have died, or 
have discont inued study  treatment due to treatment -related AEs, then that study  arm may be 
closed. If both Arms B and C meet these criteria, then the study  may be cl osed.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
MLN0128, MLN1117
Study No. C31005 Page 30of 104
Protocol Incorporating Amendment 10 03 December 2018
Throughout the study , toxi city will be evaluated according to the Nati onal Cancer Inst itute 
Commo n Termino logy Criteria f or Adverse Events (NCI CTCAE) version 4.03, effect ive date 
14June 2010 [26]. Dose modificat ion gui delines are in Sect ion 9.3.
AEs will be assessed, and clinical laboratory  values, vital signs, and electrocardiograms (ECGs) 
will be obtained to evaluate the safet y and tol erabili ty of single -agent MLN0128 and 
MLN0128+MLN1117 in co mbinat ion.
Sparse PK samples will be co llected in Cycle 1 from all pat ients enro lled in Arms B and C for 
plasma PK analysis o f MLN0128 (Arms B and C) and MLN1117 (Arm C). Blood samples for all 
PK analyses will be collected at the time po ints specified in the Treatm ent Arm  B Sparse 
Pharmacokinet icSample Breakdown and Treatm ent Arm  C Sparse P harmacokinet ic Sample 
Breakdown .
Data generated in this study  may be combined wi th data from  other studies, in which the PK of 
MLN0128 or MLN1117 is characterized for a future populat ion PK analysis.
7.2 Number of Patients
The study  planned to enroll approximately 189 patients with mccRCC from approximately 60 to 
70study  centers in North America and Europe. A patient is considered to be enrolled in the study  
when he or she has been randomized into a treatment arm.
7.3 Duration of Study
Patients will  receive study  medicat ion(s) unt il disease pr ogressi on, unacceptable toxicit y, 
withdrawal  of cons ent, or study  closure. Pati ents who discontinue study medicat ion will co mplete 
an EOT visit 30 to 40 day s after the l ast dose of study  drug. The EOT visit should be conducted 
before the init iation of subs equent ant icancer therapy, even if it occurs less than 30 days after the 
last dose of study  drug.
A final analysis o f PFS will be performed after the required number of events has been observed, 
which is expected approximately 9 months after the last pati ent has been rando mized. 
The study  will be cl osed 2 y ears after the last patient is rando mized or when the last patient 
discontinues study  treatm ent.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
MLN0128, MLN1117
Study No. C31005 Page 31of 104
Protocol Incorporating Amendment 10 03 December 2018
8.0 STUDY POPULATION
8.1 Inclusion Criteria
Each patient must meet all of the fo llowing inclusion criteria to be enrolled in the study . 
1.Male or female pat ients aged 18 y ears or ol der.
2.Histologically confirmed RCC with a clear -cell component.
3.Evidence that the RCC i s advanced or m etastati c.
4.Radiologic evidence of progressive disease (according to RECIST versio n1.1) either during or 
within 6 m onths after stopping their most recent systemic therapy  for RCC before enrollment 
into this study .
5.At least 2 prior lines of systemic therapy  for advanced m etastatic ccRCC, including at least 1 
prior line of VEGF -targeted therapy , but not m ore than 4 total prior lines of systemic therapy . 
Exposure to more than 1 line of VEGF -targeted therapy  is acceptable. Patients may also have 
received prior therapies with interferon, IL -2, anti -PD1 antibodies, cabozantinib, or oth er 
experimental agents, but not prior therapy  with any agent that targets PI3K, AKT, or mTOR. 
6.Karno fsky perform ance status ≥70% (refer to Appendix D).
7.Life expectancy  of ≥3 m onths.
8.Female pat ients who:
Are postm enopausal  for at l east 1 y ear before the Screening visit, OR
Are surgically  sterile, OR
If they  are of  childbearing potential, agree to practice 1 highly effect ive method of 
contraception and 1 additional effect ive (barrier) method (See Appendix E), at the sam e 
time, fro m the time of signing the informed consent through 90 days (or longer, as 
mandated by  local labeling [eg, USPI, SmPC, etc]) after the last dose of study  drug, OR
Agree to practice true abst inence, when this is in line wit h the preferred and usual lifest yle 
of the patient. (Periodic abst inence [eg, calendar, ovulat ion, symptother mal, postovulatio n 
methods], withdrawal, spermicides only, and lactatio nal amenorrhea are not acceptable 
methods of contraception. Female and male condoms should not be used together.)
Male patients, even if surgically  sterilized (ie, status postvasectomy) , who:
Agree to practice highly effect ive barrier contraception during the ent ire study  treatm ent 
period and through 120 day s after the l ast dose of study  drug (or l onger, as m andated by  
local labeling [eg, USPI, SmPC, etc]), OR
Agree to practice true abst inence, when this is in line wit h the preferred and usual lifest yle 
of the patient. (Periodic abst inence [eg, calendar, ovulat ion, symptothermal, postovulatio n 
methods for the female partner], withdrawal, spermicides only, and lactational amenorrhea 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
MLN0128, MLN1117
Study No. C31005 Page 32of 104
Protocol Incorporating Amendment 10 03 December 2018
are no t acceptable methods of contraception. Female and male condo ms should not be used 
together.)
Agree not to donate sperm during the course of this study or within 120 days after receiving 
their last dose of study  drug.
9.Suitable venous access for the study -required bl ood sam pling.
10.Screening clinical laboratory  values as specified below: 
Absolute neutrophil count (ANC) 2000/ L and platelet count 100,000/ L.
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) 2.5 times the 
upper limit of the norm al range (ULN).
Total  bilirubin 1.5ULN.
Estimated creatinine clearance by Cockcroft -Gault ≥40 mL/min/1.73m2(see Appendix F).
Glycosylated hemogl obin (HbA1c) <7.0%, fast ing serum glucose 130 mg/dL, and fast ing 
triglyceri des 300mg/dL.
11.At least 14 days since the end of prior sy stemic VEGF -targeted treatment (ie, sunit inib, 
pazopanib, axit inib, or sorafenib), radiotherapy , or surgi cal procedure wi th reso lution of all 
treatm ent-related toxicit y (except al opeci a and hypothy roidism) ei ther to Grade 0 or 1 
(NCI CTCAE versio n 4.03) or to Baseline.
12.At least 21 days since the last dose of bevacizumab, other antibody , or interferon.
13.Voluntary  written consen t must be given before performance of any study -related procedure 
not part of standard medical care, with the understanding that consent may be withdrawn by 
the pati ent at any  time wi thout prej udice to future medical care.
8.2 Exclusion Criteria
Patients m eeting any  of the fo llowing exclusio n criteri a are not to be enrolled in the study .
1.Central  nervous system (CNS) metastasis.
2.Other clinically significant co -morbidities, such as uncontrolled pulmo nary disease, active 
CNS di sease, active infect ion, or any  other condi tion that might compro mise the patient’s 
participat ion in the study.
3.Known human immunodeficiency virus infect ion.
4.Known hepat itis B surface ant igen-positive, or known or suspected active hepat itis C 
infect ion.
5.Manifestati ons o f malabsorption due to prior GI surgery, GI disease, or for an unknown reaso n 
that may  alter the absorpti on of  everolimus, MLN0128, or MLN1117. In addit ion, pati ents 
with enteri c stom ata are excluded.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
MLN0128, MLN1117
Study No. C31005 Page 33of 104
Protocol Incorporating Amendment 10 03 December 2018
6.Women who are either breast feeding or pregnant.
7.History  of any of the fo llowing wit hin the last 6 months before administration of the first dose 
of study  drug:
Ischemic my ocardial  event, i ncluding angina requiring therapy  and artery  
revascularization procedures.
Ischemic cerebrovascular event, including transient ischemic attack an d artery  
revascularization procedures.
Requi rement for inotropi c support (excl uding di goxin), or seri ous (uncontrolled) cardiac 
arrhy thmia (incl uding atrial  flutter/fibrillat ion, ventri cular fibrillat ion, or ventricular 
tachy cardi a).
Placement of a pacemak er for control  of rhythm.
New York Heart Associat ion Class III or IV heart failure (see Appendix G).
Pulmo nary embo lism.
8.Significant active cardio vascular or pulm onary disease incl uding:
Uncontrolled hypertensio n (ie, either systolic blood pressure >160 mm Hg or diastolic 
blood pressure >95 mm Hg). Use of antihypertensive agents to control hypertensio n before 
Cycle 1 Day  1 is allowed.
Pulmo nary hyperten sion.
Uncontrolled asthma or oxy gen saturation <90% by  arteri al blood gas analysis or pul se 
oximetry  on room  air.
Significant valvular disease; severe regurgitation or stenosis by  imaging independent of 
symptom  control  with medical intervention; or history of valve replacement.
Medically  significant (symptom atic) bradycardia.
History  of arrhy thmia requiring an implantable cardiac defibrillator.
Baseline prolongat ion of the rate -corrected QT interval (QTc; eg, repeated demonstration 
of QTc interval >480 msec , or history  of congeni tal, long-QT syndro me, or torsades de 
pointes).
9.Diagnosed or treated for another malignancy wit hin 2 y ears before administration of the first 
dose of study drug, or previously diagnosed with another malignancy and have any evidence o f 
residual disease. Pati ents wi th nonmelano ma skin cancer, superficial bladder cancer, very low 
risk prostate on observat ion, or carcino ma in situ of any ty pe are not excluded if they have 
undergone co mplete resection.
10.Prior therapy  with agents that target PI3K, AKT, or mTOR. Patients with known 
hypersensit ivity to everolimus or rapamycin derivatives are also excluded.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
MLN0128, MLN1117
Study No. C31005 Page 34of 104
Protocol Incorporating Amendment 10 03 December 2018
11.Any serious medical or psy chiatri c illness that could, in the invest igator’s opinio n, potenti ally 
interfere wi th the com pletion of treatment according to this protocol.
12.Patients who have taken a PPI within 3 days before receiving the first dose of study  drug.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
MLN0128, MLN1117
Study No. C31005 Page 35of 104
Protocol Incorporating Amendment 10 03 December 2018
9.0 STUDY DRUG
9.1 Study Drug Administration
All protocol -specific criteria for administration of MLN0128 or MLN1117 must be met and 
docum ented before study  drug administrati on. Study  drug will be administered only to eligible 
patients under the supervisio n of the invest igator or ident ified subinvest igator(s).
For Arm B, weekly MLN0128 will be administered with a light meal. Examples of a light meal are 
provi ded in Table 9.a. Patients shoul d begin consuming the light meal no more than 30 minutes 
before taking the weekly dose of MLN0128. It is recommended that each dose of MLN0128 be given orally wit h approximately (at least) 8 ounces (240 mL) of water.
Table 9.a Examples of a Light Meal
Low-Fat Breakfast Light Snack
Nutritional information Approximately 330 calories, with 9 g 
of fatApproximately 100 to 300 calories, with 1.5 g 
of fat
Example 2 slices of toast with 1 teaspoon of
low-fat margarine, 1 teaspoon of jelly, 
and 8 oz of skimmed milk3.63 oz pudding cup or 1 slice of toast with 
1teaspoon of jelly and 8 oz of skimmed milk
For Arm C, MLN0128 and MLN1117 will be administered on an empt y stom ach. Pati ents shoul d 
be instructed to refrain fro m eat ing and drinking (except for water and prescribed medicat ions) for 
2hours before and 1 hour after each dose. Each dose of MLN0128 and MLN1117 will be given 
orally  with approximately (at least) 8 ounces (240 mL) of water.
Cycl es consist of 28 day s for all  treatm ent arm s. In Treatm ent Arm  A, evero limus will be 
administered QD (every day o f a 28 -day treatm ent cy cle). In Treatment Arm B, MLN0128 will be 
administered once weekly (on Days 1, 8, 15, and 22 of a 28 -day treatment cy cle) and shoul d be 
taken on the same day  of each week. In Treatm ent Arm C, MLN0128 and MLN1117 will be 
administered together, 3 consecut ive days per week (on Days 1- 3, 8-10, 15- 17, and 22 -24 of a 
28-day treatm ent cy cle), and shoul d be taken on the same days o f each week. 
Patients should be instructed to take their study medicat ion at approximately the same time on each 
scheduled dosing day  and not to take m ore than the prescribed dose at any  time. MLN0128 and 
MLN1117 should always be taken together, at the sa me time, when dosed on the same day. 
Patients shoul d swall ow the study  medicat ion whole and not chew it, open it, or manipulate it in 
any way before swallowing. If a pat ient does not take their MLN0128 and/or MLN1117 doses 
within 12 hours after the schedul ed dosing time (for patients in Arm A or C) or within 24 hours 
after the scheduled dosing t ime (for patients in Arm B), then the dose should be skipped and 
considered a missed dose. Patients should record any missed doses in their diary  (see the Study  
Manu al) and resume drug administration at the next scheduled t ime with the prescribed dosage.
If severe emesis or mucosit is prevents the patient from taking scheduled doses, that dose will be 
skipped. If emesis occurs after study medicat ion ingestion, the dose will not be readministered, and 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
MLN0128, MLN1117
Study No. C31005 Page 36of 104
Protocol Incorporating Amendment 10 03 December 2018
patients shoul d resume dosing at the next scheduled time wit h the prescribed dosage. Patients 
shoul d record the occurrence of the emesis in their dosing diaries (see the Study  Manual). Under 
no ci rcumstance should a patient repeat a dose or double -up doses.
9.2 Reference/Control Therapy 
Everolimus can be taken either with or without food according to either the USPI [23] or Sm PC 
[24]. Patients should be instructed to take their study  medicat ion at approximately the same time 
on each scheduled dosing day and not to take more than the prescribed dose at any t ime. 
9.3 Dose Modification Guidelines
This sect ion describes dose modifi cation gui delines for study  drugs MLN0128 and MLN1117. 
Any dose modificat ions for everolimus should fo llow the guidelines provided in the current USPI 
[23] or Sm PC [24] for everolimus. Refer to Section 9.7for dose adjust ment guidelines rel ated to 
the management of clinical events. 
9.3.1 Intrapatient Dose Escalation
Intrapatient dose escalat ion is not allowed. 
9.3.2 Criteria for Beginning or Delaying a Subsequent Treatment Cycle
MLN0128 and MLN1117 should be administered in continuous cycles, which should cont inue 
unless the pat ient has a Grade 3 or greater MLN0128 -and/or MLN1117 -related event. Guidelines 
for dose interruption are in Section 9.3.3 and for dose reduction are in Section 9.3.4 . 
9.3.3 Criteria for Dose Interruption During a Cycle
Administrati on of  MLN0128 and the combinat ion of MLN0128+MLN1117 should be withheld 
for treat ment-related toxicit ies that are Grade 3 or higher despite supportive treatment per standard 
clinical practice. 
The fo llowing nonhematologic toxicit ies attributed to either MLN0128 or MLN1117 would not 
requi re dose interruption:
Grade 3 or higher nausea a nd/or emesis in the absence o f optimal ant iemetic prophylaxis. 
(Optimal ant iemetic prophylaxis is defined as an ant iemetic regimen that emplo ys both a 
5-HT3 antagonist and a corticosteroid given in standard doses and according to standard 
schedules.)
Grade 3 or higher diarrhea that occurs in the absence of optimal supportive therapy.
Grade 3 fat igue.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
MLN0128, MLN1117
Study No. C31005 Page 37of 104
Protocol Incorporating Amendment 10 03 December 2018
9.3.4 Criteria for Dose Reduction
9.3.4.1 Single -Agent MLN0128 Once Weekly (Arm B)
MLN0128 administration should be withheld for treatment -related AEs that are Grade 3 or hi gher 
despite supportive treatment per standard clinical practice. If the event resolves to Grade 1 (or 
Grade 2 for hy perglycemia or rash, as detailed in Sections 9.7.1 and 9.7.4, respectively) or to 
baseline values within 3 weeks of interrupting treatment, then the patient may resume study 
treatment at a dose reduced by  1 level (Table 9.b). If a patient does not tol erate 10 mg, then the 
investigator and the project clinician should discuss wh ether the pati ent woul d benefit fro m a 
further dose reduction.
Table 9.b Dose Modifications for Single -Agent MLN0128
Dose Level Dose Regimen MLN0128 Capsules: Number and Strength
0 30 mg QW Six 5 -mg capsules 
1 20 mg QW Four 5 -mg capsules 
2 15 mg QW Three 5 -mg capsule 
3 10 mg QW Two 5 -mg capsules 
9.3.4.2 MLN0128+MLN1117 (Arm C)
The primary  principle for dose reduction in Arm C is to maintain the 200 mg dose of MLN1117, 
which is considered the minimum efficacious dose when combined wit h MLN0128. Thus, the 
dose of MLN0128 will be reduced, if necessary , while the dose and schedule of MLN1117 is 
maintained when study  drug administration is resumed ( Table 9.c).
If the Grade 3 or higher event that led to dose interruption resolves to Grade 1 (or Grade 2 for 
hyperglycemia or rash, as detailed in Sect ions 9.7.1 and 9.7.4, respectively) or baseline value 
within 3 weeks of interrupting t reatment, then the patient may resume combinat ion study treatment 
provi ded that treatment with study  drug is thought to be beneficial for the patient by  the 
investigator and with the sponsor’s approval. In this case, the patient may resume study  treatm ent 
with MLN1117 at 200 mg QD×3 days and MLN0128 reduced by 1 dose level; for interruptions 
due to Grade 3 elevations of ALT or AST, study  treatm ent m ay be resumed at the pri or dose 
without dose reduction (Section 9.7.8 ).
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
MLN0128, MLN1117
Study No. C31005 Page 38of 104
Protocol Incorporating Amendment 10 03 December 2018
Table 9.c Dose Modifications for MLN0128 in Combination with MLN1117
Dose LevelDose QD ×3 days per week
MLN0128 Capsules: Number and Strength MLN0128 MLN1117 
0 4 mg 200 mg One 3 mg capsule and one 1 mg capsule
1 3 mg 200 mg One 3 mg capsule
2 2 mg 200 mg Two 1 mg capsules
3 1 mg 200 mg One 1 mg capsule
9.3.5 Criteria for Discontinuation of Study Drug
For pati ents in Arm A, everolimus should be discont inued according to the current guidance 
provi ded in eit her the USPI [23] or Sm PC [24] for evero limus.
If study  drug administrati on (in Arm B or Arm C) is delayed for more than 3 weeks 
(21consecut ive days) due to study drug- related toxicit y despi te supportive treatment per standard 
clinical pract ice, or more than 3 dose reductions o f study  drug are requ ired in a pat ient, then study 
drug treatment should be stopped. However, if the patient has evidence of clinical benefit and is 
considered to possibly benefit from cont inued protocol treatment, the patient may cont inue 
protocol  treatment with further dose reductions, upon review and approval by the project clinician , 
or parti cipate in the PTA program if available . 
For all pat ients, the EOT visit should be co mpleted within 30 to 40 days after the last dose of study 
drug. 
9.4 Excluded Concomitant Medications an d Procedures
9.4.1 Excluded Concomitant Medications and Procedures for Arm A 
The current USPI [23] and SmPC [24] for everolimus list the excluded medicat ions for patients 
receiving everolimus in Arm A of the study . 
In addit ion, these specific exclusio ns also apply to Arm A:
Other invest igational agents including mTOR, PI3K, and AKT inhibitors.
Other anticancer ther apies, including chemotherapy , immunotherapy , radi oimmunotherapy , 
targeted agents, radiat ion, or surgery  (pati ents can have palliat ive radiat ion or surgery  during 
the study  for pre -exist ing lesio ns). Palliat ive therapy for target lesio ns is not allowed.
Systemic corti costeroi ds (ei ther IV or oral  steroi ds), unl ess necessary  for treatm ent of a study  
drug-related AE (eg, rash). Inhalers and low -dose repl acement therapy  are all owed.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
MLN0128, MLN1117
Study No. C31005 Page 39of 104
Protocol Incorporating Amendment 10 03 December 2018
9.4.2 Excluded Concomitant Medications and Procedures for Arms B and C 
All prescrip tion and over -the-counter medicat ions, including influenza vaccines, taken by a patient 
as of the first administration o f study drug through 30 days fo llowing the last dose will be recorded 
on the designated electronic case report form (eCRF).
The fo llowing m edicat ions, therapies, and procedures are prohibited during the study :
Other invest igational agents including mTOR, PI3K, and AKT inhibitors.
Other anticancer therapies, including chemotherapy, immunotherapy , radi oimmunotherapy , 
targeted agents, radiat ion, or surgery  (pati ents can have palliat ive radiat ion or surgery  during 
the study  for pre -exist ing lesio ns).
Systemic corti costeroi ds (ei ther IV or oral  steroi ds, excluding inhalers), unless necessary  for 
treatm ent of a study  drug -related AE (eg, rash).
Strong cytochrome P450 (CYP) 1A2 inhibitors and CYP inducers should be administered only 
with caution and at the discret ion of the invest igator (see Appendix Hfor a list of these agents). 
Alternat ive treatments, if available, should be considered.
Concomitant administration of any PPI is prohibited only for pati ents randomized to 
MLN0128 + MLN1117. Patients receiving PPI therapy  before enrollment must s top using the 
PPI 3days before their first dose of study drugs. Examples of PPIs include omeprazo le, 
esomeprazo le, pantoprazole, lansoprazole, and rabeprazole.
Histamine H2 receptor antagonists may be allo wed, if needed, provided that the histamine 
H2receptor antagonist is not taken within 12 hours before and within 6 hours after MLN0128 
or MLN0128+MLN1117 administration. Patients receiving histamine H2 receptor antagonists 
before enro llment must stop using these medications for at least 24 hours before their first dose 
of study  drug. Exam ples of histamine H2 receptor antagonists include ranit idine, famot idine, 
and nizat idine. Cimet idine, a m oderate CYP1A2 inhibitor, is not recommended as a 
first-choice H2 receptor antagonist (see Appendix H).
Administrati on of  neutralizing antacids and calcium preparat ions is permitted except fro m 
4hours before until 2 hours after MLN0128 or MLN0128+MLN1117 administrat ion. Some 
antigas preparations may also have antacid properties, and should also not be permitted from 
4hours before until 2 hours after study  drug administration.
9.4.3 Potential for Drug- Drug Interactions with MLN0128 and/or MLN1117
On the basis of in vitro drug metabo lism studies, MLN1117 is primarily metabo lized by CYP3A4 
(72%), wi th minor contribut ions from CYPs 1A2 (12%), 2C9 (9%), and 2C8 (6%). Recent ly 
completed in vitro m etabo lism experiments in human hepatocytes using 14C -labeled MLN0128 
suggest that M LN0128 is metabolized primarily via CYP1A2 (approximately 31% -40%), wi th a 
minor contribution fro m CYP3A4 (approximately  11% -22%). These data suggest that MLN0128 
is also metabo lized by direct glucuronidat ion (approximately 22%) and an unident ified nonurid ine 
diphosphate gl ucuronosyltransferase pathway  (approximately  18%). The new data differ fro m the 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
MLN0128, MLN1117
Study No. C31005 Page 40of 104
Protocol Incorporating Amendment 10 03 December 2018
previous in vitro CYP phenoty ping data obtained using recombinant CYP enzymes, which 
suggested the invo lvement of CYP2C9 (approximately 35%), CYP2C19 (approxi mately 28%), 
and CYP3A4 (approximately 28%) in MLN0128 metabo lism. Neither MLN1117 nor MLN0128 
inhibits or induces any of the major CYP enzymes. On the basis o f this informat ion, the risk of a 
drug-drug interaction between MLN1117 and MLN0128 is considered to be l ow. In addi tion, 
physio logically based PK modeling and simulat ion using the new metabo lism data for MLN0128 
suggest that the risk for a metabo lism-based drug- drug interaction with MLN0128 appears to be 
low. Therefore, strong CYP1A2 inhibitors and C YP inducers should be administered with cautio n 
and at the discret ion of the investigator during the study  (see Appendix H).
There i s potenti al for ML N1117 to affect the PK of breast cancer resistance protein (BCRP) 
substrates (eg, methotrexate, imat inib, topotecan, lapatinib, rosuvastatin, etc) and organic cation 
transporter protein 1 (OCT1) or organic cat ion transporter protein 2 (OCT2) substrates 
(eg,metformin, cimet idine, am antadine, famot idine, pindo lol, etc; see Appendix I). If patients 
requi re treatm ent wi th medicat ions that are known substrates of these transporters, then these 
agents should be administered with caut ion or alternat ive treatment options should be considered. 
It is recommended that patients requiring metformin for treatment of hyperglycemia result ing 
from MLN0128+MLN1117 administration that treatment should begin wit h the l owest effect ive 
dose of met formin, and pat ients should have their blood o r serum glucose monitored closely. 
9.5 Permitted Concomitant Medications and Procedures 
Prophylactic use of ant iemetic, ant inausea, and ant idiarrheal medications is encouraged, and these 
may be administered before the first dose and subsequent doses of study drug, as needed 
throughout the study , and as clinically  indicated per standard practice. 
Other medications considered necessary  for the safety  and wellbeing of the patient may be 
administered at the discret ion of the invest igator. Any conco mitant m edicat ions added or 
discontinued during the study  shoul d be recorded on the eCRF.
9.6 Precautions and Restrictions
The use of live vaccines and close contact with those who have received live vaccines should be 
avoided during treatment with study  drug. Examples of l ive vaccines are intranasal influenza, 
measles, mumps, rubella, oral polio, Bacille Calmette -Guerin, yellow fever, varicella, and TY21a 
typhoid vaccines.
No dietary restrict ions will be imposed on study patients other than fast ing for glucose monitoring 
(refer to Secti ons 9.7.1 , 10.4.13, and 10.4.14 ). Patients receiving MLN0128 and MLN1117 in Ar m 
C shoul d refrain from  eating or drinking for 2 hours before and 1 hour after each dose (per 
Section9.1).
Patients who show evidence of hyperglycemia during the study  shoul d be encouraged to follow a 
low-carbohydrate diet.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
MLN0128, MLN1117
Study No. C31005 Page 41of 104
Protocol Incorporating Amendment 10 03 December 2018
Patients should be encouraged to drink at least 20 ounces of fluids a day , especially  on days 
requi ring fasting (per protocol), with administration of IV fluids in the clinic as indicated to avoid 
dehydrat ion.
It is not known what effects either MLN0128 or MLN1117 has on hu man pregnancy  or 
development of the embryo or fetus. Therefore, female pat ients participating in this study  shoul d 
avoid beco ming pregnant, and male patients should avo id impregnat ing a female partner. 
Nonsterilized female patients of reproductive age grou p and male patients should use effect ive 
methods of contraception through defined periods and after study  treatm ent as specified below. 
Female pat ients must m eet one of the following:
Postmenopausal  for at l east 1 year before the Screening visit, OR
Surgi cally sterile, OR
If they  are of  childbearing potential, agree to practice 1 highly effect ive method of 
contraception and 1 addit ional effect ive (barrier) method (See Appendix E), at the sam e time, 
from the time of signing of the informed consent through 90 day s(or longer, as mandated by  
local labeling [eg, USPI, SmPC, etc]) after the last dose of study  drug, OR
Agree to practice true abstinence, when this is in line wit h the preferred and usual lifest yle of 
the pati ent. (Peri odic abst inence [eg, calendar, ovulat ion, symptothermal, postovulat ion 
methods], withdrawal, spermicides only, and lactatio nal amenorrhea are not acceptable 
methods of contraceptio n. Female and male condoms should not be used together.) 
Male patients, even if surgically  sterilized (ie, status postvasectomy) must agree to one of the 
following:
Agree to practice highly effect ive barrier contraception during the ent ire study  treatm ent
period and through 120days after the l ast dose of study  drug (or l onger, as m andated by  local 
labeling [eg, USPI, SmPC, etc]), OR
Agree to practice true abstinence, when this is in line wit h the preferred and usual lifest yle of 
the pati ent. (Peri odic abs tinence [eg, calendar, ovulat ion, symptothermal, postovulat ion 
methods], withdrawal, spermicides only, and lactatio nal amenorrhea are not acceptable 
methods of contraception. Female and male condoms should not be used together.)
Agree not to donate sperm d uring the course of this study  or wi thin 120 days after receiving 
their last dose of study  drug.
9.7 Management of Clinical Events 
For current guidance on the management of clinical events for patients receiving evero limus in 
Arm A, refer to either the USPI [23] or Sm PC [24] for everolimus. 
For pati ents being treated with single -agent MLN0128 QW (Arm B), MLN0128 administration 
shoul d be wi thhel d for trea tment-related AEs that are Grade 3 or higher despite supportive 
treatm ent per standard clinical pract ice. If the event resolves to Grade 1 (or Grade 2 for 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
MLN0128, MLN1117
Study No. C31005 Page 42of 104
Protocol Incorporating Amendment 10 03 December 2018
hyperglycemia or rash, as detailed in Sect ions 9.7.1 and 9.7.4 , respectively) or to baseline values 
within 3 weeks of interrupting treatment , then the patient may  resume study  treatm ent at a dose 
reduced by  1 level  (Table 9.b).
For pati ents being treated with MLN0128+MLN1117 (Arm C), the pr imary principle for dose 
reducti on is to m aintain the 200 mg dose of MLN1117, which is considered the minimum 
efficacious dose when combined with MLN0128. Thus, the dose of MLN0128 will be reduced, if 
necessary , while the dose and schedule of MLN1117 is ma intained when study  drug 
administration is resumed ( Table 9.c).
If the Grade 3 or higher event that led to dose interruption resolves to Grade 1 (or Gr ade 2 for 
hyperglycemia or rash, as detailed in Sect ions 9.7.1 and 9.7.4 , respectively) or baseline value 
within 3 weeks of interrupting treatment, then the patient may resume combinat ion study treatment 
with MLN1117 at 200 mg QD×3 days and MLN0128 reduced by 1 do se level.
9.7.1 Management of Hyperglycemia
On the basis of the clinical experience in MLN0128 trials, most episodes of hyperglycemia observed occurred within the first 60 day s after initi ation of treatment with MLN0128 and have 
been eit her Grade 1 or Grade 2, a nd have responded quickly to oral metformin. Hyperglycemia has 
not been dose -limit ing since the inst itution of  a standard regimen for early treatment of 
hyperglycemia.
All patients developing hyperglycemia during the study  shoul d have thei r glucose cl osely
monitored by  study  staff. The invest igator may choose to continue close monitoring of patients 
who develop Grade 1 hyperglycemia (fast ing glucose >ULN ≤160 mg/dL) or, alternatively, 
consider init iating treatment with an oral hypoglycemic agent, such as me tformin. All pat ients 
with ≥Grade 2 hyperglycemia (fasting glucose >160 mg/dL) must be treated aggressively wit h oral 
hypoglycemic agents and/or insulin as clinically indicated. The invest igator should consult an 
endocrino logist, if needed, to aid in optim izing the patient’s hyperglycemia treatment plan.
It is recommended that patients be init ially treated with a fast -acting insulin sensit izer such as 
metformin at 500 mg orally QD, and t itrate up to a maximum of 1000 mg orally twice daily as 
needed. Concurr ent addit ion to m etformin of dipepti dyl pept idase -4 inhibitors (eg, sitaglipt in or 
vildaglipt in) and/or insulin should also be considered. Oral sulfo nylureas (eg, glipizide or 
glyburide) should be used with caut ion, due to the higher risk of inducing hypog lycemia in 
patients. The dose of oral hypoglycemic agents should be adjusted in pat ients with renal 
insufficiency. In addit ion, pati ents shoul d be encouraged to follow a low -carbohydrate diet once 
hyperglycemia is first observed.
If any fast ing serum gluco se reading performed at the site indicates hyperglycemia (>ULN or 
≥110 mg/dL), the study  staff shoul d first confirm that the patient was fast ing at the time o f blood 
specimen collection (ie, nothing by mouth for at least 8 hours before collection). To aggressively 
manage the hyperglycemia per standard clinical practice, the fo llowing gui delines ( Table 9.d) are 
provi ded to ai d the invest igator in init iating ant iglycemic therapies.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
MLN0128, MLN1117
Study No. C31005 Page 43of 104
Protocol Incorporating Amendment 10 03 December 2018
Table 9.d Management of Hyperglycemia
Grade Description Treatment Dose Modification
1 Fasting blood sugar 
>ULN to 160 mg/dLContinue close monitoring of blood 
sugar.
Initiate oral hy poglycemic agent.None
2 >160 to 250 mg/dL Initiate oral hypoglycemic agent and/or 
insulin if not well controlled on oral 
agent.None
≥3 >250 mg/dL Initiate oral hypoglycemic agent and/or insulin. Hold study drug(s) until ≤Grade 2. 
(a)
Resume study drug based on timing 
of recover y after maximal 
treatment: 
≤1 week: resume study drug at 
same dose and schedule.
>1 but ≤2 weeks: reduce the 
dose of MLN0128 by 1 dose 
level (See Section 9.3.4 ). (b)
>2 weeks: stop study drug(s).
Prevention/Prophylaxis:
Follow fasting glucose levels during clinic visits.
Monitor home glucometer test results.
Check HbA1c levels ever y 3 mo nths during therapy .
Recommend lifestyle modifications, as appropriate (balanced diet, limited alcohol consumption, increased 
physical activity). 
Most episodes of Grade 1 or 2 hyperglycemia respond quickly to oral metformin. Early initiation of therapy at the 
lowest therapeutic dose is recommended to prevent higher-grade hyperglycemia.
Fasting blood glucose levels ≥150 mg/dL by glucometer should be followed by closer monitoring of serum 
glucose and possible intervention. 
(a) Study drug(s) refers to MLN0128 and MLN1117. If a patient is taking both MLN0128 and MLN1117, then both 
agents should be held.(b) As described in Section 9.3.4 and Section 9.7, dose reduction applies only to MLN0128 treatment. The dose of 
MLN1117 should be maintained at 200 mg when resuming treatment after an interruption of stud y drug or dose 
modification of MLN0128.
9.7.2 Management of Hyperlipidemia
Guidance on study  drug dose m odificat ion for patients with hyperlipidemia is provided in 
Table 9.e.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
MLN0128, MLN1117
Study No. C31005 Page 44of 104
Protocol Incorporating Amendment 10 03 December 2018
Table 9.e Management of Hyperlipidemia
Grade Description Treatment Dose Modification
1 Cholesterol:
>ULN -300 mg/dL
Triglycerides:
>150 -300 mg/dLNone None
2 Cholesterol:
>300 -400 mg/dL
Triglycerides:
>300 -500 mg/dL Treat hyperlipidemia according 
to standard guidelines.
Triglycerides ≥500 mg/dL 
should be treated urgently, 
due to risk of pancreatitis.Maintain dose, if tolerable.
If toxicity becomes intolerable, interrupt study drug(s) u ntil 
recover y to ≤Grade 1. Re -initiate 
study drug(s) at the same dose level. (a)
3 Cholesterol:
>400 -500 mg/dL
Triglycerides:
>500 -1000 mg/dLSame as for Grade 2. Hold study drug(s) until recover y 
to ≤Grade 1, then reinitiate study 
drug(s) with the dose of MLN0128 reduced by 1 level (Section 9.3.4 ). (a) (b)
4 Cholesterol:
>500 mg/dL
Triglycerides:
>1000 mg/dLSame as for Grade 2. Same as for Grade 3.
Prevention/Prophylaxis:
Recommend lifestyle modifications, as appropriate (balanced diet, limit alcohol consumption, increase physical activity ).
(a) Study drug(s) refers to MLN0128 and MLN1117. If a patient is taking both MLN0128 and MLN1117, then both 
agents should be held.(b) As described in Section 9.3.4 and Section 9.7, dose reduction applies only to MLN0128 treatment. The dose of 
MLN1117 should be maintained at 200 mg when resuming treatment after an interruption of study drug or dose 
modification of MLN0128.
9.7.3 Management of Oral Mucositis
Guidance on study drug dose modificat ion for patients with oral mucosit is is provided in Table 9.f.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
MLN0128, MLN1117
Study No. C31005 Page 45of 104
Protocol Incorporating Amendment 10 03 December 2018
Table 9.f Management of Oral Mucositis
Grade Description Treatment Dose Modification
1 Asymptomatic o r mild 
symptoms.Nonalcoholic mouth wash, or 0.9% 
salt water rinse.
Consider topical corticosteroids at 
earliest signs of mucositis.None
2 Moderate pain, not interfering 
with oral intake.
Modified diet indicated.Topical analgesic mouth 
treatments.
Topical corticosteroids.
Initiate antiviral or antifungal 
therapy , if indicated.Maintain study drug(s) dose if 
tolerable. (a)
Hold study drug(s) if intolerable until recover y to 
≤Grade 1, then restart at same 
dose.
3 Severe pain, interfering with 
oral intake.Same as for Grade 2.
Consider intralesional corticosteroids.Hold study drug(s) until recover y to ≤Grade 1, then 
restart study drug(s) with the 
dose of MLN0128 reduced by 
1level (Section 9.3.4 ). (a) (b)
4 Life-threatening 
consequences.Same as for Grade 2
Consider intralesional corticosteroidsStop study drug(s). (a)
Prevention/Prophylaxis:
Initiation of a nonalcoholic mouth wash, or 0.9% salt water rinses 4 to 6 times daily is strongly recommended at 
the start of therapy before signs of mucositis develop.
Avoid using agents containing hydrogen peroxide, iodine, and thyme derivatives in management of stomatitis, as 
they may  worsen mouth ulcers.
(a) Study drug(s) refers to MLN0128 and MLN1117. If a patient is taking both MLN0128 and MLN1117, then both 
agents should be held. (b) As described in Section 9.3.4 and S ection 9.7, dose reduction applies only to MLN0128 treatment. The dose of 
MLN1117 should be maintained at 200 mg when resuming treatment after an in terruption of study drug or dose 
modification of MLN0128.
9.7.4 Management of Rash
Patients who develop Grade 4 rash should permanent ly discont inue study  treatm ent, unl ess they  
derive clinical benefit, in which case they may be retreated at a reduced dose level after recovery  to 
Grade 1 severit y. Grade 4 rash is defined as rash acneiform/papulopustular with papules and/or 
pustul es covering any  percentage of body  surface area, which may  or m ay not be associ ated wi th 
symptoms of pruritus or tenderness, and are ass ociated wi th extensive superinfection, with IV 
antibiotics indicated; life -threatening consequences (NCI CTCAE versio n4.03, effective date 
14June 2010 [26]). 
Guidance on study  drug dose m odificat ion for patients with rash is provided in Table 9.g.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
MLN0128, MLN1117
Study No. C31005 Page 46of 104
Protocol Incorporating Amendment 10 03 December 2018
Table 9.g Management of Rash
Grade Description Treatment Dose Modification
≤2 Macules/papules covering 
≤30% body surface area with 
or without symptoms.Consider treatment with topical 
steroid cream/ointment and/or oral 
antihistamines or antibiotics.None
3 Macules/papules covering 
30% body surface area with 
or without symptoms.Consider treatment with topical 
steroid cream/ointment, oral 
antihistamines, oral antibiotics, and/o r pulsed steroids.Hold study drug(s) until ≤Grade 2. (a)
Resume study drug(s) based on timing of recover y:
≤3 weeks: reduce the dose of 
MLN0128 by 1 dose level 
(Section 9.3.4 ). (a) (b)
>3 weeks: stop study drug(s). (a)
Patients who develop Grade 4 rash should permanently discontinue study treatment, unless they derive clinical 
benefit, in which case they may be retreated at a reduced dose level after recover y to Grade 1 severity. Grade 4 rash 
is defined as rash acneifor m/papulopustular with papules and/or pustules covering any percentage of body surface 
area, which may or may not be associated with symptoms of pruritus or tenderness, and are associated with extensive 
superinfection, with IV antibiotics indicated; life th reatening consequences.
Prevention/Prophylaxis:
Rash should be managed aggressively. The investigator should consider consulting a dermatologist or other 
specialist, if needed.
A skin biopsy at the site of rash should be considered as soon as possible aft er the initial episode.
(a) Study drug(s) refers to MLN0128 and MLN1117. If a patient is taking both MLN0128 and MLN1117, then both 
agents should be held. (b) As described in Section 9.3.4 and Section 9.7, dose reduction applies only to MLN0128 treatment. The dose of 
MLN1 117 should be maintained at 200 mg when resuming treatment after an interruption of study drug or dose 
modification of MLN0128.
9.7.5 Management of Nausea/Vomiting
Guidance for pati ents wi th nausea and/or vomit ing is provided in Table 9.h.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
MLN0128, MLN1117
Study No. C31005 Page 47of 104
Protocol Incorporating Amendment 10 03 December 2018
Table 9.h Management of Nausea/Vomiting
Grade Description Treatment Dose Modification
≤2 Loss of appetite with or without 
decreased oral intake; 
1 to 5 episodes of vomiting within 
24hours.Maximize antiemetic therapy .
Consider IV fluid hydration.None
≥3 Inadequate oral intake; 
≥6 episodes of vomiting within 24hours.Maximize antiemetic therapy .
Initiate tube feeding, IVfluids, or TPN.If experienced for ≤72 hours, hold 
MLN0128 until ≤Grade 1, then 
resume MLN0128 without dose modification.
If experienced for >72 hours despite 
optimal therapy, hold study drug(s) 
until ≤Grade 1, then resum
e treatment 
with the dose of MLN0128 reduced 
by 1 level. (a) (b)
Prevention/Prophylaxis:
Prophy lactic use of antiemetic, antinausea, and antidiarrheal medications are encouraged and may be used before each 
MLN0128+MLN1117 dosing as needed throughout the study.
IVF=intravenous fluids, TPN=total parental nutrition.(a) Study drug(s) refers to MLN0128 and MLN1117. If a patient is taking both MLN0128 and MLN1117, then both agents should be held. 
(b) As described in Section 9.3.4 and Section 9.7, dose reduction applies only to MLN0128 treatment. The dose of 
MLN1117 should be maintained at 200 mg when resuming treatment after an interruption of study drug or dose 
modification of MLN0128.
9.7.6 Management of Cardiac Abnormalities
Management of Patients With Possible Cardiac Instability
For pati ents showin g signs of cardi ac instabilit y after MLN0128+MLN1117 administration, 
additional monitoring onsite before clinic discharge should be considered.
Management of Patients With Left Ventricular Dysfunction
Guidance for MLN0128+MLN1117 dose adjust ment for pati ents wi th left ventri cular dysfunct ion 
is provided in Table 9.i.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
MLN0128, MLN1117
Study No. C31005 Page 48of 104
Protocol Incorporating Amendment 10 03 December 2018
Table 9.i Management of Left Ventricular Dysfunction
Grade Description Dose Modification
1 Asymptomatic decline in:
LVEF >15% from baseline values, OR
LVEF >10% to 15% from baseline values and is 
below institution’s LLN.No change; continue study drug(s) at the same dose 
and schedule. (a)
2 Symptomatic cardiac dysfunction/congestive heart 
failure.Stop study drug(s). (a)
LLN=lower limit of normal, LVEF=left ventricular ejection fraction.
(a) Study drug(s) refers to MLN0128 and MLN1117. If a patient is taking both MLN0128 and MLN1117, then both agents should be held.
Management of Patients with QTc Interval Prolongation
Patients who experience persistent symptomat ic Grade 3 or Grade 4 QTc prolongat ion without 
another cause should permanent ly discontinue study treatment.
Guidance for MLN0128+MLN1117 dose adjust ment for pati ents exhibit ing a prol onged QTc 
interval  is provided in Table 9.j.
Table 9.j Management of QTc Interval Prolongation
Grade Description Treatment Dose Modification
2 480 msec QTc 
501 msecEvaluate for other possible causes (eg, 
electroly te disturbance, concomitant 
medication, etc).None; continue study drug(s) at the same 
dose and schedule. (a)
3 QTc 501msec Evaluate for other possible causes (eg, 
electroly tedisturbance, concomitant 
medication).(a)
Consider a formal consult by a cardiologist;
Notify the sponsor’s project clinician;
Additional ECGs may be performed at 
intervals that the treating physician deems clinically appropriate until repeated QTc measure ments fall or are below the 
threshold interval that triggered the repeat measurement.Hold study drug(s). (b)
Patients who experience persistent symptomatic Grade 3 or Grade 4 QTc 
prolongation without another cause should permanently discontinue study tre atment.
(a) A list of medications known to prolong the QTc interval can be found at https://www.crediblemeds.org/new -drug -list/ 
(b) Study drug(s) refers to MLN0128 and MLN1117. If a patient is taking both MLN0128 and MLN1117, then both agents should be held.
9.7.7 Management of Other Nonhematologic Toxicities
Guidance on dose adj ustment for pati ents wi th other nonhematol ogic toxi cities is provi ded in 
Table 9.k. 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
MLN0128, MLN1117
Study No. C31005 Page 49of 104
Protocol Incorporating Amendment 10 03 December 2018
Patients who develop Grade 4 nonhematological toxicit ies (with the except ion of iso lated 
non-clinically  significant l aboratory  values) shoul d perm anently discont inue study  treatment, 
unless they derive clinical benefit, in which case they may be ret reated at a reduced dose level after 
recovery  to Grade 1 severit y. 
Table 9.k Management of Other Nonhematologic Toxicities (Including Asthenia, 
Weakness, and Fatigue)
Grade Description Treatment Dose Mod ification
1 Mild; asy mptomatic or mild 
symptoms; clinical or diagnostic 
observations only; intervention 
not indicated.Initiate appropriate medical 
therapy  and monitor.If tolerable, then no adjustment is 
required.
2 Moderate; minimal, local or 
noninvasive intervention 
indicated.Initiate appropriate medical 
therapy  and monitor.If tolerable, no adjustment required.
If toxicity becomes intolerable, 
hold study drug(s) until recover y 
to ≤Grade 1, then reinitiate at 
same dose. 
≥3 Severe or medical ly significant 
but not immediately life-
threatening; hospitalization or 
prolongation of hospitalization indicatedHold study drug(s) until recover y to 
≤Grade1. Reinitiate study drug(s) 
with the dose of MLN0128 reduced 
by 1 level (Section 9.3.4 ) (a) (b)
Patients who develop Grade 4 
nonhematological toxicities (with the 
exception of isolated non -clinically 
significant laboratory values) should 
perman ently discontinue study 
treatment, unless they derive clinical 
benefit, in which case they may be 
retreated at a reduced dose level after 
recover y to Grade 1 severity.
(a) Study drug(s) refers to MLN0128 and MLN1117. If a patient is taking both MLN0128 and MLN1117, then both 
agents should be held. (b) As described in Section 9.3.4 and Section 9.7, dose reduction applies only to MLN0128 treatment. The dose of 
MLN1117 should be maintained at 200 mg when resumi ng treatment after an interruption of study drug or dose 
modification of MLN0128.
9.7.8 Management of AST/ALT Elevations
Patients who develop Grade 3 or Grade 4 AST/ALT elevat ion in combinat ion with Grade 2 total  
bilirubin elevat ion when alternat ive causes canno t be ident ified (ie, Hy’s Law) should permanent ly 
discontinue study  treatm ent.
Guidance on dose adj ustment for pati ents wi th AST/ALT el evati ons is provi ded in Table 9.l.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
MLN0128, MLN1117
Study No. C31005 Page 50of 104
Protocol Incorporating Amendment 10 03 December 2018
Table 9.l Management of AST/ALT Elevations
Grade Description Treatment Dose Modification
1 >ULN to 3 ULN None None
2 Asymptomatic with levels 3 to 
5ULN; >3 ULN with the 
appearance of worsening fatigue, 
nausea, vomiting, right upper 
quadrant pain or tenderness, fever, rash, or eosinophilia.Closely monitor LFTs at least weekly or more frequently as indicated.
Assess patient for other causes of transaminitis (eg, past 
medical history, c oncomitant 
medications).None
3 >5 to 20 ULN; >5 ULN 
for >2 weeksSame as for Grade 2. Hold study drug(s) until ≤Grade 1; 
Restart MLN0128 and MLN1117 at 
the same doses. (a)
Permanently discontinue study 
treatment if in combination with Grade 2 total bil irubin elevation 
when alternative causes cannot be 
identified.
4 >20ULN Same as for Grade 2. Stop study drug(s). (a)
Prevention/Prophylaxis:
Ensure proper screening of patients for study participation.
LFTs=liver function tests.(a) Study drug(s) refers to MLN0128 and MLN1117. If a patient is taking both MLN0128 and MLN1117, then both 
agents should be held.
9.7.9 Management of Noninfectious Pneumonitis
Guidance for the management of pneumo nitis is provided in Table 9.m.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
MLN0128, MLN1117
Study No. C31005 Page 51of 104
Protocol Incorporating Amendment 10 03 December 2018
Table 9.m Management of Noninfectious Pneumonitis
Grade Description Treatment MLN0128 Dose Modification
1 Asymptomatic: Radiographic findings only. Rule out infection and 
closely  monito r.None
2 Symptomatic:
Not interfering with activities of daily 
living.Rule out infection and 
consider treatment with corticosteroids until symptoms improve to 
≤Grade 1.Interrupt study drug(s) 
When symptoms ≤Grade 1, 
reinitiate study drug(s) with the dose of MLN0128 reduced by 1 level (Section 
9.3.4). 
If no recove ry within 4
weeks, 
then discontinue study 
drug(s). (a,b)
3 Symptomatic:
Interfering with activities of daily living;
Requires administration of oxygen.Rule out infection and 
consider treatment with 
corticosteroids until symptoms improve to 
≤Grade 1.Interrupt study drug(s) until 
symptoms resolve to ≤Grade 1. (a)
Consider reinitiating study drug(s) with the dose of MLN0128 reduced by 1 level 
(Section 9.3.4 ). (b)
If toxicity recurs at Grade 3, discontinue study drug(s).
4 Life-threatening:
Ventilatory support indicated.Rule out infection and 
consider treatment with 
corticosteroids.Stop study drug(s). (a)
(a) Study drug(s) refers to MLN0128 and MLN1117. If a patient is taking both MLN0128 and MLN1117, then both 
agents should be held. (b) As described in Section 9.3.4 and Section 9.7, dose reduction applies only to MLN0128 treatment. The dose of 
MLN1117 should be maintained at 200 mg when resuming treatment after an interruption of study drug or dose modification of MLN01 28.
9.7.10 Management of Opportunistic Infections
Opportuni stic infect ions, such as Pneumocystis jirovecii (carinii ) pneumonia (PJP, PCP), are a 
known risk for patients receiving everolimus treatment; and prophylaxis for PJP/PCP should be 
considered when conco mitant use of corti costeroi ds or other immunosuppressive agents is 
requi red (refer to Section 9.4and Sect ion 9.5for guidance regarding conco mitant medicat ion use). 
Although opportunist ic infections, including PCP, have not been observed in patients receiving 
MLN0128 or MLN1117 treatment, opportun istic infect ions should be considered during 
diagnosti c evaluat ion of symptomat ic pat ients.
9.7.11 Blinding and Unblinding
Not applicable. This is an open- label study .
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
MLN0128, MLN1117
Study No. C31005 Page 52of 104
Protocol Incorporating Amendment 10 03 December 2018
9.8 Description of Investigational Agents
MLN0128 will be supplied as capsules for oral administrat ion. MLN0128 is available in 3 dose 
strengths (1, 3, and 5 mg), each containing 1, 3, and 5 mg of MLN0128, respect ively, in addit ion to 
the following inact ive ingredients: microcrystalline cellulose (so lid filler/diluents), magnesium 
stearate (l ubricant), and hard gelat in capsule.
All 3 dose strengths are formulated into size -2 capsules, and each dose strength is different iated by 
color, as listed below:
1mg MLN0128 capsules: white opaque.
3mg MLN0128 capsules: Swedish orange opaque.
5mg MLN0128 capsules: gray  opaque.
MLN1117 will be supplied as 100 mg capsules for oral administration. Each 100 mg capsule 
contains 100 mg o f MLN1117 and the following inact ive ingredients: hard gelat in capsule and 
small amount of collo idal silicon dio xide. See the M LN0128, MLN1117, and 
MLN0128+MLN1117 IBs for full details. 
Everolimus is co mmercially available and will be supplied by Millennium as 10 mg, 5 mg, and 
2.5mg tablets for oral administration.
9.9 Preparation, Reconstitution, and Dispensation
MLN0128 and MLN111 7 dosage forms will be provided in labeled bottles in accordance with all 
applicable regulat ions. Materials provided by the sponsor should be dispensed to patients with 
clear administration instructions from the invest igator.
MLN0128 and MLN1117 are anticancer drugs and, as with other potentially toxic co mpounds, 
cauti on shoul d be exercised when handling MLN0128 and MLN1117 capsules.
9.10 Packaging and Labeling
MLN0128 and MLN1117 will be provided by Millennium and will be handled at the invest igative 
site as op en-label material.
MLN0128 will be provided in 30 -ct, 60 -cc high -densit y polyethylene (HDPE) bottles with 
polypropylene, child- resistant caps and induct ion seal . MLN1117 will be provided in 14 -ct, 30 -cc 
HDPE bottl es wi th child -resistant caps and induct ion seal. 
MLN0128 and MLN1117 are packaged and labeled in accordance with all applicable regulat ions.
Everolimus will be supplied by Millennium to all participat ing sites. Everolimus will be provided 
as blister packs and will be labeled per all requirements s pecified by  governing regul ations.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
MLN0128, MLN1117
Study No. C31005 Page 53of 104
Protocol Incorporating Amendment 10 03 December 2018
9.11 Storage, Handling, and Accountability
Upon recei pt at the invest igative site, MLN0128 and MLN1117 should be stored in the original 
bottles unt il use and stored at room temperature from 15°C to 30°C (59°F to 86°F). All 
temperature excursio ns will be reported to the sponsor for assessment and authorization for 
continued use. All invest igational supplies must be stored in a secure area with controlled access 
and will be stored in original packaging. All MLN0128 and MLN1117 su pplies shoul d be used 
before the retest expiry date. 
Everolimus should be stored according to instructions provided in the USPI [23] or Sm PC [24].
A drug dispensing log, including records of drug received fro m the sponsor and drug dispensed to 
the pati ents, will be provided and kept at the study  site. Storage area temperature conditions must 
be monitored and recorded daily . A daily tem perature l og will also be kept at the study  site.
Because MLN0128 and MLN1117 are an investigational agents, they should be handled wit h due 
care. In case of contact with broken capsules, raising dust should be avo ided during the clean -up 
operati on. The product may be harm ful if inhaled, ingested, or absorbed through the skin. Gloves 
and protective clothing should be worn during the clean -up operati on. The area shoul d be 
ventilated and the spill site washed after material pick -up is com plete. The spilled material should 
be disposed o f as hazardous medical waste in co mpliance wit h federal, state, and local regulat ions. 
In case of contact with the powder (eg, from a broken capsule), the skin should be washed 
immediately  with soap and copi ous am ounts of water for at least 15 mi nutes. In case of contact 
with the ey es, copi ous am ounts of water should be used to flush the ey es for at l east 15 minutes. 
Medical personnel should be notified.
Patients will  receive instructi ons for hom e storage and administration of MLN0128 and 
MLN1117.Patients will  be instructed to return any  unused study  drug in the ori ginal packaging alo ng with 
their com pleted di ary cards at the appropri ate visi ts.
Please refer to the Study  Manual for addit ional instructi ons.
9.12 Other Protocol -Specified Materials
Not ap plicable.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
MLN0128, MLN1117
Study No. C31005 Page 54of 104
Protocol Incorporating Amendment 10 03 December 2018
10.0 STUDY CONDUCT
This tri al will be conducted in com pliance wi th the protocol , Good Clinical Pract ice (GCP), 
applicable regulatory  requi rements, and Internat ional Conference on Harmonisat ion (ICH) 
guidelines.
10.1 Study Personnel and Organizations
The co ntact informat ion for the Millennium project clinician for this study , the central laboratory  
and any  addi tional clinical laboratories, the coordinat ing invest igator for each member 
state/country  (where applicable), the Interactive Web Response System prov ider, and the contract 
research organizat ion (CRO) team may be found in the Study Manual. A full list of invest igators is 
available in the sponsor’s investigator database.
10.2 Arrangements for Recruitment of Patients
Recrui tment and enro llment strategies for t his study ma y include recruit ment from the 
investigator’s local practice or referrals from other physicians. If advert isements become part of 
the recruit ment strategy , they  will be reviewed by  the inst itutional review board 
(IRB)/independent ethics co mmit tee (IEC).
10.3 Treatment Group Assignments
A centralized rando mizat ion procedure IXRS will be used for treatment group assignment. 
Patients who meet the eligibilit y criteria will be stratified according to the number of prior lines o f 
therapy  (1, > 1 prior line) and the International Metastatic Renal Cell Carcino ma Database 
Consortium risk category (favorable, intermediate, or poor) [22], and will be rando mized at a ratio 
of 1:1:1 to one of 3 treatment arms:
Arm A: single -agent everolimus, 10 mg QD (every day  of a 28 -day treatm ent cy cle).
Arm B: single- agent MLN0128, 30 mg QW (on Days 1, 8, 15, an d 22 of a 28- day treatm ent 
cycle).
Arm C: combinat ion of MLN0128 4 mg+MLN1117 200 mg, both QD 3 day s per week (on 
Days 1 -3, 8-10, 15- 17, and 22 -24 of a 28- day treatment cy cle).
The first dose of study  drug m ust be administered wi thin 5 days after randomiza tion on study .
10.4 Study Procedures
Patients will  be evaluated at scheduled visits over the fo llowing study  periods: Screening, 
Treatment, and EOT. Evaluations during the Screening period are to be conducted within 28days 
before administration of the first do se of study  drug. Unl ess otherwise noted, evaluat ions during 
the Treatment period must occur before study drug administration. Tests and procedures should be 
perform ed on schedule for all visits but occasional changes are allowable (±2 days) for holidays, 
vacations, and other administrative reasons, starting after the complet ion of Cycle 2 Day  1. The 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
MLN0128, MLN1117
Study No. C31005 Page 55of 104
Protocol Incorporating Amendment 10 03 December 2018
timing of PK assessments is specified in the Treatment Arm B Sparse Pharmacokinet icSample 
Breakdown and Treatm ent Arm  C Sparse P harmacokinet ic Sample Breakdown .
All EOT evaluat ions should occur within 30 (+10) days after the last dose of study drug, or before 
the start of subsequent antineoplastic therapy .
Refer to the Schedule of Events for the timing of assessments. Addit ional details are provided as 
necessary  in the secti ons that follow.
10.4.1 Informed Consent
Each patient must provide written informed consent before any  study-requi red procedures are 
conducted, unless those procedures are performed as part of the patient’s standard care.
10.4.2 Patient Demographics
The date of birth, race, ethnicit y, and sex of the patient are to be recorded during Screening.
10.4.3 Medical History
Durin g the Screening period, a complete medical history  will be com piled for each pat ient. The 
history  will emphasize the background and progress of the patient’s malignancy  and include a 
descript ion of prior therapies for it. In addit ion, conco mitant m edicat ions will be recorded as 
specified in Section 10.4.8 .
10.4.4 Physical Examination
A physical examinat ion will be completed per standard of care at the times specified in the 
Schedule of Events .
10.4.5 Patient Height and Weight
Height will be measured only during Screening (within 28 days before the first dose of study drug 
[ie, MLN0128, MLN0128+MLN1117, or everolimus]). Body weight will be measured at the visits 
specified in the Schedule of Events .
10.4.6 Vital Signs
Vital sign measurements include diastolic and systolic blood pressure, heart rate, and temperature. 
Vital signs will  be measured at the visits specified in the Schedule of Events .
10.4.7 Pregnancy Test
A serum  pregnancy test will be performed for women of childbearing potential at Screening. A 
urine pregnancy test must be performed predose on Day 1 of every cycle with negat ive results 
available before the first dose may be administered in that cycle. A ser um pregnancy  test may also 
be perform ed wi thin 3 days before dosing in place of the Day  1 urine test.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
MLN0128, MLN1117
Study No. C31005 Page 56of 104
Protocol Incorporating Amendment 10 03 December 2018
10.4.8 Concomitant Medications and Procedures
Medicat ions used by the pat ient and therapeutic procedures completed by the pat ient will be 
recorded in the eCRF fr om the first dose of study drug through 30 days after the last dose of stud y 
drug. See Section 9.4and Section 9.5for a list of medicat ions and therapies that are prohibited 
and/or allowed during the study .
10.4.9 AEs
Moni toring of AEs, serious and nonserious, will be conducted throughout the study as specified in 
the Schedule of Events . Refer to Section 11.0 for details regarding definit ions, documentation, and 
reporting of pretreatment events (PTEs), AEs, and SAEs.
10.4.10 Enrollment
A pat ient is considered to be enrolled in the study  when they  have been randomized into a 
treatm ent arm. Procedures for complet ion of the enrollment informat ion are described in the Study 
Manual.10.4.11 ECG
A single, 12 -lead ECG will be administered at the time po ints specified in the Schedule of Events . 
Addit ional ECGs may be obtained as clinically indicated.
10.4.12 Clinical Laboratory Evaluations
Clinical laboratory  evaluat ions will be performed locally. Clinical laboratory evaluat ions will be 
perform ed as outlined below:
Blood sam ples f or analysis of the fo llowing clinical chemistry  and hematol ogical param eters and 
urine samples for urinalysis will be obtained as specified in the Schedule of Events . Specimens for 
analysis of the clinical  chemistry , hematol ogic, and coagul ation parameters shown in Table 10.a
and urine specimens for analysis o f the param eters shown in Table 10.b will be obtained as 
specified in Schedule of Events .
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
MLN0128, MLN1117
Study No. C31005 Page 57of 104
Protocol Incorporating Amendment 10 03 December 2018
Table 10.a Clinical Chemistry, Hematology, and Coagulation Tests
Hematology and Coagulation Serum Chemistry
Hematocrit
Hemoglobin
Leukocytes with differential
Neutrophils (ANC)
Platelet (count)
Activated partial thromboplastin timeProthrombin time/international 
normalized ratioAlbumin
Alkaline phosphatase
ALT
Amylase
AST
Bilirubin (total and direct)Blood urea nitrogen or urea 
Calcium (total)
Carbon dioxide or bicarbonate
Chloride
CreatinineGamma glutamyl transferase
Glucose
HbA1c (only at the time points specified in 
the Schedule of Events ).
Lactate dehydrogenase
Magnesium
Phosphate
Potassium
Sodium
Protein (total)Urate
Table 10.b Clinical Urinalysis Tests
Urinalysis
Bilirubin
GlucoseKetones
Leukocytes
Nitrite
Occult bloodpH
Protein
Specific gravity
Turbidity  
ColorUrobilinogen
Prospective mo nitoring for hy perlipidemia will be managed through fast ing lipid testing. 
Sampling for the fast ing lipid profile ( Appendix A(Schedule o f Events).
Table 10.c) will be obtained at the times specified in Appendix A(Schedule o f Events).
Table 10.c Fasting Lipid Profile
Fasting Lipid Profile
Cholesterol (total)
TriglyceridesHigh -density lipoprotein cholesterol
Low-density  lipoprotein cholesterol
10.4.13 Fasting Serum Glucose
Fasting serum glucose will be measured in the clinic at the time points specified in Appendix A
(Schedule of Events). Patients are required to fast overnight (nothing except water and/or 
medicat ions after midnight or for a minimum of 8 hours before the assessment) for each of these 
measurements. For patients receiving everolimus in Arm A or MLN0128 and MLN1117 in 
Arm C, the sample should be taken approximately 2 hours after dose administration with pat ients 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
MLN0128, MLN1117
Study No. C31005 Page 58of 104
Protocol Incorporating Amendment 10 03 December 2018
continuing to fast until after that sample is taken. For patients receiving MLN0128 QW in ArmB, 
the sam ple shoul d be taken predose; after predose blood draws are complete, patients receiving 
MLN0128 QW in Arm B should consume a light meal before dosing (Section 9.1). In-home 
glucose m onitoring is not requi red on day s when fasting glucose is measured in the clinic.
10.4.14 In-Home Daily Fasting Glucose Monitoring
In addit ion to obtaining fast ing glucose levels at the clinic visit s as outlined in Appendix A
(Schedule of Events), all pat ients randomized to receive MLN0128 (ie, Arms B and C) will be 
given a gluco meter to m onitor thei r daily  fasting blood gl ucose (FBG) l evels at ho me. The level 
shoul d be collected daily, predose on dosing days, and at approximately the same time each day . 
Before checking their blood glucose levels, pat ients should fast overnight (nothing except water 
and/or medications after midnight or for a minimu m of 8 hours before the assessment). After 
fasted testing is co mplete, patients in Arm B should consume a light meal before MLN0128 dosing 
(Secti on9.1).
On Cycle 1 Day 1, the patient will be provided an in -home gluco meter. Patients will be trained on 
proper use of the gluco meter and instructed to collect a daily FBG level every morning (predose on 
dosing days), starting on Cycle 1 Day  2. Pati ents will  be instructed to bring the glucometer with 
them to each study  visit so that the data collected can be reviewed and recorded in the source 
docum ents. Invest igators will be responsible for reviewing the ho me glucose monitoring logs for 
hyperglycemia.
The patient will be instructed to contact the site immediately if the value is abnormal 
(ie,150mg/dL) for further instructions on the management of their hyperglycemia. 
Hyperglycemia observed during home glucose monitoring should be confirmed in the clinic.
If no irregularit ies in the FBG level are observed during a minimum of 2 consecut ive months, then 
the frequency o f in-home FBG testing can be reduced to a minimum frequen cy of once weekly , 
depending on the invest igator’s judgement and approval. Patients will cont inue to notify the 
investigator of FBG levels that exceed 150 mg/dL and, if blood glucose levels are not well 
controlled, or if the patient requires either oral hy poglycemic agents or insulin to control blood 
glucose levels, then the frequency o f in-home testing of FBG levels will be reinstated to daily. See 
also Section 9.7.1 .
10.4.15 Disease Assessment
Patients will  undergo con trast-enhanced imaging (CT or MRI) to monitor the overall disease 
burden unless contraindicated for a particular patient in accordance wit h RECIST version 1.1 [25]. 
As m uch as possible, the same imaging modalit ies and methods should be used for patients 
throughout the study. CT scans of the chest, in addition to CTs or MRIs of the abdomen and pelvis, 
will be obtained at Screening and all subsequent time points. Supplemental x -ray and/or bone 
scanning may be performed, but these methods are not suitable for lesio n measurement. Object ive 
assessments will be performed at each time po int as described in the Schedule of Events . 
Anatomical measurements (summed across target lesio ns) and the presence of nonta rget l esions 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
MLN0128, MLN1117
Study No. C31005 Page 59 of 104
Protocol Incorporating Amendment 10 03 December 2018
will be documented at Baseline/Screening, and the status of target, nontarget, and new lesions will 
be assessed at each subsequent imaging time point. When possible, the same qualified physician 
will interpret results to reduce variability.
Disease assessment images will be collected and reviewed by a sponsor-specified central imaging 
vendor. Radiographic images will also be maintained at the site, and test results and physician’s 
findings will be filed in patient source documents.
In the event of antitumor response, the sponsor may request electronic images for those patients 
who demonstrate tumor reduction.
10.4.16 PK Measurements
Sparse PK sampling to characterize the PK of MLN0128 (Arms B and C) and MLN1117 (Arm C), 
including patients who receive crossover treatment, will be performed at the times indicated in the 
Treatment Arm B Sparse Pharmacokinetic Sample Breakdown and Treatment Arm C Sparse 
Pharmacokinetic Sample Breakdown.
When the timing of a PK blood sample coincides with vital sign measurements, the vital sign 
measurement should be obtained before the PK blood sample. 
In addition to the PK sample collections specified, a blood sample to measure MLN0128 and 
MLN1117 concentrations should be obtained, if clinically feasible, at the time of a serious or 
unusual AE that is judged by the investigator to be treatment-related, irrespective of the cycle, day, 
or stage of occurrence of the AE. The date and exact time of the unscheduled sample collection 
should be recorded. Details on the collection, storage, processing, handling, and shipping of PK 
samples are in the Study Manual.
PK data for MLN0128 and MLN1117 collected in this study may be combined with similar data 
from other studies for future population PK analysis.  The results of the population PK analysis will 
not be presented in the clinical study report and may be presented in a separate population PK 
analysis report at a later time. 
10.4.17 Pharmacodynam ic Measurements
No pharmacodynamic measurements will be made. 
10.4.18 DNA Measurements
CCI
Property of Takeda: For Non-Commercial Use Or Only and Subject to the Applicable Terms of Usemaging aging 
sician’s sician’
those phose 
d C) andC) an
med at thmed at
anddTreTr
ital signtal sign
samamppmmmle
d, a bloo a blo
if clinicif clinic
to be trto be 
te and ete and 
ectctioion, n
N1117 N1117
populatopula
inical stnical s
er time. time
codynaodyn
odynamdynam
DNA MDNAked
perty of Take
MLN0128, MLN1117
Study No. C31005 Page 60 of 104
Protocol Incorporating Amendment 10 03 December 2018
 
 
 
 
 
 
10.4.19 Banked Tumor Specimen Measurements; Tumor Biopsies
Banked formalin-fixed, paraffin-embedded tumor ti ssue (or fresh tumor biopsy as described below 
in this section) should be obtained at Screening for assessment of candidate biomarkers predictive 
of response, including, but not limited to somatic gene alterations and expression of markers such 
as PTEN, PIK3CA, mTOR, and phosphorylated (p-) AKT, p-S6, and p-4E-BP1. It is anticipated 
that developing these potential biomarkers of anti tumor activity mediated by the combination of 
MLN0128 and MLN1117 will require analysis of the d ata from this study in combination with data 
from other clinical studies of this combination and each single agent.
If either a paraffin-embedded tumor block or a minimum of 15 unstained slides are not available, 
then the patient will be required to undergo a fresh tumor biopsy at Screening as indicated in the 
Schedule of Events.  If fresh tumor biopsy collection is uns uccessful, enrollment is contingent upon 
discussion with the sponsor.
Detailed instructions for the collection, processing, and shipment of the fresh tumor biopsy 
samples are provided in the Study Manual.
10.4.20 QOL and Symptom Assessments
The QOL instruments, EORTC QLQ-C30 and FKSI-DRS, will be administered as specified in 
Appendix A (Schedule of Events), and they must be completed before other assessments are 
performed or study drug is administered.
The EORTC QLQ-C30 incorporates 5 functional scales (physical functioning, role functioning, 
emotional functioning, cognitive functioning, and social functioning); 1 global health status scale; 
3 symptom scales (fatigue, nausea and vomiting, and pain); and 6 single items  (dyspnea, insomnia, 
appetite loss, constipation, diarrhea, and financial difficulties) (See  Appendix J) . The time recall 
period for this instrument is 1 week (the past week). The EORTC QLQ-C30 is a reliable and valid 
measure of health-related QOL in patients with cancer [27]. The instrument consists of a brief 
(30-item) questionnaire that has been validated and used in many countries. 
The FKSI-DRS is a validated, 9-item questionnaire derived from the 15-item FSKI-15 
questionnaire desi gned to assess the effect of disease-rel ated symptoms on patients with kidney 
cancer [28] (see Appendix K) .CCI
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable psy as dsy as d
date biodate bio
d expresexpre
and pnd p-4E-4
yymediatmedi
m tm this shis 
ingle agngle a
um om of f1
h tumor bh tumor
tioon is un is 
processinrocess
nual.ual.
ssessmesessm
TC QLQC QL
f EventsEvent
ug ig is adms ad
C30C30 ini
ioioning, nin
cales (faales
oss, conss, co
for this for thi
sure of sure o
300--itiem
The Therms of Use
qrms
TermeT e
MLN0128, MLN1117
Study No. C31005 Page 61of 104
Protocol Incorporating Amendment 10 03 December 2018
10.5 Completion of Treatment
Patients will  be considered to have completed treatment if they  discontinue study  drug f or any  of 
the reasons outlined in Sect ion 10.7.
The m aximum  durati on of  treatment for pati ents will  be 24 months unless, after discussion 
between the invest igator and sponsor, it is determined that a pati ent woul d derive benefit from  
continued treatment bey ond 24 m onths.
10.6 Completion of Study
Patients will be considered to have co mpleted the study if they wit hdraw from the study for any of 
the reasons outlined in Sect ion 10.8.
10.7 Discontinuation of Treatment With Study Drug and Patient Replacement
Treatment with study  drug m ay be discont inued for any of the fo llowing reasons:
AE.
Protocol  violation.
Progressive disease. 
Symptom atic deteri oration. 
Study  terminated by  sponsor.
Withdrawal by pat ient.
Lost to follow -up.
Other.
Patients m ust discont inue study  drug if they  experience di sease progressi on or unacceptable 
toxicity, or if they  becom e pregnant. 
Once study  drug has been discont inued, all study  procedures outlined for the EOT visit will be 
completed as specified in Appendix A(Schedule of Events). The primary  reason for study  drug 
discontinuat ion will  be recorded on the eCRF.
10.8 Withdrawal of Patients From Study
A pat ient may be wi thdrawn from  the study  for any  of the f ollowing reasons:
Lost to follow -up.
Study  terminated by  sponsor.
Withdrawal by pat ient.
Other.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
MLN0128, MLN1117
Study No. C31005 Page 62of 104
Protocol Incorporating Amendment 10 03 December 2018
The consequence of study  withdrawal  is that no new informat ion will be collected from the 
withdrawn pati ent and added to the exist ing data or an y database. Data on survival may  be 
obtained fro m publicly available databases and sources. 
10.9 Study Compliance
Study  drug will be administered or dispensed only to eligible pat ients under the supervisio n of the 
investigator or ident ified subinvest igator(s). The appropriate study personnel will maintain records 
of study  drug recei pt and dispensing.
Patients will  receive a sufficient quant ity of study  drug for each treatment cycle and a diary  in 
which to record their dosing. The study  center staff will check t he patient’s diary versus the 
patient’s supply  of remaining study drug at each study  visit to ensure proper com pliance wi th 
dosing. Patients who are not compliant with the dosing schedule may be withdrawn from the study.
10.10 Post-Trial Access Program
If an ope n-label, roll over, PTA program  becom es an opti on and the investigator and the sponsor 
agree that a patient would derive benefit fro m continued treatment or might be harmed without 
continued access to the medicat ion, the pati ent m ay be given the opportuni tyto enroll. 
In the event of study closure by the sponsor, continued access to study treatment will be terminated 
for pati ents who are no longer benefit ing from treatm ent (eg, thei r disease has progressed or 
treatm ent is no longer tolerable), the benefit -risk assessment is no longer favorable, or an 
appropriate alternat ive therapy beco mes available. The PTA program may be terminated in a 
country  or geographic regio n or terminated by the sponsor if study  treatm ent can no longer be
supplied or study  drug beco mes available either commercially  or vi a another access mechanism. 
Related SAEs during the PTA program must be reported to Takeda Global Pharmacovigilance 
departm ent or desi gnee. This includes deaths that the invest igator considers related to study  drug 
that occur after the EOT visit. Refer to Section 11.0 for details regarding definit ions, 
docum entati on, and reporting of SAEs .
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
MLN0128, MLN1117
Study No. C31005 Page 63of 104
Protocol Incorporating Amendment 10 03 December 2018
11.0 ADVERSE EVENTS
11.1 Definitions
11.1.1 PTE Definition
A PTE i s any  untoward m edical occurrence in a patient or subject who has signed informed 
consent to participate in a study  but before administrati on of  any study  medicat ion; it does not 
necessarily have to have a causal relations hip with study  participati on.
11.1.2 AE Definition
AE means any untoward medical occurrence in a patient or subject administered a pharmaceut ical 
product; the untoward medical occurrence does not necessarily have a causal relat ionship wit h this 
treatm ent. An AE c an therefore be any unfavorable and unintended sign (including an abnormal 
laboratory  finding), symptom, or disease temporally  associ ated wi th the use of a m edicinal 
(invest igational) product whether or not it is related to the medicinal product. This incl udes any 
newly occurring event, or a previous condit ion that has increased in severit y or frequency since the 
administration of study  drug.
An abnormal laboratory  value will not be assessed as an AE unless that value leads to 
discontinuat ion or delay in tr eatm ent, dose modification, therapeutic intervent ion, or is considered 
by the investigator to be a clinically significant change fro m Baseline.
11.1.3 SAE Definition
SAE m eans any untoward medical occurrence that at any  dose:
Results in death.
Is life-threatening (refers to an AE in which the patient was at risk of death at the time of the 
event. It does not refer to an event which hypothetically might have caused death if it were 
more severe).
Requi res inpat ienthospitalization or prolongation of an existing hospitalization (see 
clarificati onin the paragraph in Sect ion 11.2 on planned hospitalizat ions).
Results in persistent or significant disability or incapacity . (Disabilit y is defined as a 
substant ial disrupt ion of a person’s abilit y to conduct normal life functions .)
Is a congenital anomaly/birth defect .
Is a medically important event . This refers to a n AE that may not result in death, be 
immediately  life threatening, or require hospitalization, but may be considered serious when, 
based on appropriate medical judgment, may  jeopardi ze the pati ent, requi re medical or 
surgi cal interventi on to prevent one o f the outcom es listed above, or invo lves suspected 
transmissio n via a medicinal product of an infect ious agent. Examples of such medical events 
include allergic bronchospasm requiring intensive treatment in an emergency room or at home, 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
MLN0128, MLN1117
Study No. C31005 Page 64 of 104
Protocol Incorporating Amendment 10 03 December 2018
blood dyscrasias or convulsions that do not  result in inpatient hospitalization, or the 
development of drug dependency or drug abuse; an y organism, virus, or i nfectious particle 
(eg, prion protein transmitting transmissible spongiform encephalopathy), pathogenic or 
nonpathogenic, is considered an infectious agent.
In this study, intensity for each AE, including any lab abnormality, will be determined using the 
NCI CTCAE version 4.03, effective date 14 June 2010 [26]. Clarification should be made between 
an SAE and an AE that is considered severe in intensity (Grade 3 or 4), because the terms serious 
and severe are NOT synonymous. The general term severe is often used to describe the intensity 
(severity) of a specific event; the event itself, however, may be of rela tively minor medical 
significance (such as a Grade 3 headache). This is NOT the same as serious , which is based on 
patient/event outcome or action criteria described above, and is usually associated with events that 
pose a threat to a patient’s life or ability to function. A severe AE (Grade 3 or 4) does not 
necessarily need to be considered serious. For example, a white blood cell count of 1000/mm3to 
less than 2000/mm3is considered Grade 3 (severe) but may  not be considered serious. Seriousness 
(not intensity) serves as a guide for de fining regulatory reporting obligations.
11.2 Procedures for Recording and Reporting AEs and SAEs
All AEs spontaneously reported by the patient and/or in response to an open question from study 
personnel or revealed by observation, physical examination, or other diagnostic procedures will be 
recorded on the appropriate page  of the eCRF (see Section  11.3 for the period of observation). Any 
clinically relevant deterioration in laboratory assessments or other clinical finding is considered an 
AE. When possible, signs and symptoms indicating a common underlying pathology should be 
noted as 1 comprehensive event.
Regardless of causality, SAEs and serious PTEs (as defined in Section  11.1)  must be reported (see 
Section  11.3 for the period of observation) by the investigator to the Takeda Global 
Pharmacovigilance department or designee (conta ct information provided belo w). This should be 
done by faxing the SAE Form within 24 hours after becoming aware of the event. The SAE Form, 
created specifically by Takeda, will be provided to each clinical study site. A sample of the SAE 
Form may be found in the Study Manual. Follo w-up information on the SAE or serious PTE may 
be requested by Takeda. SAE report information must be consistent with the data provided on the 
eCRF.
SAE Reporting Contact Information
United States and CanadaCCI
CCI
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Usesing the ing th
ade betwde bet
e terms terms
ibe the ibe the
minor minor m
s, whicwhic
associatassocia
rade 3 oade 3
lood celood ce
be consbe con
ortiting obng oiiii
Es and Ss and
d/or in re/or in r
examinaexamin
F (see Sesee S
ory assery ass
ms indicms indi
nd seriod ser
observobserf
ment orment o
E Form wForm
byyTakeTaky
nd in thd in t
yyTakedTakeyy
da
rty
MLN0128, MLN1117
Study No. C31005 Page 65of 104
Protocol Incorporating Amendment 10 03 December 2018
Planned hospi tal admissio nsor surgical procedures for an illness or disease that existed before 
study  drug was given are not to be considered AEs unless the condit ion deteri orated in an 
unexpected manner during the trial (eg, surgery  was perform ed earlier or l ater than planned).
For both seri ous and nonserious AEs, the invest igator must determine both the intensity of the 
event and the relat ionship of the event to study  drug administration. For serious PTEs, the 
investigator must determine both the intensit y of the event and the rel ationship of the event to 
study  procedures.
Intensit y for each AE, including any lab abnormality , will  be determined using the NCI CTCAE 
versio n4.03, effect ive date 14 June 2010 [29]. The criteria are provided in the Study  Manual.
Relationship to study  drug administration will be determined by the invest igator responding yes 
or no to this quest ion: Is there a reasonable possibilit y that the AE is associated with the study  
drug?
11.3 Monitoring of AEs and Period of Observation
AEs, both nonserious an d seri ous, will  be monitored throughout the study  as fo llows: 
AEs will be reported from first dose of study  drug through 30 day s after administration of the 
last dose of study  drug and recorded in the eCRFs. 
Serious PTEs will be reported to the Takeda Gl obal Pharmacovigilance departm ent or 
designee fro m the tim e of the si gning of the informed consent form up to first dose of study  
drug, but will not be recorded in the eCRF.
Related and unrelated SAEs will be reported to the Takeda Global Pharmacovigilance
departm ent or desi gnee fro m the first dose of study drug through 30 days after administration 
of the l ast dose of study  drug and recorded in the eCRF. After this period, only  related SAEs 
must be reported to the Takeda Global Pharmacovigilance depart ment or desi gnee. SAEs 
shoul d be m onitored until they  are resolved or are clearly  determined to be due to a patient’s 
stable or chronic condit ion or intercurrent illness(es).
11.4 Procedures for Reporting Drug Exposure During Pregnancy and Birth Events
If a woman be comes pregnant or suspects that she is pregnant while participating in this study  or 
during the PTA program, she must inform the investigator immediately and permanently discontinue study  drug. The sponsor m ust al so be contacted immediately  by faxing a com pleted 
Pregnancy Form to the Takeda Global Pharmacovigila nce depart ment or designee ( Secti on 11.2). 
The pregnancy must be fo llowed for the final pr egnancy outcom e.
If a female partner of a male patient becomes pregnant during the male pat ient’s participat ion in 
this study  or during the PTA program, the sponsor must also be contacted immediately by faxing a 
completed Pregnancy Form to the Takeda Globa l Pharmacovigilance department or designee (see 
Secti on 11.2). Every  effort shoul d be made to follo w the pregnancy for the final pregnancy  
outcom e.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
MLN0128, MLN1117
Study No. C31005 Page 66 of 104
Protocol Incorporating Amendment 10 03 December 2018
11.5 Procedures for Reporting Product Complaints
A product complaint is a verbal, written, or electronic expression that implies dissatisfaction 
regarding the identity, strength, purity, quality , or stability of a drug product. Individuals who 
identify a potential product complaint situati on should immediately contact the Medical 
Information and report the complaint. The contact 
information is as follows:
Medical Information Center:
Phone:
Fax:
Email:
Hours: Mon-Fri, 9 AM-7 PM, ET
Whenever possible, the associated product should be maintained in accordance with the label 
instructions pending further guidance from a Millennium Quality representative.
Product complaints in and of themselves are not AEs. If a product complaint results in an SAE, an 
SAE form should be completed and sent to  (refer to Section  11.2) .
11.6 Safety Reporting to Investigators, IRBs or IECs, and Regulatory Authorities
The sponsor will be responsible for reporting all suspected unexpected serious adverse reactions 
(SUSARs) and any other applicable SAEs to regulatory authorities, including the European 
Medicines Agency, investigators, and IRBs or IECs, as applicable, in accordance with national 
regulations in the countries where the study is conducted. Relative to the first awareness of the 
event by/or further provision to the sponsor or sponsor’s designee, SUSARs will be submitted to 
the regulatory authorities as an expedited report within 7 calendar days for fatal and 
life-threatening events and 15 calendar days for other serious events, unless otherwise required by 
national regulations. The sponsor will also prepare an expedited report for other safety issues 
where these might materially alter the current benefit-risk assessment of an investigational 
medicinal product or that would be sufficient to consider changes in the investigational medicinal 
product’s administration or in the overall conduct of the trial. The investigational site also will 
forward a copy of all expedited reports to the IRB or IEC in accordance with national regulations.CCI
CCI
CCI
Property of Takeda: For Non-Commercial Use Only and Subject to the M, ETET
d in accoin ac
alitality repy re
a produca produ
 (refer t(refer
Bs or IEor I
g all susall su
s to reguto re
IRBs orRBs o
he studye stud
he spone spo
n expedexped
15 calen5 cal
e sponsospons
ateriallyateria
or that or that
nistrationistra
pyyofofy alfble Terms of Useontact ntact 
e Applicabl
a
MLN0128, MLN1117
Study No. C31005 Page 67of 104
Protocol Incorporating Amendment 10 03 December 2018
12.0 STUDY- SPECIFIC COMMITTEES
No steering committee, data safety  monitoring commi ttee, or clinical endpoint committee will be 
used in this study .
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
MLN0128, MLN1117
Study No. C31005 Page 68of 104
Protocol Incorporating Amendment 10 03 December 2018
13.0 DATA HANDLING AND RE CORDKEEPING
The full details of procedures for data handling will be documented i n the Data Management Plan. 
If selected for coding, AEs, PTEs, medical history, and concurrent condit ions will be coded using 
the Medi cal Dict ionary for Regulatory  Activities (MedDRA). Drugs will be coded using the 
World Heal th Organizat ion (WHO) Drug Dict ionary.
13.1 eCRFs
Com pleted eCRFs are required for each randomized subject.
The sponsor or its designee will supply invest igative sites with access to eCRFs and will make 
arrangements to train appropriate site staff in the use of the eCRF. These forms are used to transmit  
the informat ion collected in the performance of this study  to the sponsor, CRO partners, and 
regul atory  authori ties. Invest igative sites must complete eCRFs in English.
After complet ion of the entry process, computer logic checks will be run t o identify items, such as 
inconsistent dates, missing data, and questionable values. Queries may be issued by Takeda 
personnel (or designees) and will be answered by the site. 
Any change of, modificat ion of, or addit ion to the data on the eCRFs should be made by  the 
investigator or appropriate site personnel . Corrections to eCRFs are recorded in an audit trail that 
captures the old informat ion, the new information, ident ificat ion of the person making the 
correcti on, the date the correction was made, and th e reason for change. 
The principal invest igator must review the eCRFs for completeness and accuracy and must sign 
and date the appropriate eCRFs as indicated. Furthermore, the principal invest igator must retain 
full responsibilit y for the accuracy  and aut henticity of all data entered on the eCRFs .
eCRFs will be reviewed for completeness and acceptabilit y at the study  site during peri odic visi ts 
by study  monitors. The sponsor or i ts designee will be permitted to review the subject’s medical 
and hospital rec ords pertinent to the study to ensure accuracy of the eCRFs. The completed eCRFs 
are the sole property  of the sponsor and should not be made available in any form to third parties, 
except for authorized representatives of appropriate governmental healt h orregulatory  authorities, 
without wri tten permissio n of the sponsor.
13.2 Record Retention
The invest igator agrees to keep the records stipulated in Section 13.1 and those documents that 
include (but are not limited to) the study -specific documents, the ident ificat ion log of all 
participat ing subjects, medical records, temporary media such as thermal sensit ive paper, source 
worksheets, all original signed and dated informed consent forms, subject authorizat ion forms 
regarding the use of personal healt h information (if separate from the informed consent forms), 
electroni c copy  of eCRFs, incl uding the audi t trail, and detailed records of drug disposit ion to 
enab le evaluat ions or audits from regulatory  authori ties, the sponsor or its designees. Any  source 
docum entati on printed on degradable thermal sensitive paper should be photocopied by the site 
and filed wit h the original in the subject’s chart to ensure long t erm legibilit y. Furtherm ore, 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
MLN0128, MLN1117
Study No. C31005 Page 69of 104
Protocol Incorporating Amendment 10 03 December 2018
ICH E6 Secti on 4.9.5 requires the invest igator to retain essent ial documents specified in ICH E6 
(Secti on8) until at least 2 y ears after the last approval of a market ing applicat ion for a specified 
drug indicat ion being invest igated or, if an applicatio n is not approved, until at least 2 years after 
the invest igation is discontinued and regulatory authorities are notified. In addit ion, ICH E6 
Secti on4.9.5 states that the study  records should be retained unt il an am ount of time specified by  
applicable regulatory  requi rements or for a time specified in the Clinical Study  Site Agreement 
between the invest igator and sponsor.
Refer to the Clinical Study Site Agreement for the sponsor’s requirements on record retention. The 
investiga tor shoul d contact and receive written approval fro m the sponsor before disposing of any 
such documents.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
MLN0128, MLN1117
Study No. C31005 Page 70of 104
Protocol Incorporating Amendment 10 03 December 2018
14.0 STATISTICAL METHODS
14.1 Statistical and Analytical Plans
A stati stical analysis plan will be prepared and finalized before database lock. This document will 
provi de further details regarding the definit ion of analysis variables and analysis methodology  to 
address all study  object ives.
14.1.1 Analysis Sets
Full analysis set: all rando mized patients.
Safety analysis set: patients who receive at least 1 dose of stu dy drug.
Response -evaluable analysis set: patients who receive at least 1 dose of study  drug, have 
measurable disease at Baseline, and have 1 postbaseline disease assessment.
14.1.2 Analysis of Demographics and Other Baseline Characteristics
Dem ographic (age, sex) and baseline characterist ics (wei ght, hei ght, and other parameters, as 
appropriate) will be summarized by  treatm ent arm  (ie, evero limus, MLN0128, or 
MLN0128+MLN1117).
14.1.3 Efficacy Analysis
Primary Efficacy Endpoint
The primary endpo int is PFS, defined as the time from the date of rando mizat ion to the date of first 
docum entati on of  progressi on or death due to any  cause, whichever occurs first. For a patient 
whose disease has not progressed and is last known to be alive, PFS will be censored at the last 
response assessment that is SD or better. The primary  efficacy analysis will be based on the full 
analysis set. 
The Kaplan -Meier m ethod will be used to analyze the distribut ion of PFS for each treatment arm. 
Kaplan -Meier survival curves, the 25th, 50th (media n), and 75th percent iles, along wit h associated 
2-sided 95% CIs, hazard ratio along wit h associated 95% CI, and Kaplan -Meier est imates at 
relevant time po ints will be presented. The primary hypothesis is to be tested at the 
0.15 significance level (2 -sided ). The p -values from a stratified log -rank test and hazard ratios and 
will be presented for each pair -wise comparison.
Secondary Efficacy EndpointsSecondary  efficacy endpo ints include OS, ORR, TTP, CBR with SD of any durat ion, and CBR 
with SD durati on of  at least 4 m onths. 
OS is defined as the time fro m the date of rando mization to the date of death. Patients without 
docum entati on of  death at the time of analysis will be censored at the date last known to be alive. 
OS will be analyzed using similar method s as the primary endpo int of PFS in the full analysis set.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
MLN0128, MLN1117
Study No. C31005 Page 71of 104
Protocol Incorporating Amendment 10 03 December 2018
Object ive response rate is defined as the proportion of patients who achieve a best response of CR 
or PR. CBR is defined as the proportion of patients who achieve a best response of CR, PR, or SD. 
The CBR will also be presented for a best response of CR, PR, and SD of at least 4 months. A 
stratified Cochran -Mantel -Haenszel test will be used to compare ORR and CBR between 
treatm ent arms. The Mantel -Haenszel est imate of the odds ratio and the associat ed 95% CIs will be 
presented for each pair -wise comparison.
TTP is defined as the time fro m the date of randomizat ion to the date of first documentation of 
progression. For a patient whose disease has not progressed, TTP will be censored at the last 
respon se assessment that is SD or better. TTP will be analyzed using similar methods as the 
primary  endpoint of PFS in the full analysis set.
14.1.4 PK Analysis
Sparse PK data for MLN0128 and MLN1117 are being co llected to contribute to a future 
popul ation PK analysis. These data may be co mbined with data from other studies in which the PK 
of MLN0128 or MLN1117 is characterized for populat ion PK analysis. The results of populat ion 
PK analysis will be presented in a separate report. 
14.1.5 Pharmacodynamic Analysis 
Not applica ble.
14.1.6 Other Analyses 
Patient -Reported Outcomes
Patient-reported outcome (PRO) assessments using the EORTC QLQ -C30 and FKSI -DRS 
questionnaires will be analyzed to determine if response to therapy and side effects of therapy are 
accompanied by measurable cha nges in the PROs. Published scoring manuals and guidelines will 
be used to generate scale scores and handle missing data. 
Descript ive statistics for baseline values, actual values, and the change fro m Baseline will be 
presented at each scheduled time poin t for each of the funct ional and symptom scores, and the 
global health status/QOL score from the EORTC QLQ- C30, and the FKSI -DRS score. Differences 
between treatment arms in the EORTC QLQ -C30 and FKSI -DRS scores will be evaluated. 
Longi tudinal analysis of PRO scores will be performed using linear mixed models. 
14.1.7 Safety Analysis
Safety will be evalua ted by  the incidence of AEs, severit y and t ype of AEs, and by changes fro m 
Baseline in the pat ient’s vit al signs, weight, and clinical laboratory results using th e safet y analys is 
set. Exposure to each study  drug (i e, MLN0128, MLN1117, andeverolimus )willbesummarized
and reasons for discont inuat ion will be tabulated. Safet y will be summarized by  treatm ent arm  
(evero limus, MLN0128, MLN0128+MLN1117).
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
MLN0128, MLN1117
Study No. C31005 Page 72of 104
Protocol Incorporating Amendment 10 03 December 2018
TEAEs that occur after administration of the first dose of study drug and through 30 days after the 
last dose of study  drug will be tabulated. 
AEs will be tabulated according to the MedDRA and will include the fo llowing categori es:
TEAEs.
Drug -related TEAEs.
Grade 3 or higher TEAEs.
Grade 3 or higher drug- related TEAEs.
The m ost comm only reported TEAEs. 
SAEs.
A listing of TEAEs result ing in study  drug di scont inuat ion will be provided.
Descript ive statistics for the actual values of clinical laboratory paramete rs (and/or change from 
Baseline in clinical laboratory  parameters) will be presented for all scheduled measurements over 
time. 
Shift tables for laboratory  parameters will be generated based on changes in NCI CTCAE grade 
from Baseline to the worst postbase line value.
Concomitant medicat ions will be coded using the WHO Drug Dict ionary. The number and 
percentage of patients taking conco mitant m edicat ions will be tabulated by WHO drug generic 
term in the safety  analysis set.
ECG Analysis
ECG intervals (QT and QTc wi th Fridericia correction, and PR), QRS duration, and ventricular 
rate will be summarized at each scheduled time point, along with mean change fro m Baseline to 
each post -treatm ent time point. The number and percentage of patients with ECG abnormalit ies 
will be summarized at each time po int.
14.2 Interim Analysis and Criteria for Early Termination 
Study  data will be reviewed after the first 30 patients in each arm have received 2 cy cles of study  
drug. If at the end of cycle 2, 50% or more patients in a treatm ent arm  (ie, Arm  B [single agent 
MLN0128] or Arm C (MLN0128+MLN1117) have either progressive disease or have died, or 
have discont inued study  treatment due to treatment -related AEs, then that study  arm may be 
closed. If both Arms B and C meet this cr iteria, then the study  may be cl osed.
14.3 Determination of Sample Size
Approximately  189 pati ents will be enrolled in the 3 treatment arms. 
The primary  efficacy  endpoint i s PFS. Assuming that the median PFS is 5 months for everolimus 
[20] and that MLN0128 (either as a single agent or in co mbinat ion with MLN1117) can improve 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
MLN0128, MLN1117
Study No. C31005 Page 73of 104
Protocol Incorporating Amendment 10 03 December 2018
the median PF S to 8 months (hazard ratio of 0.625), then a total of 95 PFS events are needed for 
each pair -wise co mpar ison and approximately 63 patients are required for each treatment arm. The 
calculat ions are based on a power of 80%, 2 -sided alpha o f 15%, and a dropo ut rate of 10% due to 
either lost to foll ow-up or wi thdrawal of consent. 
The sample size for the study  assumes the total accrual will be approximately  14 m onths, where 
10% of the patients are enrolled wit hin the first 3 mo nths and 40% are enrolled at the end of 
7months. The final analysis for the pair -wise co mparisons of PFS between single -agent 
MLN0128 and evero limus and between the co mbination of MLN0128+MLN1117 and everolimus 
will occur approximately  9 months after the l ast pati ent is rando mized.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
MLN0128, MLN1117
Study No. C31005 Page 74of 104
Protocol Incorporating Amendment 10 03 December 2018
15.0 QUALI TY CONTROL AND QUALI TY ASSURANCE
15.1 Study -Site Monitoring Visits
Moni toring visit s to the study  site will  be made peri odically  during the study  to ensure that all 
aspects of the protocol are fo llowed. Source documents will be reviewed for verificat ion of data
recorded on the eCRFs. Source documents are defined as original documents, data, and records. 
The invest igator and inst itution guarantee access to source documents by  the sponsor or i ts 
designee (CRO) and by  the IRB or IEC.
All aspects of the study and it s documentation will be subject to review by the sponsor or designee 
(as long as blinding is not jeopardized), including but not limited to the Invest igator’s Binder, 
study  medicat ion, subject medical records, informed consent documentation, documentation of 
subject authorizat ion to use personal healt h information (if separate fro m the inform ed consent 
forms), and review o f eCRFs and associated source documents. It is important that the invest igator 
and other study  personnel are available during the mo nitoring visits and that sufficient time is 
devoted to the process.
15.2 Protocol Deviations
The invest igator should not deviate fro m the protocol , except where necessary  to eliminate an 
immediate hazard to study subjects. Should other unexpected circumstances arise that will require 
deviat ion from protocol -specified procedures, the investigator should consult with the sponsor or 
designee (and IRB or IEC, as required) to determine the appropriate course of action. There will be 
no exempt ions (a prospectively approved deviat ion) from the inclusio n or exclusio n criteria.
The site should document all protocol deviat ions in the subject’s source documents. In the event of 
a significant devi ation, the si te shoul d notify  the sponsor or i ts desi gnee (and IRB or IEC, as 
requi red). Si gnificant devi ations include, but are not limited to, those that invo lve fraud or 
misconduct, increase the health risk to the subject, or confound interpretation of primary study 
assessment. A Protocol Deviation Form should be completed by the site and signed by the sponsor 
or desi gnee for any  significant deviat ion from the protocol.
The invest igator should document all protocol deviations.
15.3 Quality Assurance Audits and Regulatory Agency Inspections
The study  site also m ay be subject to qualit y assurance audi ts by  the sponsor or desi gnees. In this 
circumstance, the sponsor -designated audi tor will  contact the si te in advance to arrange an 
auditing visit. The auditor may ask to visit the facilit ies where laboratory  samples are collected, 
where the medication is stored and prepared, and any  other facili ty used during the study . In 
addition, there is the possibilit y that this study may be inspected by regulatory agencies, including 
those of foreign governments (eg, the FDA, the United Kingdo m Medicine s and Healthcare 
products Regulatory  Agency , the Pharmaceut icals and Medical Devices Agency o f Japan). If the 
study  site is contacted for an inspect ion by a regulatory  body , the sponsor should be notified 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
MLN0128, MLN1117
Study No. C31005 Page 75of 104
Protocol Incorporating Amendment 10 03 December 2018
immediately . The invest igator and inst itution guarant ee access for qualit y assurance auditors to all 
study  docum ents as described in Section 15.1.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
MLN0128, MLN1117
Study No. C31005 Page 76of 104
Protocol Incorporating Amendment 10 03 December 2018
16.0 ETHICAL ASPECTS OF T HE STUDY
This study  will be cond ucted wi th the highest respect for the individual participants (ie, subjects) 
according to the protocol, the ethical principles that have their origin in the Declaration o f 
Helsinki, and the ICH Harmonised Tripart ite Guideline for GCP. Each investigator wi ll conduct 
the study  according to applicable local or regional regulatory  requi rements and align his or her 
conduct in accordance with the “Responsibilit ies of the Invest igator” that are listed in Appendix B. 
The principles of Helsinki are addressed through the protocol and through appendices containing 
requi rements for informed consent and invest igator responsibilities.
16.1 IRB and/or IEC Approval
IRBs and IECs must be constituted according to the applicable state and federal/local requirements 
of each participat ing regio n. The sponsor or designee will require documentation noting all names 
and tit les of members who make up the respective IRB or IEC. If any member of the IRB or IEC 
has di rect parti cipat ion in this study , written notification regarding his or her abstinence fro m 
voting must also be obtained. Those American sites unwilling to provide names and tit les of all 
members due to privacy  and conflict o f interest concerns should instead provide a Federal Wide 
Assurance Number or comparable number assigned by the Department of Health and Human 
Services.
The sponsor or designee will supply relevant documents for submissio n to the respective IRB or 
IEC for the protocol’s review and approval. This protocol, the IB, a copy  of the inform ed consent 
form, and, if applicable, subject recruit ment materials and/or advertisements and other documents 
requi red by all applicable laws and regulat ions, must be submitted t o a central or local IRB or IEC 
for approval . The IRB’s or IEC’s written approval of the protocol and subject informed consent 
must be obtained and submitted to the sponsor or designee before commencement of the study  
(ie,before shipment of the sponsor -supplied drug or study specific screening activit y). The IRB or 
IEC approval must refer to the study  by exact protocol  title, number, and versio n date; ident ify 
versio ns of other documents (eg, informed consent form) reviewed; and state the approval date. 
The sponsor will notify  the si te once the sponsor has confirmed the adequacy  of site regul atory  
docum entati on and, when applicable, the sponsor has received permissio n from competent 
authori ty to begin the tri al. Unt il the site receives notification no proto col activities, including 
screening, may  occur.
Sites m ust adhere to all requirements stipulated by  their respect ive IRB or IEC. This may include 
notification to the IRB or IEC regarding protocol amendments, updates to the informed consent 
form, recrui tment materials intended for viewing by  subjects, l ocal safety  reporti ng requirements, 
reports and updates regarding the ongoing review of the study  at intervals specified by  the 
respective IRB or IEC, and submissio n of the investigator’s final status report t o IRB or IEC. All 
IRB and IEC approvals and relevant documentation for these items must be provided to the sponsor or its designee.
Subject incentives should not exert undue influence for participat ion. Payments to subjects must 
be approved by the IRB or I EC and sponsor.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
MLN0128, MLN1117
Study No. C31005 Page 77of 104
Protocol Incorporating Amendment 10 03 December 2018
16.2 Subject Information, Informed Consent, and Subject Authorization
Written consent documents will embody  the elements of informed consent as described in the 
Declaration of Helsinki and the ICH Guidelines for GCP and will be in accordance with all 
applicable laws and regulations. The informed consent form, subject authorizat ion form (if 
applicable), and subject informat ion sheet (if applicable) describe the planned and permitted uses, 
transfers, and disclo sures of the subject’s personal and personal healt h informat ion for purposes of 
conducting the study. The informed consent form and the subject informat ion sheet (if applicable) 
further explain the nature of the study, its object ives, and potential risks and benefit s, as well as the 
date in formed consent i s given. The informed consent form will detail the requirements of the 
participant and the fact that he or she is free to withdraw at any  time wi thout giving a reason and 
without prej udice to hi s or her further m edical care.
The invest igato r is responsible for the preparation, content, and IRB or IEC approval of the 
inform ed consent form  and if applicable, the subject authorization form. The informed consent 
form, subject authorizat ion form (if applicable), and subject information sheet (if applicable) must 
be approved by both the IRB or IEC and the sponsor before use.
The informed consent form, subject authorizat ion form  (if applicable), and subject informat ion 
sheet (if applicable) must be written in a language fully co mprehensible to the p rospective subject. 
It is the responsibilit y of the invest igator to explain the detailed elements of the informed consent 
form, subject authorizat ion form (if applicable), and subject informat ion sheet (if applicable) to the 
subject. Information should be given in both oral and written form whenever possible and in the 
manner deemed appropriate by the IRB or IEC. In the event the subject is not capable of rendering 
adequate written informed consent, then the subject’s legally  acceptable representative may 
provi de such consent for the subject in accordance with applicable laws and regulat ions.
The subject, or the subject’s legally acceptable representative, must be given ample opportunit y to: 
(1) inquire about details of the study and (2) decide whether or not to participate in the study. If the 
subject, or the subject’s legally acceptable representative, determines he or she will part icipate in 
the study , then the informed consent form and subject authorizat ion form (if applicable) m ust be 
signed and dated by the subject, or the subject’s legally  acceptable representative, at the time of 
consent and before the subject entering into the study . The subject or the subject’s legally 
acceptable representative should be instructed to sign using their legal names, no t nicknames, 
using blue or black ballpo int ink. The invest igator must also sign and date the informed consent 
form and subject authorizat ion (if applicable) at the time o f consent and before the subject entering 
into the study; however, the sponsor may  allow a designee of the invest igator to sign to the extent 
permitted by  applicable law.
Once signed, the original informed consent form, subject authorization form (if applicable), and subject informat ion sheet (if applicable) will be stored in the invest igator’s site file. The 
investigator must document the date the subject signs the informed consent in the subject’s medical record. Copies of the signed informed consent form, the signed subject authorization for m 
(if applicable), and subject informat ion sheet (if applicable) shall be given to the subject.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
MLN0128, MLN1117
Study No. C31005 Page 78of 104
Protocol Incorporating Amendment 10 03 December 2018
All revised informed consent forms must be reviewed and signed by relevant subjects or the 
relevant subject’s legally  acceptable representative in the same manner as the original informed 
consent. The date th e revised consent was ob tained shoul d be recorded in the subject’s medical 
record, and the subject should receive a copy  of the revised informed consent form.
16.3 Subject Confidentiality
The sponsor and designees affirm and upho ld the principle of the subject’ s right to protection 
against invasio n of privacy. Throughout this study , a subject’s source data will only be linked to 
the sponsor’s clinical study  database or documentation via a unique ident ificat ion number. As 
permitted by all applicable laws and regu lations, limited subject attributes, such as sex, age, or date 
of birth, and subject init ials may be used to verify the subject and accuracy o f the subject’s unique 
ident ificat ion number.
To com ply with ICH Guidelines for GCP and to verify co mpliance with this protocol , the sponsor 
requi res the investigator to permit its monitor or designee’s monitor, representatives fro m any 
regul atory  authori ty (eg, FDA, Medi cines and Heal thcare products Regul atory  Agency, 
Pharmaceut icals and Medical Devices Agency), the sponsor’s designated auditors, and the 
appropriate IRBs and IECs to review the subject’s original medical records (source data or 
docum ents), including, but not limited to, laboratory  test resul t reports, ECG reports, admissio n 
and discharge summaries for hospital admissio ns occurring during a subject’s study participation, 
and autopsy  reports. Access to a subject’s original medical records requires the specific 
authori zation of the subject as part of the informed consent process (see Section 16.2).
Copi es of  any subject source documents that are provided to the sponsor must have certain 
personally ident ifiable informat ion rem oved (ie, subject name, add ress, and other ident ifier fields 
not collected on the subject’s [e]CRF).
16.4 Publication, Disclosure, and Clinical Trial Registration Policy
16.4.1 Publication and Disclosure
The investigator is obliged to provide the sponsor with complete test results and all data derived by 
the invest igator from the study . During and after the study , only  the sponsor m ay make study  
inform ation available to other study  invest igators or to regulatory  agencies, except as required by  
law or regul ation. Except as otherwise allowable in the clinical study  site agreement, any  public 
disclosure (including publicly accessible websites) related to the protocol or study  resul ts, other 
than study  recrui tment m aterials and/or advertisements, is the sole responsibilit y of the sponsor.
The sponsor may publish any data and informat ion fro m the study (including data and informatio n 
generated by  the invest igator) without the consent of the invest igator. Manuscript authorship for 
any peer -reviewed publicat ion will appropriately reflect contribut ions to the production and 
review of the document. All publicat ions and presentations must be prepared in accordance with 
this secti on and the Clinical Study  Site Agreement. In the event of any discrepancy  between the 
protocol  and the Clinical Study  Site Agreemen t, the Clinical Study  Site Agreement will prevail.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
MLN0128, MLN1117
Study No. C31005 Page 79of 104
Protocol Incorporating Amendment 10 03 December 2018
16.4.2 Clinical Trial Registration
In order to ensure that informat ion on clinical trials reaches the public in a timely manner and to 
comply with applicable laws, regulat ions and guidance, Takeda will, at a minimum register 
intervent ional clinical tri als it sponsors anywhere in the worl d on ClinicalTrials.gov or other 
publicly  accessible websites before start of study , as defined in Takeda Policy/Standard . Takeda 
contact informat ion, along wi th invest igator’s cit y, state (as applicable), country , and recrui ting 
status will be registered and available for public viewing. 
For some registries, Takeda will assist callers in lo cating trial sites closest to their ho mes by 
provi ding the invest igator name, address, and p hone number to the callers request ing trial 
inform ation. Once subjects receive invest igator contact informat ion, they  may call  the si te 
requesting enrollment into the trial. The invest igative sites are encouraged to handle the trial 
inquiries according to their established subject screening process. If the caller asks addit ional 
questions bey ond the topic of trial enro llment, they should be referred to the sponsor. 
Any invest igator who objects to Takeda providing this informat ion to callers must provide Takeda 
with a wri tten noti ce request ing that their informat ion not be listed on the registry site. 
16.4.3 Clinical Trial Results Disclosure
Takeda will post the results of clinical trials on ClinicalTrials.gov or other publicly  accessible 
websites, as required by Takeda Policy/Standard, applicable laws, and/or regulat ions.
16.5 Insurance and Compensation for Injury
Each subject in the study  must be insured in accordance with the regulations applicable to the site 
where the subject is participat ing. If a local underwriter is required, then the sponsor or sponsor’s 
designee will obtain clinical study  insurance against the risk o f injury to clinical study subjects. 
Refer to the Clini cal Study  Site Agreement regarding the sponsor’s policy on subject 
compensat ion and treatment for injury. If the investigator has questions regarding this po licy, he or 
she should contact the sponsor or sponsor’s designee.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
MLN0128, MLN1117
Study No. C31005 Page 80of 104
Protocol Incorporating Amendment 10 03 December 2018
17.0 REFERENCES
1. Z naor A, Lortet -Tieulent J, Laversanne M, Jemal A, Bray  F. Internati onal Vari ations and 
Trends in Renal Cell Carcino ma Incidence and Mortalit y. Eur Urol  2015;67(3):519 -30.
2.Li P, Znaor A, Hol catova I, Fabianova E, Mates D, Wozniak MB, et al. Regional Geographic 
Variations in Kidney Cancer Incidence Rates in European Countries. European Urology 2014.
3.Chow WH, Dong LM, Devesa SS. Epidemio logy and ri sk factors for kidney cancer. Nature 
Reviews Urology  2010;7(5):245 -57.
4.Lipworth L, Tarone RE, Lund L, McL aughlin JK. Epidemio logic characteri stics and risk 
factors for renal cell cancer. Clin Epidemio l 2009;1:33 -43.
5.Gudas LJ, Fu L, Minton DR, Mongan NP, Nanus DM. The role o f HIF1alpha in renal cell 
carcino ma tumorigenesis. J Mol Med (Berl) 2014;92(8):825-36.
6.Brugarol as J. Mo lecular genetics of clear -cell renal cell  carcinom a. Journal  of Clinical  
Onco logy 2014;32(18):1968 -76.
7.Audenet F, Yates DR, Cancel -Tassin G, Cussenot O, Roupret M. Genetic pathways invo lved 
in carcinogenesis o f clear cell renal cell carcino ma: genomics towards personalized medicine. 
BJU Int 2012;109(12):1864 -70.
8.Pantuck AJ, Zeng G, Belldegrun AS, Figlin RA. Pathobio logy, prognosis, and targeted therapy 
for renal  cell carcino ma: explo iting the hypoxia -induced pathway. Clin Cancer Res 
2003;9(13):4641-52.
9.Laplante M, Sabatini, DM. mTOR Signaling in Growth Control and Disease. Cell 
2012;149(2):274-93.
10.Laplante M, Sabatini DM. mTOR Signaling. Cold Spring Harb Perspect Bio l 2012;4(2).
11.Sabat ini DM. mTOR and cancer: insights into a complex relat ionship. Nature Reviews Cancer 
2006;6(9):729 -34.
12.Benjamin D, Colo mbi M, Moroni  C, Hall  MN. Rapamycin passes the torch: a new generat ion 
of mTOR inhibitors. Nature Reviews Drug Discovery  2011;10(11):868-80.
13.Vilar E, Perez -Garcia J, Tabernero J. Pushing the envelope in the mTOR pathway: the second 
generat ion of inhibitors. Molecular Cancer Therapeutics 2011;10(3):395-403.
14.Thoreen CC, Kang SA, Chang JW, Liu Q, Zhang J, Gao Y, et al. An ATP -competitive 
mammalian target of rapamyc in inhibitor reveals rapamycin -resistant funct ions of mTORC1. 
Journal  of Biological Chemistry  2009;284(12):8023 -32.
15.Thoreen CC, Sabat ini DM. Rapamycin inhibit s mTORC1, but not completely. Autophagy  
2009;5(5):725 -6.
16.Chresta CM, Davies BR, Hickson I, Harding T, Cosulich S, Critchlow SE, et al. AZD8055 is a 
potent, select ive, and orally bioavailable ATP -competi tive mammalian target of rapamycin 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
MLN0128, MLN1117
Study No. C31005 Page 81of 104
Protocol Incorporating Amendment 10 03 December 2018
kinase inhibitor with in vitro and in vivo ant itumor activit y. Cancer Research 
2010;70(1):288 -98.
17.Rodri k-Outmezguine VS, Chandarlapat y S, Pagano NC, Poulikakos PI, Scaltriti M, Moskatel 
E, et al. mTOR kinase inhibit ion causes feedback- dependent biphasic regulat ion of AKT 
signaling. Cancer Discov 2011;1(3):248 -59.
18.O'Reilly KE, Rojo F, She QB, Solit D, Mill s GB, Smith D, et al. mTOR Inhibit ion Induces 
Upstream Receptor Ty rosine Kinase Si gnaling and Act ivates Akt. Cancer Res 
2006;66(3):1500-8.
19.Tabernero J, Rojo F, Calvo E, Burris H, Judson I, Hazell K, et al. Dose -and 
schedule -dependent inhibit ion of the mammalian target of rapamycin pathway wit h 
evero limus: a phase I tumor pharmacodynamic study in pat ients with advanced so lid tumors. J 
Clin Onco l 2008;26(10):1603-10.
20.Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, et al. Phase 3 tria l of 
evero limus for metastatic renal cell carcino ma : final results and analysis o f prognostic factors. 
Cancer 2010;116(18):4256 -65.
21.Cho DC, Cohen MB, Panka DJ, Co llins M, Ghebremichael M, Atkins MB, et al. The efficacy  
of the novel dual PI3 -kinase/mTO R inhibitor NVP -BEZ235 compared with rapamyc in in renal 
cell carcino ma. Clinical Cancer Research 2010;16(14):3628 -38.
22.Ko JJ, Xie W, Kroeger N, Lee JL, Rini BI, Knox JJ, et al. The Internat ional Metastatic Renal 
Cell Carcino ma Database Consortium model as a prognostic tool in pat ients with metastati c 
renal cell carcino ma previously  treated wi th first-line targeted therapy : a popul ation-based 
study. Lancet Oncol  2015;16(3):293 -300.
23.AFINITOR (everolimus) [package insert]. East Hanover, NJ: Novartis Pha rmaceuti cals 
Corporati on, 2015.
24.Afinitor [Summary  of Product Characterist ics]. Horsham, West Sussex, UK: Novart is 
Europharm  Limi ted, 2014.
25.Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response 
evaluat ion criteria in solid tum ours: revi sed RECIST gui deline (versio n 1.1). Eur J Cancer 
2009;45(2):228 -47.
26.Commo n Termino logy Criteria for Adverse Events (CTCAE), Version 4.03. U.S. Department  
of Heal th and Human Services National Cancer Institute. 14 June 2010.
27.Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European 
Organizat ion for Research and Treat ment of Cancer QLQ -C30: a qualit y-of-life instrument for 
use in internat ional clinical trials in onco logy. Journal of the National Canc er Inst itute 
1993;85(5):365 -76.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
MLN0128, MLN1117
Study No. C31005 Page 82of 104
Protocol Incorporating Amendment 10 03 December 2018
28.Cella D, Yount S, Brucker PS, Du H, Bukowski R, Vogelzang N, et al. Development and 
validat ion of a scale to measure disease -related symptom s of kidney  cancer. Val ue in Healt h 
2007;10(4):285 -93.
29.Commo n Termino logy Criteria for Adverse Events (CTCAE). National Cancer Inst itute, 
National Inst itutes of Healt h, U.S. Department of Health and Human Services Series v4.03. 
June 14, 2010. Publicat ion No. 09 -5410.
30.Karno fsky D, Burchenal J. The Clinical Evaluat ion of Chemoth erapeut ic Agents in Cancer. In: 
MacLeod C, editor. Evaluat ion of Chemotherapeutic Agents: Symposium Held at the New 
York Academy  of Medicine. New York: Columbia Universit y Press; 1949, p. 191 -205.
31.Peus D, Newcomb N, Hofer S. Appraisal of the Karno fsky Performance Status and proposal of 
a simple algorithmic system for its evaluat ion. BMC Med Inform Decis Mak 2013;13:72.
32.Cockcroft DW, Gault MH. Prediction of creat inine clearance fro m serum  creat inine. Nephron 
1976;16(1):31 -41.
33.The Cri teria Co mmit tee of New York Heart Associat ion. Nom enclature and Criteria for 
Diagnosis of Diseases of the Heart and Great Vessels. 9 ed. Boston, MA: Little, Brown & Co; 
1994.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
MLN0128, MLN1117
Study No. C31005 Page 83of 104
Protocol Incorporating Amendment 10 03 December 2018
Appendix ASchedule of Events
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
MLN0128, MLN1117
Study No. C31005 Page 84of 104
Protocol Incorporating Amendment 10 03 December 2018
CONFIDENTIALSchedule of Events
Screening (a) Cycle 1 Cycle 2 Cycle 3 Cycle 4 Cycle 5Cycle 6 and 
Beyond
EOT(b) Days -28 to -1 Day 1 Day 15 Day 1 Day 15 Day 1Day 
28 Day 1 Day 1 Day 1 Day 28
Informed co nsent X
Inclusion/exclusion criteria X X
Demographics X
Medical history X
Physical examination (c) X X X X X X X XX X
Height X
Weight X X X X X X X X
Vital signs (d) X X X X X X X X X X
Karnofsky performance status X X X X X X X X
Single, 12 -lead ECG (e) X X X X X X X X
EORTC -QLQ -C30 X X X X X X X
FKSI -DRS X X X X X X X
Radiographic tumor assessment by 
RECIST version 1.1 (f)X X X
Monitoring of concomitant 
medications and proceduresRecorded from first dose of study drug through 30 days after the last dose of study drug
AE reporting Recorded from first dose of study drug through 30 days after the last dose of study drug
SAEs (g) will be reported from signing of the informed consent form through 30 days after the last dose of study drug.
Dosing ( h)
Treatment Arm A Everolimus QD continuously 
Treatment Arm B MLN0128 QW continuously 
Treatment Arm C MLN0128+MLN1117 QD×3 each week continuously (on Days 1 -3, 8-10, 15- 17, and 22 -24 of a 
28-day treatment cycle)
Patient diary review (i) X X X X X X X X X X X
Samples/Laboratory Assessments
Pregnancy test (j) X1 X1 X1 X1 X1 X1
Hematology/Chemistry (k) X1 X1 X1 X1 X1 X1 X1 X1 X1
Coagulation (PT/INR, aPTT) X1 X1 X1 X1 X1 X1 X1
Fasting serum glucose (l) X1 X1 X1 X1 X1 X1 X1
In-home daily  fasting glucose 
monitoring (m)X
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
MLN0128, MLN1117
Study No. C31005 Page 85 of 104
Protocol Incorporating Amendment 10 03 December 2018
CONFIDENTIALSchedule of Events
Screening (a) Cycle 1 Cycle 2 Cycle 3 Cycle 4 Cycle 5Cycle 6 and 
Beyond
EOT(b) Days -28 to -1 Day 1 Day 15 Day 1 Day 15 Day 1Day 
28 Day 1 Day 1 Day 1 Day 28
HbA1c X X1 Q 3 cycles 
(n)
Fasting lipid profile (o) X X X X X X X
Urinalysis X X X X X X X
Tumor tissue (banked) or fresh 
biopsy sample (q)X
Blood sample for PK (r) Refer to  Treatment Arm B Sparse Ph armacokinetic Sample Breakdown
and Treatment Arm C Sparse Pharmacokinetic Sample Breakdown
aPTT=activated partial thromboplastin time, C=cycle, INR=international normalized ratio, OSFU=overall survival follow-up, PC EO T=Precrossover End-of-Treatment, 
PFSFU=progression-free survival follow-up, PT=prothrombin time, Q=every.
Tests and procedures should be performed on schedule, but occasional changes are allowable (±2 days) for holidays, vacations, an d other administrative reasons, starting after the 
completion of Cycle 2 Day 1.(a) Unless otherwise noted, the Screening visit (and all screening assessments) must occur within 28 days before the day of the f irst dose of study drug (Cycle 1 Day 1). The 
informed consent form may be signed more than 28 days before Cycle 1 Day 1. Screening assessments performed no more than 3 days  before D1 will qualify a s baseline assessments 
and need not be repeated, unless otherwise specified. 
(b) Patients will attend an EOT/Early Termination visit 30 to 40 days after receiving their last dose of study drug or at the st art of subsequent anticancer therapy. If subsequent 
anticancer therapy is required before 30 days after the last dose, the EOT/Early Termination visit should be conducted before th e initiation of subsequent anticancer therapy. The study 
will be closed when the last patient discontinues treatment. (c) Complete physical examination at Screening. Symptom-directed physical examinations at Cycle 1 Day 1, Cycle 1 Day 15, Cycle 2  Day 1, Cycle 2 Day 15, Day 1 on each cycle 
thereafter and during the EOT/Early Termination visit. The Cycle 1 Day 1 physical examination and medical history are not requi red if the physical examination at Screening was 
conducted and medical history obtained within 4 days before administration of the first dose of study drug (Cycle 1 Day 1).(d) Perform vital signs measurement before study drug administration except on Cycle 1 Day 15, when patients should take their d ose or doses of study drug early in the morning at 
home. Vital sign measurements include blood pressure (diastolic and systolic), heart rate, and temperature.
(e) Single, 12-lead ECGs will be collected predose on Day 1 of every cycle and during the EOT visit. When the timing of an ECG c oincides with blood samples, the ECG should be 
completed first. All scheduled ECGs should be performed after the subject has rested quietly for at least 5 minutes in a supine position.
(f) Radiological evaluations will be employed to assess the status of the patient’s underlying disease. Contrast-enhanced imagin g of the same imaging modality (CT or MRI) should 
be used for a patient throughout the study unless contraindicated. Baseline CT of the chest and CT or MRI scan of the abdomen an d pelvis must be obtained within 4 weeks before the 
first dose of study drug. Contrast-enhanced CT or MRI scans will be obtained on Day 28 (±3 days) of every 3 cycles (ie, Cycle 3 Day 28, Cycle 6 Day 28, etc). A contrast-enhanced CCI
CCI
Property of Takeda: For Non-Commercial Use Only andndd
ly Arm B SpaArm B Sp
Arm C Spm C Sllyly
eOzed ratio, ed rat
ges are alles are a
essments)sment
cle 1 Day e 1 Da
o 40 days 40 day
ose, the Ese, the 
ent. 
ymptommptom -d
visit. The isit. Th
4 days bedays 
study drustudy d
lood pressod pr
ected predcted pr
s should bshould
ll be emplbe emp
ut the studut the stu
ntrasttra-enheject to the Applicable Terms of UseT
le 55CycCyica
pp
Day 1Day 1Apppppppp
heot hXXtoooo
XXctjejejeje
Subje
nd Su
MLN0128, MLN1117
Study No. C31005 Page 86 of 104
Protocol Incorporating Amendment 10 03 December 2018
CONFIDENTIALCT or MRI scan is not required at the EOT visit for patients with documented radiographic disease progression. 
After the patient has completed 12 cycles of treatment, disease asse ssment may be performed every 6 cycles (after previous asses sment) or otherwise per investigator’s discretion. 
(g) Including serious PTEs; see Section  11.0.
(h) The first dose of study drug must be administered within 5 days after randomization on study. In Arm B, weekly MLN0128 will be administered with a light meal; in Arm C, 
MLN0128+MLN1117 will be administered on an empty stomach (see Section 9.1).
(i) The study center staff will check the patient diary versus the patient’s supply of study drug (ie, MLN0128, MLN1117, or evero limus, as applicable) to assess compliance.
(j) A serum pregnancy test will be performed for women of childbearing potential at Screening. A urine pregnancy test must be pe rformed predose on Day 1 of every cycle with 
negative results available before the first dose may be administered in that cycle. A serum pregnancy test may also be performe d within 3 days before dosing in place of the Day 1 
urine test.(k) Refer to Section  10.4.12 for a list of the required clinical laboratory assessments. Laboratory assessments may be performed within 1 day before the req uired study visit. Safety 
laboratory results must be available and reviewed by the investigator before study drug administration. Electrolyte levels shoul d be corrected as needed before study drug 
administration. 
(l) Fasting serum glucose will be measured in the clinic. Patients are required to fast overnight (nothing except water and/or m edications after midnight or for a minimum of 8 hours 
before the assessment) for each of these measurements. For patients receiving everolimus in Arm A or MLN0128 and MLN1117 in Arm  C, the sample should be taken approximately 
2 hours after dose administration with the patient continuing to fast until after that sample is taken. For patients receiving M LN0128 QW in Arm B, the sample should be taken 
predose; after predose blood draws are complete, patients receiving MLN0128 QW in Arm B should consume a light meal before dosin g (Section 9.1). In-home glucose monitoring 
is not required on days when fasting glucose is measured in the clinic.
See Sections  9.7.1 and 10.4.14 for further instructions. 
(m) Patients will be given a glucometer on Cycle 1 Day 1 to monitor daily fasting glucose levels at home and will be instructed to notify the study clinician when the fasting glucose 
is abnormal (ie, ≥150 mg/dL). See Sections  9.7.1 and 10.4.14 for further instructions.
(n) Every 3 cycles from Cycle 6 (ie, Cycle 6, Cycle 9, etc).(o) Total cholesterol, high density lipoprotein cholesterol, low density lipoprotein, and triglycerides.
(p)
(q) Archived tumor tissue, either paraffin blocks or a minimum of 15 unstained slides (paraffin blocks preferred) should be obta ined from a previous resection or biopsy that was 
done as part of the patient’s standard ca re. These samples will be evaluated for candidate biomarkers predictive of response. T umor tissue is to be collected only from enrolled patients 
and can be collected and sent to the sponsor after initiation of protocol treatment. If archival tumor tissue is not available, a tumor biopsy can be performed before the patient begins 
treatment with study drug(s). See Section  10.4.19 for requirements.
(r) Blood specimens for PK analysis will be collected from patients randomized to Arms B (single-agent MLN0128) and C (MLN0128+M LN1117 combination) perr the  Treatment 
Arm B Sparse Pharmacokinetic Sample Breakdown and Treatment Arm C Sparse Pharmacokinetic Sample Breakdown.  Blood specimens for PK analysis will not be collected from 
patients randomized to Arm A (single-agent everolimus).CCI
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of UseT
ent)nt)or othor o
28 will b28 will b e
7, or ever7, or ev
est must bt mus
be performbe perfo
s may be pmay be
ctrolyte lectrolyte
ing exceping exce
A or MLN0r MLN
ken. For pn. For 
B should cshould
glucose levucose l
ons.ons.
poprotein,oprote
15 unstain5 unst
evaluated aluate
protocol trotocol
ements.ements.
rom patienm pat
nddTreatmTrea
limus).imus).ercia
MLN0128, MLN1117
Study No. C31005 Page 87of 104
Protocol Incorporating Amendm ent 10 03 Decembe r 2018
CONFIDENTIALTreatment Arm B Sparse Pharmacokinetic Sample Breakdown
Cycle 1
Day 1 (a) Day 15 (b)
PK PK
At time of clinic visit (anytime postdose) X1
Approximately 1 hour after previous PK sample collection X1
1-2 hours postdose (±15 min) X1
3-6 hours postdose (±30 min) X2 (c)
This PK sampling schedule applies to patients receiving crossover treatment as well as to patients initially randomized to Arm B.
X#=the number of samples required (eg, 2 samples=X2).
(a) Subjects should bring a light meal with them to this visit. After completion of fasting serum glucose sampling, subjects will begin consuming the meal within 
30min before dosing, after which they will take their regularly scheduled doses of MLN0128. The exact date/time of meal consumptio n, MLN0128 dosing, and PK 
sampling must be recorded in the eCRF. Over the course of the study, a distribution of sampling times within this time range is encouraged.
(b) Subjects will take their regularly scheduled doses of MLN0128 at home with a light meal and will record the exact date/ti me of me al consumption and dose 
administration in their subject diaries. Subjects will then report to the clinic for the scheduled visit, during which they w ill provide PK samples. The date/time of 
meal consumption, dosing, and PK sampling must be recorded in the eCRF. Over the course of the study, a distribution of clinic visit/sampling times (eg, morning 
through late afternoon) for this visit is encouraged.(c) Two samples will be taken no less than 1 hr apart within the specified window.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
MLN0128, MLN1117
Study No. C31005 Page 88of 104
Protocol Incorporating Amendm ent 10 03 Decembe r 2018
CONFIDENTIALTreatment Arm C Sparse P harmacokinetic Sample Breakdown
Cycle 1
Day 1 Day 15
PK PK
At time of clinic visit (anytime postdose) (a) X1
Approximately 1 hour after the last PK sample X1
1-2 hours postdose (b) X1
3-6 hours postdose (b) X1
This PK sampling schedule applies to patients receiving crossover treatment as well as to patients initially randomized to Arm C.
X#=the number of samples required (eg, 2 samples=X2).
(a) On Cy cle 1 Day  15, patients should take their dose or doses of study drug early in the morning at home, and note the date and time that the dose was taken. 
Patients should also note the date/time of the previous dose. Two postdose PK plasma specimens will be collected at the clini c. The first specimen may be collected 
after arrival at the clinic an d the second specimen collected approximately 1 hour after the first. The date/time of dosing and PK sampling must be recorde d in the 
eCRF . Over the course of the study, a distribution of clinic visit/sampling times (eg, morning through late afternoon) for this visit is encouraged. 
(b) On Cycle 1 Day 1, PK plasma specimens can be collected at any time during the sampling window. The date and time of MLN01 28 dosing on Cycle 1 Day 1 and 
the date/time of PK sampling must be recorded in the eCRF . Over the course of the study, a distribution of sampling times within the windows is encouraged.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
MLN0128, MLN1117
Study No. C31005 Page 89of 104
Protocol Incorporating Amendment 10 03 December 2018
Appendix BResponsibilities of the Investigator
Clinical research studies sponsored by  the sponsor are subject to ICH GCP and all the applicable 
local laws and regulat ions. The responsibilit ies imposed on invest igators by  the FDA are 
summar ized in the “Statement of Invest igator” (Form FDA 1572), which must be completed and 
signed before the invest igator may participate in this study .
The invest igator agrees to assume the fo llowing responsibilit ies by signing Form FDA 1572:
1. Conduct the st udy in accordance wit h the protocol.
2.Personally conduct or supervise the staff who will assist in the protocol.
3.Ensure that study -related procedures, including study -specific (nonroutine/nonstandard panel) 
screening assessments are NOT performed on potent ial subjects, before the receipt of written 
approval  from relevant governing bodies/authorit ies.
4.Ensure that all co lleagues and emplo yees assist ing in the conduct of the study are informed of 
these obligat ions.
5.Secure prior approval o f the study and any cha nges by an appropriate IRB/IEC that conform to 
21 Code of Federal Regulations (CFR) Part 56, ICH, and local regulatory  requi rements.
6.Ensure that the IRB/IEC will be responsible for init ial review, continuing review, and approva l 
of the protocol. Promptly r eport to the IRB/IEC all changes in research act ivity and all 
anticipated risks to subjects. Make at least y early reports on the progress of the study  to the 
IRB/IEC, and issue a final report within 3 months of study  com pletion.
7.Ensure that requirements fo r informed consent, as outlined in 21 CFR Part 50, ICH, and local 
regul ations, are m et.
8.Obtain valid informed consent from each subject who participates in the study , and docum ent 
the date of consent in the subject’s medical chart. Valid informed consent i s the m ost current 
versio n approved by the IRB/IEC. Each informed consent form should contain a subject 
authori zation sect ion that describes the uses and disclosures of a subject’s personal 
inform ation (including personal health informat ion) that will take place in connect ion wit h the 
study . If an informed consent form does not include such a subject authorization, then the 
investigator must obtain a separate subject authorization form from each subject or the 
subject’s legally acceptable representative.
9.Prepare and maintain adequate case histories of all persons entered into the study , incl uding 
eCRFs, hospital records, laboratory  resul ts, etc, and maintain these data for a minimum o f 
2years fo llowing notificat ion by the sponsor that all invest igations hav e been discont inued or 
that the regulatory  authori ty has approved the marketing applicat ion. The invest igator should 
contact and receive written approval fro m the sponsor before disposing o f any such 
docum ents.
10.Allow possible inspection and copying by the regulatory  authori ty of GCP -specified essent ial 
docum ents.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
MLN0128, MLN1117
Study No. C31005 Page 90of 104
Protocol Incorporating Amendment 10 03 December 2018
11.Maintain current records of the receipt, administratio n, and disposit ion of sponsor -supplied 
drugs, and return all unused sponsor -supplied drugs to the sponsor. 
12.Report adverse reactions to the sponsor prompt ly. In the event of an SAE, notify the sponsor 
within 24 hours.
13.If the invest igator/institution retains the services of any individual or party to perform 
trial-related duti es and funct ions, the invest igator/inst itution shoul d ensure that thi s individual 
or party  is qualified to perform those trial -related duti es and funct ions and should implement 
procedures to ensure the integrit y of the tri al-related duti es and funct ions performed and any 
data generated.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
MLN0128, MLN1117
Study No. C31005 Page 91of 104
Protocol Incorporating Amendment 10 03 December 2018
Appendix CInvestigator Consent to Use of Personal Information
Takeda will co llect and retain personal information of the invest igator, including his or her name, 
address, and other personally identifiable informat ion. In addit ion, the invest igator’s personal 
information may be transferred to other parties located in countries throughout the world (eg, the 
United Kingdom, United States, and Japan), including the following:
Takeda, its affiliates, and licensing partners.
Business partners assist ing Takeda, its aff iliates, and licensing partners.
Regulatory  agencies and other health authorit ies.
IRBs and IECs.
The invest igator’s personal informat ion may be retained, processed, and transferred by Takeda 
and these other parties for research purposes including the following:
Assessment of the suitabilit y of invest igator for the study  and/or other clinical studies.
Management, monitoring, inspect ion, and audit of the study .
Analysis, review, and verificat ion of the study  results.
Safety reporti ng and pharmacovigilanc e relating to the study .
Preparati on and submissio n of regulatory  filings, correspondence, and communicat ions to 
regul atory  agencies rel ating to the study .
Preparati on and submissio n of regulatory  filings, correspondence, and communicat ions to 
regul atory  agencies relat ing to other medications used in other clinical studies that may contain 
the same chemical com pound present in the study  medicat ion.
Inspect ions and invest igations by regulatory  authorit ies relat ing to the study.
Self-inspect ion and internal a udit within Takeda, i ts affiliates, and licensing partners.
Archiving and audit of study  records.
Posting investigator site contact informat ion, study details and results on publicly accessible 
clinical trial registries, databases, and websites.
The invest igator’s personal informat ion may be transferred to other countries that do not have data 
protecti on laws that offer the same level of protection as data protection laws in invest igator’s own 
country .
The invest igator acknowledges and consents to the use o f his or her personal informat ion by 
Takeda and other parties for the purposes described above.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
MLN0128, MLN1117
Study No. C31005 Page 92of 104
Protocol Incorporating Amendment 10 03 December 2018
Appendix DKarnofsky Performance Status
Karnofsky Performance Status
Condition Percent Description 
Able to carry on normal 
activity  and to work. No 
special care is needed.100 Normal, no complaints, no evidence of disease.
90 Able to carry on normal activity, minor signs or symptoms of disease.
80 Normal activity with effort, some signs or symptoms of disease.
Unable to work. Able to 
live at home, care for most 
personal needs. A varying 
degree of assistance is 
needed.70 Cares for self. Unable to carry on normal activity or to do active work.
60 Requires occasional assistance, but is able to care for most of his needs.
50 Requires considerable assistance and frequent medical care.
Unable to care for self. 
Requires equivalent of institutional or hospital care. Disease may be progressing rapidly. 40 Disabled, requires special care and assistance.
30 Severely  disabled, hospitalization is indicated although death not imminent.
20 Hospitalization necessary, ver y sick, active supportive treatment necessary.
10 Moribund, fatal processes progressing rapidly.
0 Dead.
Sources:Karnofsky, DA, Burchenal, JH. The Clinical Evaluation of Chemotherapeutic Agents in Cancer. In Evaluation of 
Chemotherapeutic Agents: Symposium Held at the New York Academy of Medicine, MacLeod CM (ed). (New York, Columbia University Press), 1949, 191-205. [30]
Péus D, Newcomb N, Hofer S. Appraisal of the Karnofsky Performance Status and proposal of a simple algorith mic 
system for its evaluation. BMC Med Inform Decis Mak. 2013 Jul 19;13:72. [31]
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
MLN0128, MLN1117
Study No. C31005 Page 93of 104
Protocol Incorporating Amendment 10 03 December 2018
Appendix EMethods of Con traception Considered to be Effective
Acceptable Methods Considered Highly Effective
Birth control  methods that can achieve a failure rate of less than 1% per year when used 
consistent ly and correctly  are considered as highly  effect ive. Such methods includ e:
Combined (estrogen and progestogen containing) hormonal contraception associated with 
inhibit ion of ovulation (a):
–Oral.
–Intravaginal .
–Transdermal .
Progestogen -only hormonal contracepti on associ ated wi th inhibit ion of ovulation (a):
–Oral.
–Injectable .
–Implantable (b) .
Intrauterine device (b) .
Intrauterine hormone -releasing system (b).
Bilateral tubal occlusio n (b) .
Vasectomized partner (b) (c) .
Sexual abst inence (d) .
Methods that are Considered Less Highly Effective
Acceptable birth control methods that resul t in a failure rate of more than 1% per y ear incl ude:
Progestogen -only oral horm onal contracepti on, where inhibit ion of ovulation is not the 
primary  mode of  action.
Male or female condo m with or wi thout spermicide (e) .
Cap, diaphragm, or sponge with spermicide (e) .
__________________________________________________
Source: European Heads of Medicines Agencies (HMA) Clinical Trial Facilitation Group (CTFG); see hma.eu/fileadmin/dateien/Human_Medicines/01 -About_HMA/Working_Groups/CTFG/2014_09_HMA_ 
CTFG_ Contraception.pdf
(a) Hormonal contraception may be susceptible to interaction with the investigational medicinal product, which may reduce the efficacy of the contraception method.
(b) Contraception methods that in the context of this guidance are conside red to have low user dependency.
(c) Vasectomized partner is a highly effective birth control method provided that partner is the sole sexual partner of 
the woman of childbearing potential participant of the study and that the vasectomized partner has rece ived medical 
assessment of the surgical success.(d) In the context of this guidance sexual abstinence is considered a highly effective method only if defined as refraining from heterosexual intercourse during the entire period of risk associated with the study treatments. The 
reliability of sexual abstinence needs to be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the subject.(e) A combination of male condom with either cap, diaphragm or sponge with spermicide (double -barrier methods)
are also considered acceptable, but not highly effective, birth control methods.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
MLN0128, MLN1117
Study No. C31005 Page 94of 104
Protocol Incorporating Amendment 10 03 December 2018
Appendix FCockcroft -Gault Equation
For m en:
Creatinine Clearance = (140-age [years]) weight [kg]
72(serum creat inine [mg/dL])
OR
Creatinine Clearance = (140-age [years]) weight [kg]
0.81(serum creatinine [µmo l/L])
For wom en:
Creatinine Clearance = 0.85 (140 -age [y ears]) weight [kg]
72(serum creat inine [mg/dL])
ORCreatinine Clearance = 0.85 (140-age [y ears])
weight [kg]
0.81(serum creatinine [µmo l/L])
Source: Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 
1976;16(1):31 -41 [32].
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
MLN0128, MLN1117
Study No. C31005 Page 95of 104
Protocol Incorporating Amendment 10 03 December 2018
Appendix GNew York Heart Association Classification of Cardiac Disease
Class Functional Capacity Objective Assessment
I Patients with cardiac disease but without resulting limitations of 
physical activity. Ordinary physical activity does not cause undue 
fatigue, palpitation, dyspnea, or anginal pain.No objective evidence of 
cardiovascular disease.
II Patients with cardiac disease resu lting in slight limitation of physical 
activity . They  are comfortable at rest. Ordinary physical activity 
results in fatigue, palpitation, dyspnea, or anginal pain.Objective evidence of minimal 
cardiovascular disease.
III Patients with cardiac disease re sulting in marked limitation of 
physical activity. They are comfortable at rest. Less than ordinary 
activity  causes fatigue, palpitation, dyspnea, or anginal pain.Objective evidence of moderately 
severe cardiovascular disease.
IV Patients with cardiac di sease resulting in inability to carry on any 
physical activity without discomfort. Symptoms of heart failure or 
the anginal syndrome may be present even at rest. If any physical 
activity  is undertaken, discomfort is increased.Objective evidence of severe 
cardiovascular disease.
Source: The Criteria Committee of New York Heart Association. Nomenclature and Criteria for Diagnosis of Diseases of the Heart and Great Vessels. Ninth Ed. Boston, MA: Little, Brown & Co; 1994:253-256 [33].
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
MLN0128, MLN1117
Study No. C31005 Page 96of 104
Protocol Incorporating Amendment 10 03 December 2018
Appendix HList of Relevant Cytochrome P450 Inhibitors and Inducers
Moderate CYP1A2 Inhibitors
Cimetidine Methoxsalen 
Strong CYP1A2 Inhibitors
Fluvoxamine Ciprofloxacin
Clinically Significant Enzyme Inducers
Carbamazepine Rifabutin St. Jo hn’s wort
Phenobarbital Rifampin Phenytoin
Rifapentine 
Source: fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ 
ucm093664.htm.
Note that these lists are not exhaustive.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
MLN0128, MLN1117
Study No. C31005 Page 97of 104
Protocol Incorporating Amendment 10 03 December 2018
Appendix I List of BCRP, OCT1, and OCT2 Substrates
BCRP, OCT1, and OCT2 Substr ates
BCRP Substrates OCT1 and OCT2 Substrates
Methotrexate Metformin
Imatinib Cimetidine
Topotecan Amantadine
Lapatinib Famotidine
Rosuvastatin Pindolol
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
MLN0128, MLN1117
Study No. C31005 Page 98of 104
Protocol Incorporating Amendment 10 03 December 2018
Appendix J EORTC QLQ -C30 Version 3
:
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
MLN0128, MLN1117
Study No. C31005 Page 99of 104
Protocol Incorporating Amendment 10 03 December 2018
©Copyri ght 1995 E ORTC Quality of Life S tudy Group.  All rights  reserved.  Vers ion 3.0During the pas t week: Not at A QuiteVery
all little a bit much
17.Have you had diarrhea ? 1 2 3 4
18.Were you tire d? 1 2 3 4
19.Did pain inte rfere with your da ily activities ? 1 2 3 4
20.Have you had difficulty i n concentrati ng on thi ngs,
like rea ding a  newspape r or w atchi ng television? 1 2 3 4
21.Did you fe el tens e? 1 2 3 4
22.Did you w orry? 1 2 3 4
23.Did you fe el irrita ble? 1 2 3 4
24.Did you fe el depres sed? 1 2 3 4
25.Have you had difficulty re membering thi ngs? 1 2 3 4
26.Has your phys ical condi tion or me dical treatment
interfered w ith your family life? 1 2 3 4
27.Has your phys ical condi tion or me dical treatment
interfered w ith your social activities? 1 2 3 4
28.Has your phys ical condi tion or me dical treatment
caused you fina ncial difficultie s? 1 2 3 4
For the  follo wing ques tions  pleas e circle the number betw een 1 and 7 that
best applies  to you
29.How would you ra te your overa ll health during the pa st week?
1 2 3 4 5 6 7
 Very poor          E xcellent
30.How would you ra te your overa ll quality of life  during  the past week?
1 2 3 4 5 6 7
 Very poor          E xcellent
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
MLN0128, MLN1117
Study No. C31005 Page 100of 104
Protocol Incorporating Amendment 10 03 December 2018
Appendix KFunctional Assessment of Cancer Therapy Kidney Symptom 
Index -Disease -Related Symptoms
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
MLN0128, MLN1117
Study No. C31005 Page 101of 104
Protocol Incorporating Amendment 10 03 December 2018
Appendix LDetailed Description of Amendments to Text
The primary sections o f the protocol affected by the changes in Amendment 10are indicated. The 
corresponding text has been revised throughout the protocol.
Change #1: Removed long -term follow-up and the option for cross -over treatment, and added the 
option for pati ents to transfer to a Post -Trial Access program . 
The primary  change occurs in Section 7.1Overview of Study  Design.
Initial wording: Patients will  receive MLN0128, MLN0128+MLN1117, or everolimus unt il 
they experience disease progression or unacceptable toxicit y, withdraw 
consent, or die. Pati ents who experience progressive disease per RECIST 
versio n 1.1 during treatment with everolimus may be eligible to cross over to 
receive treatment with either MLN0128 or MLN0128+MLN1117. Patients 
who discont inue study treatment for reasons oth er than progressive disease will 
continue to have PFS fo llow-up visi ts every  2 months (±1 week) for the first 6 
months after the End -of-Treatm ent (EOT) visit, then every 3 months (±1 week) 
until disease progression or start of another anticancer therapy, w hichever 
occurs first. After disease progression or start of another anticancer therapy , 
patients will  be followed f or OS every  3 months (±1 week).
Amended or new 
wording:Patients will  receive MLN0128, MLN0128+MLN1117, or everolimus unt il 
they experience disease progression or unacceptable toxicit y, withdraw 
consent, die, or transfer to the Post -Trial Access program . or die. Patients 
who experience progressive disease per R ECIST version 1.1 during treatment 
with everolimus m ay be eligible to cross over to receive treatment with eit her 
MLN0128 or MLN0128+MLN1117. Patients who discontinue study treatment 
for reasons other than progressive disease will continue to have PFS fo llow-up 
visits every 2 months (±1 week) for the first 6 months after the 
End-of-Treatm ent (EOT) visit, then every 3 months (±1 week) until disease 
progression or start of another anticancer therapy, whichever occurs first. After 
disease progression or start of another anti cancer therapy, patients will be 
followed for OS every  3 months (±1 week). 
The study  design figure ( Figure 7.a) was al so m odified. 
This change also occurs in Section 2.0, Section 7.3, Section 10.4, Section 10.9, and t he Schedule of 
Events. 
Rationale for Change : The study  is to be cl osed.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
MLN0128, MLN1117
Study No. C31005 Page 102of 104
Protocol Incorporating Amendment 10 03 December 2018
Change # 2: Study closure was defined as then the last patient discont inues treatmen t. 
The primary  change occurs in Section 7.3Durati on of  Study .
Initial wording: The study will be clo sed 2 years after the last patient is rando mized or when the 
last pati ent discont inues study treatment.
Amended or new 
wording: The study will be clo sed 2 years after the last patient is rando mized or when the 
last pati ent discont inues study trea tment.
This change also occurs in Sect ion 2.0Study  Summary  and the Schedule of Events.
Rationale for Change: The study  is be closed. 
Change # 3: A new sect ion was added (10.10) detailing the Post -Trial Access program .
New or amended 
wording:If an open -label, rollover, PTA program becomes an option and the 
investigator and the sponsor agree that a patient would derive benefit 
from continued treatment or might be harmed without continued access 
to the medication, the patient may be given the opp ortunity to enroll. 
In the event of study closure by the sponsor, continued access to study treatment will be terminated for patients who are no longer benefiting 
from treatment (eg
, their disease has progressed or treatment is no longer 
tolerable), the benefit -risk assessment is no longer favorable, or an 
appropriate alternative therapy becomes available. The PTA program 
may be terminated in a country or geographic region or termina ted by the 
sponsor if study treatment can no longer be supplied or study drug 
becomes available either commercially or via another access mechanism.. 
Related SAEs during the PTA program must be reported to Takeda Global Pharmacovigilance department or des ignee. This includes deaths 
that the investigator considers related to study drug that occur after the EOT visit. Refer to Section 11.0 for details regarding definitions, 
documentation, and reporting of SAEs.
Rationale for Change: A PTA program was added to allow continued treatment after study 
closure f or any  patients receiving benefit.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
MLN0128, MLN1117
Study No. C31005 Page 103of 104
Protocol Incorporating Amendment 10 03 December 2018
Change #4: Modified the exclusion criterion relat ing to PPIs.
The primary  change occurs in Section 8.2Exclusio n Cri teria#5,
Initial wording: 12.Patients requi ring daily  or chroni c use of a proton pum p inhibitor (PPI) 
and/or having taken a PPI within 7 days before receiving the first dose of 
study drug.
Amended or new 
wording:12.Patients who have taken a PPI within 73days before receiving the first 
dose of study  drug.
Rationale for Change : Thi s change was m ade to allow more flexibilit y in pat ient enrollment 
based on data on MLN0128 metabo lism. 
This change also occurs in Sect ion2.0.
Change #5: Revised the restrictions on concomitant use of PPIs. 
The primary  change occurs in Se ction9.4.2 Excluded Concomitant Medicat ions and Procedures 
for Arms B and C . 
Initial wording: Concomitant administration of any PPI is not permitted during the study . 
Patients receiving PPI therapy  before enro llment must stop using the PPI 7 
days before their first dose of study  drugs. Exam ples of PPIs include 
omepraz ole, esom eprazo le, pantoprazole , lansoprazol e, and rabeprazol e.
Amended or New 
Wording:Concomitant administration of any PPI is not permitted during the 
study prohibited only for patients randomized to MLN0128 + 
MLN1117 . Patients receiving PPI therapy before enro llment must stop 
using the PPI 73 days before their first dose of study  drugs. Exam ples 
of PPIs include o mepraz ole, eso meprazo le, pantoprazole, lansoprazole, 
and rabeprazo le. 
Rationale for Change: This change was m ade to update the recommendat ions on concomitant 
medicat ion use during the study  based on data on MLN0128 metabo lism. 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
MLN0128, MLN1117
Study No. C31005 Page 104of 104
Protocol Incorporating Amendment 10 03 December 2018
Change # 6: Physical examinat ions after Screening were changed to symptom -directed physical  
examinat ions.
The primary  change occurs in the Schedule of Events.
Initial wording: Com plete physical  examinat ion at Screening, at Cycle 1 Day , Cycle 1 Day  15, 
Cycle 2 Day  1, Cy clle 2 Day  15, Day  1 of each cycl e therafter and during the 
EOT/Early Terminat ion Visit. 
Amended or new 
wording:Com plete physical  examinat ion at Screening . Symp tom-directed physical 
examinations at Cy cle 1 Day  1, Cy cle 1 Day  15, Cycle 2 Day  1, Cy cle 2 Day  
15, Day  1 on each cycle thereafter, and during the EOT/Early Terminat ion 
visit.
Rationale for Change: Com plete physical examinations were not felt necessary  atsubsequent 
visits. 
Change # 7: The requirement for a confirmatory  scan 4 weeks fro m the previous can for patients 
with a CR or PR was removed.
The primary  change occurs in the Schedule of Events.
Deleted text: A confirmatory  scan shoul d be perform ed at approximately  4 weeks from  the 
previous scan for all pat ients with a com plete or parti al response. 
Rationale for Change: The confirmatory  scan was not felt necessary . 
Change # 8: A recommendat ion was added for radiographic assessments every 6 mo nths, or at the 
investigator’s discret ion, after 12 cycles of treatment. 
The primary change occurs in the Schedule of Events. 
New wording: After the patient has completed 12 cycles of treatment, disease 
assessment may be performed every 6 cycles (after previous 
assessment) or otherwise per investigator’s discretion.
Rationale for Change: To clarify t iming of assessments after 12 cy cles o f treatm ent.
Change # 9:The requirement for weight to be measured at Day 15 of Cycles 1 an d 2 was remo ved.
The primary change occurs in the Schedule of Events. 
Rationale for Change: Weight measurement was not felt necessary at these timepo ints. 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
䢢
䢢䢢䢢
䢢
䢢䢢
䢢
(/(&7521,& 6,*1$785(6 
Signed by Meaning of Signature Server Date 
(dd-MMM-yyyy HH:mm ‘UTC’) 

  

  

  

  


   


   


   


   


   


   


   


   


   


   


   


   


   


   


   


GHDF䣃䣯䣧䣰䣦䣯䣧䣰䣶䢢䢳䢲䢢䢪䣈䣴䣣䣰䣥䣧䢫䢢䣶䣱䢢䣃䢢䣒䣪䣣䣵䣧䢢䢴䢮䢢䣑䣲䣧䣰䢯䣮䣣䣤䣧䣮䢢䣕䣶䣷䣦䣻䢢䣶䣱䢢䣇䣸䣣䣮䣷䣣䣶 䣧䢢䣶䣪䣧䢢䣇䣨䣨䣫䣥䣣䣥䣻䢢䣣䣰䣦䢢䣕䣣䣨䣧䣶䣻䢢䣱䣨䢢䣕䣫䣰䣩䣮䣧䢯䣃䣩䣧䣰䣶
䣏䣎䣐䢲䢳䢴䢺䢢䣣䣰䣦䢢䣶䣪䣧䢢䣅䣱䣯䣤䣫䣰䣣䣶䣫䣱䣰䢢䣱䣨䢢䣏䣎䣐䢲䢳䢴䢺䢭䣏䣎䣐䢳䢳䢳䢹䢢䣅䣱䣯䣲䣣䣴䣧䣦䢢䣙䣫䣶䣪䢢䣇䣸 䣧䣴䣱䣮䣫䣯䣷䣵䢢䣫䣰䢢䣶䣪䣧䢢䣖䣴䣧䣣䣶䣯䣧䣰䣶䢢䣱䣨䢢䣃䣦䣷䣮䣶
䣒䣣䣶䣫䣧䣰䣶䣵䢢䣙䣫䣶䣪䢢䣃䣦䣸䣣䣰䣥䣧䣦䢢䣱䣴䢢䣏䣧䣶䣣䣵䣶䣣䣶䣫䣥䢢䣅䣮䣧䣣䣴䢯䣅䣧䣮䣮䢢䣔䣧䣰䣣䣮䢢䣅䣧䣮䣮䢢䣅䣣䣴䣥 䣫䣰䣱䣯䣣䢢䣖䣪䣣䣶䢢䣊䣣䣵䢢䣒䣴䣱䣩䣴䣧䣵䣵䣧䣦䢢䣱䣰䢢䣘䣣䣵䣥䣷䣮䣣䣴
䣇䣰䣦䣱䣶䣪䣧䣮䣫䣣䣮䢢䣉䣴䣱䣹䣶䣪䢢䣈䣣䣥䣶䣱䣴䢯䣖䣣䣴䣩䣧䣶䣧䣦䢢䣖䣪䣧䣴䣣䣲䣻
%LRVWDWLVWLFV$SSURYDO 'HF87&
&OLQLFDO3KDUPDFRORJ\$SSURYDO 'HF87&
&OLQLFDO6FLHQFH$SSURYDO 'HF87&
&OLQLFDO6FLHQFH$SSURYDO 'HF87&PPD eT eate te
ble THH:mm ‘UH:mmTer
ble87&87&

'HFHF
'H